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In this work mutations were described using the nomenclature according to the 
human genome variation society (hgvs) (den Dunnen and Antonarakis, 2000; HGVS, 
2013). Genes and proteins stated in this work followed the guidelines according to 
the HUGO Gene Nomenclature Committee (HGNC) for human (Wain et al., 2002), 
the Mouse Genome Informatics Database (MGI) for mouse (MGI, 2011) and 
Xenbase Gene Nomenclature Guidelines for Xenopus laevis (Xenbase, 2013). 
The abbreviation qPCR was used for quantitative real-time PCR and RT-qPCR for 








CHARGE syndrome is a complex malformation syndrome affecting several organ 
systems like the central nervous system, ear, eye and heart. Heterozygous loss of 
function mutations in CHD7, a conserved chromatin remodelling enzyme, are 
responsible to cause about two-thirds of CHARGE syndrome cases. CHD7 is present 
in large multi-subunit complexes regulating gene transcription in a time and cell type 
specific manner.  
In this work, it was shown by co-immunoprecipitation and Duolink proximity 
ligation assay that CHD7 interacts with the WAR complex members WDR5, ASH2L 
and RBBP5. Additional direct yeast two-hybrid experiments revealed that CHD7 is 
most likely associated to this complex via its direct interaction partner CHD8.  
The WAR complex is one “core” complex of the methyltransferase KMT2D. 
Mutations in KMT2D are the main cause of Kabuki syndrome, a developmental 
disorder, showing a remarkable phenotypic overlap to features present in CHARGE 
syndrome. The results of this work demonstrate a possible link of CHD7 and 
KMT2D to the same regulatory process of chromatin remodelling and chromatin 
modification, which might explain the phenotypic overlap of CHARGE syndrome 
and Kabuki syndrome. 
It was proposed that CHARGE syndrome belongs to the neurocristopathies. Recent 
studies demonstrated that CHD7 is required for the formation of multipotent neural 
crest cells. However, little is known about CHD7 target genes in the process of 
neural crest cell development. Within this work a genome-wide microarray analysis 







)) of the Whirligig mouse line which carries a nonsense 
mutation in the Chd7 gene. 98 genes were identified to be differentially expressed 
comparing homozygous (Chd7
Whi/Whi
) to wild-type (Chd7
+/+
) embryos. In fact, many 
of these genes are involved in the development of neural crest cells, for example, the 
specification of neural crest cells, epithelial-to-mesenchymal-transition and guidance 
of migrating neural crest cells. In this work it was demonstrated that the regulatory 
effect of Chd7 on Sema3a, a secreted signalling molecule known to have 
chemorepulsive properties for axons and to guide migrating neural crest cells, is 
conserved in mouse and Xenopus laevis. Further, a regulatory effect on neural crest 





In this work three non-synonymous mutations were identified in CHD7 negative 
CHARGE patients within the SEMA3A gene and the SEMA3D gene, respectively. 
SEMA3A mutations are known to be involved in the pathogenesis of Kallmann 
syndrome, a genetic disorder, which represents the mild phenotypic end of CHARGE 
syndrome. It is assumed that SEMA3A and SEMA3D act as modifiers contributing 
to a more severe phenotype in CHARGE patients if they are mutated. This would 
explain the high inter- and intra-familial variability observed in CHARGE syndrome.  
In general, the results discovered in this work help to better understand the 







1.1 The chromodomain helicase DNA-binding protein 7 
CHD7 (Chromodomain helicase DNA-binding protein 7) belongs to the CHD 
(Chromodomain helicase DNA-binding protein) family of ATP (adenosine 
triphosphate)-dependent chromatin remodelling enzymes which regulate gene 
transcription (Kim et al., 2008b). In human the CHD family consists of nine 
members which share two chromatin domains located at the N-terminus and a 
SWI2/SNF2-like ATPase/helicase domain (Woodage et al., 1997; Flaus et al., 2006; 
Flanagan et al., 2007). According to domain and sequence similarities the nine 
members of the CHD family are divided into three subgroups. CHD7 belongs to 
subgroup III which is characterised by three conserved regions (CR1-3), a SANT 
(Switching-defective protein 3, Adaptor 2, Nuclear receptor corepressor, 
Transcription factor IIIB) domain and two BRK (Brahma and Kismet) domains 
located at the C-terminal region (J. A. Hall and Georgel, 2007; Marfella and 
Imbalzano, 2007). CHD7 is located on chromosome 8 (8q12) and it consists of 38 
exons with a genomic size of 188 kb (Vissers et al., 2004). CHD7 is highly 
conserved in different species, such as mouse, chick, zebrafish, Xenopus laevis and 
others where orthologs were identified (Bosman et al., 2005; Aramaki et al., 2007; 
Bajpai et al., 2010).  
1.2 CHD7 exists in large multi-subunit complexes 
It is known that chromatin remodelling enzymes form multi-subunit complexes 
which regulate gene transcription in a certain way depending on the composition of 
proteins within these complexes (Mohrmann and Verrijzer, 2005; Trotter and Archer, 
2008; Ho et al., 2009b). Schnetz et al. (2010) showed in mouse embryonic stem cells 
that CHD7 binds OCT4 (octamer binding transcription factor 4), SOX2 (SRY (sex 
determining region Y)-box 2), NANOG (Nanog homeobox) and the enhancer 
binding protein P300. Another co-localisation of CHD7 was described by Bajpai et 
al. (2010), who found CHD7 to be associated with members of the remodelling 
BAF/PBAF complex (Brahma-associated factor/Polybromo- and BRG1-associated 






described the involvement of a complex consisting of CHD7, PPARɣ (peroxisome 
proliferator activated receptor gamma), NLK (Nemo-Like Kinase) and SETDB1 
(SET domain, bifurcated 1) in the process of adipogenesis and osteoblastogenesis in 
mouse bone marrow mesenchymal progenitor cells. Furthermore, it was shown by 
our group that CHD7 interacts indirectly and directly with the chromatin remodeler 
CHD8 (Chromodomain helicase DNA-binding protein 8) (Batsukh et al., 2010). 
Yates et al. (2010) demonstrated that Chd8 is associated with the WAR complex 
(WDR5 (WD repeat domain 5), ASH2L (absent, small, or homeotic-like) and 
RBBP5 (retinoblastoma binding protein 5)). Another factor also associated with the 
WAR complex is the methyltransferase KMT2D (lysine (K)-specific 
methyltransferase 2D) (OMIM 602113). An alternative symbol is MLL2 (mixed 
lineage leucemia 2). KMT2D belongs to the SET1 (histone lysine methyltransferase 
Set1) family and is responsible for histone 3 lysine 4 (H3K4) di- and trimethylation 
(Song JJ, 2008). Members of the SET1 family of enzymes are commonly associated 
with multi-subunit complexes which are important for the activation of the 
methyltransferase (Miller et al., 2001; Yokoyama et al., 2004; Wysocka et al., 2005; 
Steward et al., 2006; Ernst and Vakoc, 2012). One “core” complex consists of 
WDR5, ASH2L and RBBP5 (Steward et al., 2006; Song JJ, 2008; Yates et al., 2010). 
Yates et al. (2010) described the MLL (mixed lineage leucemia) associated WAR 
complex as a positive regulator of HOXA2 (homeobox A2) transcription. 
Furthermore, it is known that WDR5, ASH2L and RBBP5 form a subcomplex in the 
absence of MLL (Fig. 1) (Dou et al., 2006; Steward et al., 2006; Thompson et al., 
2008; Thompson BA, 2008). Yates et al. (2010) demonstrated a direct interaction of 
CHD8 with each component of the WAR complex that seem to function as a 







Figure 1: Possible composition of the MLL methyltransferase complex.  
(A). MLL is associated via WDR5 with the WAR complex (WDR5, ASH2L and RBBP5). ASH2L is 
required for trimethylation of H3K4 by the MLL complex. (B) CHD8 seems to bind in the absence of 
MLL to the WAR complex. This complex might function as a chromatin remodeler which negatively 
regulates HOXA2 expression. Figure modified after Steward et al. (2006). 
Vissers et al. (2004) identified heterozygous mutations within the CHD7 gene to be 
responsible for a malformation syndrome, called CHARGE syndrome. 
1.3 CHARGE syndrome 
CHARGE syndrome is an autosomal dominant malformation syndrome (OMIM 
214800) firstly described in 1979 independently by Hall and Hittner (B. D. Hall, 
1979; Hittner et al., 1979). Two years later Pagon et al. (1981) determined the 
acronym CHARGE association (coloboma, heart defects, atresia choanae, retarded 
growth and development, genital hypoplasia, ear anomalies/deafness) describing the 
main features seen in patients and proposed the diagnostic criteria for CHARGE 
association. Over the years these criteria were refined several times. Blake et al. 
(1998) defined major (coloboma, atresia of the choanae, cranial nerve disorder and 
abnormalities of the ear) and minor criteria (heart defects, genital hypoplasia, short 
stature, developmental delay, tracheoesophageal fistula, orofacial cleft and 
characteristic facial gestalt) to diagnose CHARGE syndrome. Four major criteria or 
three major criteria and three out of seven minor criteria must be reported to fulfil the 
diagnostic criteria of CHARGE syndrome (Blake et al., 1998). An update was 


































term “CHARGE association” was changed into “CHARGE syndrome” (Vissers et 
al., 2004; Bergman et al., 2011). Due to the spectrum of malformations, it was 
hypothesised long time ago that CHARGE syndrome belongs to the 
neurocristopathies (Siebert et al., 1985; Wright et al., 1986).  
1.4 Neural crest cells - the explorer of the vertebral embryo 
Neural crest cells (NCCs) are a migratory, multipotent cell population which 
delaminates from the neural fold or dorsal neural tube (Fig. 2) (Gammill and 
Bronner-Fraser, 2003). NCCs migrate along specific pathways to populate different 
niches of the embryo (Rickmann et al., 1985; Kontges and Lumsden, 1996; Morin-
Kensicki and Eisen, 1997). Therefore, they are also called the explorers of the 
vertebral embryo (Gammill and Bronner-Fraser, 2003; Kuriyama and Mayor, 2008).  
 






The neural plate border (green) separates the neuroectoderm (purple) from the ectoderm (blue) and is 
specified by signalling from these two tissues and the underlying mesoderm (yellow). During 
neurulation the neuroectoderm differentiates into the neural plate due to the elevating neural plate 
border building neural folds. Further elevation of the neural folds forms the neural tube. The dorsal 
region of the neural tube where the neural folds joined is now referred to as the neural crest. Neural 
crest cells delaminate from the dorsal region of the neural tube. Figure taken from Gammill and 
Bronner-Fraser (2003). 
Depending on the localisation within the embryo NCCs give rise to different cell 
types like neurons, muscle, cartilage or pigment cells (Fig. 3). Therefore, they 
contribute to the formation of many tissues and organs like heart, skin or the 
peripheral nervous system (Kuriyama and Mayor, 2008). NCCs are divided into four 
major groups depending on the region of the longitudinal axis of the embryo where 
the NCCs delaminate: cranial (cephalic) neural crest, trunk neural crest, vagal and 
sacral neural crest and cardiac neural crest (Gilbert, 2000). 
Cranial NCCs differentiate into different sections of the face like jaw and bones of 
the middle ear, connective tissue, cartilage, odontoblasts and glia cells (Gilbert, 
2000). Depending on the migratory pathway trunk NCCs form melanocytes, dorsal 
root ganglia, adrenal medulla and sympathetic ganglia (Gilbert, 2000). Vagal and 
sacral NCCs differentiate into the parasympathic nerves of the gut which allow its 
peristaltic movements (Gilbert, 2000). The cardiac NCCs form the entire 
musculoconnective tissue wall of the cardiac outflow tract and contribute to the 
septum that separates the pulmonary circulation from the aorta (Gilbert, 2000; Kirby 
and Hutson, 2010). Furthermore, this type of NCCs differentiates into cartilage, 







Figure 3: Differentiation of neural crest cells.  
Neural crest cells (NCCs) delaminate from the dorsal region of the neural tube and differentiate into 
multiple cell types. Depending on the region along the longitudinal axis of the embryo different types 
of NCCs are distinguished which differentiate into different cell types. Cranial NCCs contribute to 
derivatives of the head region, for instance, neurons and glia of cranial ganglia, cartilage, bones and 
connective tissue. Trunk NCCs differentiate into melanocytes, sensory neurons and sympathetic 
ganglia or the adrenal medulla. Figure taken from Knecht and Bronner-Fraser (2002). 
1.5 NCC development 
The NCC development is a complex process of different events starting with the 
induction of NCCs at the border of the neural plate by interactions of different 
signals from the surrounding tissues (Knecht and Bronner-Fraser, 2002; Gammill and 
Bronner-Fraser, 2003). One of the characteristics of NCCs is their ability to migrate. 
A process called epithelial-mesenchymal transition (EMT) takes place that enables 
NCCs to delaminate from the dorsal most region of the neural tube and to migrate 
along specific pathways until they reach their destination where they differentiate 
into their predetermined cell types (Gammill and Bronner-Fraser, 2003). During 
EMT fundamental changes in cell morphology and cell adhesion occur (Kuriyama 
and Mayor, 2008). The typical apical-basal polarity found in the epithelium of 
premigratory NCCs is lost due to replacement of tight junctions by gap junctions, 
allowing the exchange of molecules and ions from one cell to the other (Lampe and 
Lau, 2000; Kuriyama and Mayor, 2008). A group of transmembrane proteins, namely 






Kuriyama and Mayor (2008) assumed that a reduction of type I cadherins in 
combination with an increase in type II cadherins are linked to NCC EMT. 
Furthermore, they supposed that matrix metalloproteases which digest the 
extracellular matrix are required for EMT (Kuriyama and Mayor, 2008). 
Once EMT is completed NCCs migrate in clusters along specific pathways to their 
destination (Kuriyama and Mayor, 2008; Kirby and Hutson, 2010). It has been 
shown that migrating NCCs are guided by different factors via ligand-receptor 
signalling (Yazdani and Terman, 2006; Kuriyama and Mayor, 2008). 
1.6 NCC guidance and signalling factors 
The guidance of migrating NCCs is a complex mechanism which involves different 
factors that interact with each other to provide the information to NCCs so they know 
where to go. Table 1 shows an overview about some guidance and signalling factors 
known to play a role during NCC migration. 
Table 1: Function of factors involved in early migration and guidance of neural crest cells. 
name classification and function for NCCs 
α4β1 integrin receptor, controls migration and survival  
tenascinC ECM protein, enables delamination 
WNT1 growth factor, initiates migration 
TCF transcription factor, initiates migration 
FoxD3 transcription factor, initiates migration 
Sox10 transcription factor, initiates migration 
semaphorin family guidance molecule that can attract or repel 
neurophilin family receptor for semaphorins 
plexin family receptor for semaphorins 
ephrin family guidance molecule that can attract or repel 
Ephrin family receptor for ephrins  
Slit family guidance molecule that can attract or repel 
Robo family receptor for Slits 
HoxA1/B1 transcription factor, regulates EphA2 expression 
Table modified after Kirby and Hutson (2010). 






Semaphorins and their receptors neurophilins and plexins 
Some of these guidance factors are members of the semaphorin family which are 
conserved across divergent animal phyla (Yazdani and Terman, 2006). These 
transmembrane proteins can attract or repel NCCs. In human and mouse 20 
semaphorins exist which can be divided into eight classes (Yazdani and Terman, 
2006; Kuriyama and Mayor, 2008). Semaphorins primarily act as ligands (Yazdani 
and Terman, 2006). All of them possess a conserved sema domain of about 500 
amino acids that plays a role during binding to their receptors neurophilins and 
plexins (Yazdani and Terman, 2006). The members of the transmembrane receptor 
family neurophilin and plexin are expressed in migrating NCCs. Binding of 
semaphorins to their receptors leads to alteration of the cytoskeleton by reorganising 
actin filaments and microtubule (Yu and Kolodkin, 1999). Furthermore, semaphorins 
and its receptors are involved in the correct migratory patterning of NCCs (Eickholt 
et al., 1999; Brown et al., 2001; Gitler et al., 2004; Lepore et al., 2006; Sato et al., 
2006). It has been shown that Sema4D (sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 4D) either inhibits or enables cell 
migration and axon outgrowth depending on the member of the plexin receptor 
family, Sema4D binds to (Yazdani and Terman, 2006). However, the molecular 
mechanism behind the function of semaphorins is barely understood.  
Ephrins and Eph receptors 
Ephrins serve as ligands for Eph receptors which belong to the subfamily of receptor 
tyrosine kinases (Kuriyama and Mayor, 2008). Both, ligands and receptors are 
membrane-bound proteins, so binding of ephrins to their receptors requires direct 
cell-cell interaction (Kuriyama and Mayor, 2008). Ephrins are involved in the 
guidance of axons and in cell migration (Egea and Klein, 2007; Rohani et al., 2011). 
Until now 13 Eph receptors and eight ephrins are known in mammals (Kuriyama and 
Mayor, 2008). It has been shown in Xenopus laevis that NCCs express Eph receptors 
while the ligands are expressed in regions of the embryonic tissue where NCCs 
should either migrate or not migrate (A. Smith et al., 1997). The underlying 







Slits and Robo receptors 
The slit/Robo signalling pathway is involved in different processes, such as guidance 
of axons and trunk NCCs (Kuriyama and Mayor, 2008; Kirby and Hutson, 2010). In 
mammals three slit ligands and four Robo receptors have been identified until now 
(Kuriyama and Mayor, 2008). Like semaphorins and ephrins, slits can act 
bifunctionally having either a stimulating or repulsing effect on migrating NCCs (De 
Bellard et al., 2003; Kuriyama and Mayor, 2008). 
Most of the described factors (semaphorins, ephrins and slits) were shown to act as 
negative regulators preventing migrating NCCs from invading the region of their 
expression (Kuriyama and Mayor, 2008). Further factors involved in the process of 
NCCs guidance exist. However, the whole machinery behind this guidance process 
of NCCs is hardly understood. 
1.7 Xenopus laevis as a model organism for studying NCC development 
Since NCCs are a feature of vertebrates, they cannot be studied in traditional model 
organisms like flies, nematodes or yeast. Historically, NCC development has been 
studied in amphibian embryos like the African clawed frog Xenopus laevis (Collazo 
et al., 1993). This animal model has the advantage of a relatively fast reproduction 
cycle and a high number of offspring (Parisis, 2012; Xenbase, n.d.). Furthermore, the 
breeding can be manipulated by superovulation, so female frogs can lay eggs three to 
four times a year (Parisis, 2012; Xenbase, n.d.). Amphibian embryos develop 
externally from the mother animal, so they are easily accessible (Parisis, 2012; 
Xenbase, n.d.). Oocytes are relatively big with > 1 mm in diameter and can be 
manipulated (Parisis, 2012; Xenbase, n.d.). One example is the injection of 
Morpholinos (MO) into the developing oocyte. 
MO are synthetic oligonucleotides consisting of about 25 subunits which comprise of 
a nucleic acid base bound to a morpholine ring and a non-ionic phosphorodiamidate 
group linkage (GeneTools, n.d.). MO are used as a tool to knockdown gene functions 
without degrading their target RNA (GeneTools, n.d.). Blocking the translation or 
modifying pre-mRNA splicing or inhibiting miRNA is the mechanism by which MO 
knockdown gene expression (GeneTools, n.d.). 
Bajpai et al. (2010) performed MO knockdown experiments with Xenopus laevis 






of Chd7 revealed features of CHARGE syndrome in Xenopus laevis embryos (Bajpai 
et al., 2010). Furthermore, Chd7 knockdown experiments demonstrated that the 
expression of genes involved in early induction of NCCs are not affected while the 
expression of sox9 (SRY (sex determining region Y)-box 9), twist (basic helix-loop-
helix transcription factor twist) and slug/snail (Zinc finger protein Slug/ snail family 
zinc finger) which are involved in NCC specification and early migration processes 
were downregulated (Bajpai et al., 2010). Therefore, Bajpai et al. (2010) assumed 
that Chd7 is involved in the regulation of genes which play a role in the formation of 
migrating NCCs. However, the question in which way Chd7 is involved in the EMT 
process and in the guidance of migrating NCCs was not answered. 
1.8 The mouse as a model organism and its advantages 
Mouse is a common model organism used for basic research in genetics and human 
diseases. One of the most striking advantages of the mouse is their similarity to 
humans in genetics, anatomy and physiology (Simmons, 2008). Over 90 % of the 
mouse genome resembles the human genome, therefore the mouse afford a good 
model to study human diseases (Waterston et al., 2002). The mouse genome can be 
manipulated to induce diseases found in humans either by directly affecting a target 
gene (knock-out or knock-in) or indirectly by large-scale mutagenesis programmes 
using chemicals or radiation to induce mutations (Hardouin and Nagy, 2000). 
For functional analysis in this work the CHD7 deficient Whirligig mouse line was 
available that was kindly provided by K. P. Steel (Sanger Centre, Cambridge, United 
Kingdom) and the Helmholtz Zentrum Munich, Germany. These mice carry a 
nonsense mutation in exon 11 of the Chd7 gene generated by large-scale ENU (N-
ethyl-N-nitrosourea) mutagenesis programme (Hrabe de Angelis et al., 2000; Hawker 
et al., 2005). Homozygous mice (Chd7
Whi/Whi
) die at embryonic stage 10.5 (E10.5) 
whereas heterozygous mice (Chd7
Whi/+
) resemble many features found in CHARGE 
patients, such as eye and heart defects, ear anomalies, cleft lip and palate and choanal 
atresia (Bosman et al., 2005). Therefore, the Whirligig mouse line provides a good 






1.9 Aim of the work 
Chromatin remodelling enzymes exist in large multi-subunit complexes (Schnetz et 
al., 2010). Are there further CHD7 complex compositions than the ones described in 
the literature? CHD8 interacts with the WAR complex (Yates et al., 2010). 
Furthermore, it was demonstrated by our working group that CHD8 interacts with 
CHD7 (Batsukh et al., 2010). Is CHD7 also associated with the WAR complex? 
Does CHD7 interact with the members of the WAR complex WDR5, ASH2L and 
RBBP5? To answer these questions, interaction studies were planned. Co-
immunoprecipitation (Co-IP) experiments using HeLa cells should be performed. If 
CHD7 interacts with components of the WAR complex, where in the cell do the 
interactions take place? Therefore, Duolink proximity ligation assays (PLA) should 
be performed. Are the identified interactions direct ones? To clarify this question, 
direct yeast two-hybrid (Y2H) experiments were planned. 
Little is known about the pathogenesis behind CHARGE syndrome. What kinds of 
genes are regulated by CHD7 and what happens if CHD7 is mutated? To analyse the 
regulatory effect of CHD7 on other genes, a genome-wide microarray analysis 
should be performed on whole embryos of the Whirligig mouse line. The expression 
profile of heterozygous (Chd7
Whi/+
) and homozygous (Chd7
Whi/Whi
) animals should be 
compared to the expression profile of wild-type (Chd7
+/+
) embryos of the same 
gender. For the confirmation of the microarray data a RT-qPCR (reverse 
transcription-quantitative real-time polymerase chain reaction) was planned to 
perform on some of the identified genes. Is there a gender specific effect on the 
expression of these genes? To validate this question, the RT-qPCR should be 
repeated for the same genes using RNA of embryos of the Whirligig mouse line 
having the opposite gender than the embryos analysed by the microarray.  
Depending on the dataset revealed by the genome-wide microarray analysis, further 
experiments for certain candidate genes could be performed. An option was the 
functional analysis of candidate genes in different cell lines, in the mouse model or 
other animal models, such as Xenopus laevis. If required, DNA (deoxyribonucleic 
acid) samples from CHARGE syndrome patient were available. 
Altogether, the aim of this work was to find genes which are regulated by CHD7 and 
play a role in CHARGE syndrome. Another aim was to identify further interacting 






should contribute to better understand the mechanisms behind the pathogenesis of 
CHARGE syndrome. 





2 Materials and methods 
2.1 Materials 
This section includes all material used to conduct the experiments of this work with 
further category subdivisions. 
2.1.1 Instruments 
All instruments used to perform the experiments in this work are listed in table 2. 
Table 2: Instruments 
device name company 
ABI PRISM
®
 7900HT Sequence Detection 
System 
Applied Biosystems, Darmstadt 
advanced primus 96 (PCR cycler) Peqlab, Erlangen 
autoclave Webeco, Fridolfing 
Basic pH Meter PB-11 Sartorius, Goettingen 
Synergy
TM
 Mx BioTek, Bad Friedrichshall 
camera (agarose gel documentation) Vilbert Lourmat, Eberhardzell 
centrifuges: 








confocal laser scanning microscope Olympus, Hamburg 
drying oven Memmert, Schwabach 
electrophorese chamber Owl Scientific  
film processor AGFA, Cologne 
fluorescence microscope BX60 Olympus, Munich 
FluorChem
® 
Q Alpha Innotech 
forceps HWC 110-10 Hammacher, Solingen 
freezer: 
- 20 °C 
- 80 °C 
Liebherr, Ochsenhausen 
SANYO, Munich 
haemocytometer chamber Brand, Wertheim 
heat sealer Privileg, Stuttgart 





device name company 
IKA
®






Adolf Kuehner AG 
SANYO, Munich 
Kranich 
magnetic stirrer IKA, Staufen 
micro centrifuge Roth, Karlsruhe 
Microlab Star
LET
 Hamilton, Hoechst 
micro scissors Roth, Karlsruhe 
microscope Leitz, Wetzlar 
microwave type WR800 Privileg, Stuttgart 
Multi 60 well tray lid sterile Sarstedt, Nuembrecht 
NanoDrop
TM
 8000 Thermo Scientific, Schwerte 
Novex
®
 Mini Cell (western blot chamber) Invitrogen, Karlsruhe 
pipettes: 
1000 µl, 200 µl 100 µl, 20 µl, 10 µl 
100 µl  






 Eppendorf, Hamburg 
power supply: 
Apelex PS 304 minipac II 
Power PAC 3000 
Biostep, Jahnsdorf 
BIO-RAD, Munich 







pump (Multifix Typ MC 1000 PEC) Kranich GmbH 
rocking shaker Heidolph, Schwabach 
rotating mixer Karl Hecht, Sondheim / Rhoen 
rotator SB2 Stuart, Staffordshire (UK) 






spectral photometer Eppendorf, Hamburg 
SpeedVac concentrator SVC 100H Schuett, Goettingen 





device name company 
steriliser Memmert, Schwabach 
sterile laboratory hood HERAsafe, Schwerte 
tank blot Bio-Rad, Munich 
thermomixer 5436 Eppendorf, Hamburg 
TissueLyser TL Qiagen, Hilden 
Turboblotter
TM
  Schleicher & Schuell, Dassel 
UV table ECX-F20-M PeqLab, Erlangen 
Vortex-Genie
®
 2 Scientific industries 
waterbath Koettermann, Uetze/Haenigsen 
X-ray cassette Rego  X-ray, Augsburg 
7900HT Fast Real-Time PCR-System Applied Biosystems, Darmstadt 
3500xL genetic Analyzer Applied Biosystems, Darmstadt 
2720 Thermalcycler Applied Biosystems, Darmstadt 
2.1.2 Consumable materials 
Table 3 gives an overview about the consumable materials and the manufacturing 
companies. 
Table 3: Consumable materials 
product name company 
ABgene Diamond Ultra 384 well PCR plate Thermo Scientific, Schwerte 
cell culture flasks: 
25 cm² with filter 
75 cm² with filter 






 Film (Clear blue X-Ray film) Thermo Scientific, Schwerte 




cuvette Sarstedt, Nuembrecht 
E-Cups (2 ml, 1.5 ml, 750 µl) Sarstedt, Nuembrecht 
Falcon tubes (15 ml, 50 ml) CellSTAR, Darmstadt 
 





product name company 
Filter tips (1000 µl, 200 µl, 100 µl, 20 µl, 10 µl) Kisker, Steinfurt 
Folded Filters Satorius, Goettingen 
Glass pipettes Schuett, Goettingen 
Hybond
TM
 CExtra, Nitrocellulose 0.45 µm Amersham, Freiburg 
Hybond
TM
 P, PVDF Transfer Membran 0.45 µm Amersham, Freiburg 
Micro Screwtube 1.5 ml Sarstedt, Nuembrecht 
MultiScreen
®
 Filter Plates Merck Millipore, Darmstadt 
NuPAGE
®
 4-12 % Bis-Tris Gel Invitrogen, Karlsruhe 
NuPAGE
®
 3-8 % Tris-Acetate Gel Invitrogen, Karlsruhe 
PCR-Cups Invitrogen, Karlsruhe 
Petri dish (big) 
Greiner Bio-one, 
Frickenhausen 
Petri dish (small) Thermo Scientific, Schwerte 
Pipette tips Eppendorf, Hamburg 
QPCR Adhesive Clear Seals 4titude, Berlin 
scalpel Pfm medical, Cologne 
Serological pipettes (10 ml, 5 ml, 2 ml) Sarstedt, Nuembrecht 
Serological pipettes (25 ml) 
Greiner Bio-one, 
Frickenhausen 
sterile surgical blades Braun, Tuttlingen 
Superfrost
®
 Plus (Menzel-Glaeser) Thermo Scientific, Schwerte 
Transfection tube Sarstedt, Nuembrecht 
Transfer pipettes 3.5 ml Sarstedt, Nuembrecht 
Whatman Paper Schleicher and Schuell 
6-well plate Sarstedt, Nuembrecht 
24 well plate Sarstedt, Nuembrecht 
96-well plate (qPCR) 4titude, Berlin 
96-well plate (Bradford) Thermo Scientific, Schwerte 




BD Bioscines, Erembodegem 
(Belgium) 
 






The Kits used in this work are listed in table 4.  
Table 4: Kits 
product name company 
BigDye
®
 Life Technologies, Darmstadt 
Duolink In Situ Detection Reagents Orange Olink, Uppsala (Sweden) 
Duolink In Situ PLA probe anti-Goat PLUS Olink, Uppsala (Sweden) 
Duolink In Situ PLA probe anti-Rabbit MINUS Olink, Uppsala (Sweden) 
DYEnamic ET Terminator Cycle Sequencing Kit 
(ET-Mix)             
GE Healthcare, Munich 
Immunoprecipitation Kit (Protein G) Roche, Penzberg 
In-Fusion
TM
 Advantage PCR Cloning Kit Clontech, Heidelberg 
Mini Plasmid Kit Qiagen, Hilden 
mMESSAGE mMACHINE
®
 SP6 Transcription 
Kit 
Life Technologies, Darmstadt 
mMESSAGE mMACHINE
®
 T7 Transcription 
Kit 
Life Technologies, Darmstadt 
MSB
®
 Spin PCRapace Invitek, Berlin 
NE-PER Nuclear and Cytoplasmic Extraction 
Reagents 
Thermo Scientific, Schwerte 
Novocastra
TM










  HiPure Plasmid (Midiprep Kit) Invitrogen, Karlsruhe 
QIAquick Gel Extraction Kit Qiagen, Hilden 
RNAspin Mini GE Healthcare, Munich 
RNeasy
®
 mini Kit (250) Qiagen, Hilden 
SuperSignal
TM
 West Pico Chemiluminescent 
Substrate 
Thermo Scientific, Schwerte 
Xfect
TM
 Clontech, Heidelberg 
2.1.4 Ready to use buffers and mediums 
Table 5 includes buffers and mediums which were ready to use as well as the 
companies selling these products.  





Table 5: Ready to use buffers and mediums 
product name company 
Aqua-Poly/Mount Coverslipping Medium Polysciences, Eppelheim 
BSA (100 x) BioLabs, Frankfurt am Main 
Developer G153 A+B AGFA, Cologne 
3,3'-Diaminobenzidine (DAB) Roche, Penzberg 
Direct lysis buffer Peqlab, Erlangen 
Dulbecco’s Modified Eagle Medium (DMEM) PAN Biotech, Nuremberg 
Dulbecco's Phosphate-Buffered Saline (DPBS) PAN Biotech, Nuremberg 
Fetal bovine serum PAN Biotech, Nuremberg 
MEM NEAA 




 LDS Sample Buffer (4 x)                            Invitrogen, Karlsruhe 
NuPAGE
®
 MES SDS Running Buffer (20 x)                   Invitrogen, Karlsruhe 
NuPAGE
®
 MOPS SDS Running Buffer (20 x)                Invitrogen, Karlsruhe 
NuPAGE
®
 Tris-Acetate SDS Running Buffer (20 x)       Invitrogen, Karlsruhe 
NuPAGE
® 
Transfer Buffer (20 x)                                     Invitrogen, Karlsruhe 
OPTI-MEM
®
 I + GlutaMax
 
- I Invitrogen, Karlsruhe 
P1   Resuspension buffer                                                    Qiagen, Hilden 
P2   Lysis Puffer                                                                   Qiagen, Hilden 
P3   Neutralisation buffer                                                   Qiagen, Hilden 
Rapidfixer AGFA, Cologne 
S.O.C. Medium                                                                     Invitrogen, Karlsruhe 
TE-Buffer Invitrogen, Karlsruhe 
TrypLE
TM
 Express Invitrogen, Karlsruhe 
2.1.5 Chemicals 
In table 6 all chemicals which were used for the experiments in this work and the 
corresponding companies selling these products are listed. 





Table 6: Chemicals 
product name company 
Acetic acid Merck, Darmstadt 
Acetic Anhydrite Sigma, Hamburg 
Acetone Merck, Darmstadt 
Agar-Agar, Kobe I Roth, Karlsruhe 
Agarose Bio-Budget, Krefeld 
Albumin Fraction V (bovine serum albumin (BSA)) Roth, Karlsruhe 
Ampicillin Roth, Karlsruhe 
Ampuwa  Fresenius, Bad Homburg 
Aprotinin Sigma-Aldrich, Deisenhofen 
β-Mercaptoethanol Sigma-Aldrich, Deisenhofen 
Boehringer Mannheim Blocking Reagent (BMB) Roche, Penzberg 
5-Brom-4-chlor-3-indolylphosphate (BCIP)  Roche, Penzberg 
Bromphenolblue Roth, Karlsruhe 
Calcium chloride (CaCl2) Roth, Karlsruhe 
3-[(3-Cholamidopropyl)dimethylammonio]-1- 
 propanesulfonate (CHAPS) 
Sigma-Aldrich, Deisenhofen 
Chloroform J.T. Baker, Griesheim 
Coomassie
® 
Brilliant Blue R250 Powder 
SERVA Electrophoresis, 
Heidelberg 
Desoxy-Nucleotid-Triphosphate (dNTPs) (100 
mM) 
Invitrogen, Karlsruhe 
Diethylpyrocarbonat (DEPC) Roth, Karlsruhe 
Dimethyl sulfoxid (DMSO) Merck, Darmstadt 
Disodium phosphate (Na2HPO4) Roth, Karlsruhe 
1,4-Dithiothreitol (DTT) Invitrogen, Karlsruhe 
DO Supplement (-Ade/-His/-Leu/-Trp) Clontech, Heidelberg 
Ethanol J.T. Baker, Griesheim 
Ethidium bromide AppliChem, Darmstadt 
Ethylene diamine tetraacetic acid (EDTA) AppliChem, Darmstadt 
Ethylene glycol tetraacetic acid (EGTA) AppliChem, Darmstadt 





product name company 
Ficoll 400 Sigma-Aldrich, Deisenhofen 
FITC Phalloidin Sigma-Aldrich, Deisenhofen 
Formaldehyde Invitrogen, Karlsruhe 
Formamid Roth, Karlsruhe 
Glycerol Roth, Karlsruhe 
Glycin Roth, Karlsruhe 
G-Protein Roche, Penzberg 
Guanidin hydrochloride Serva, Heidelberg 
Heparin Roth, Karlsruhe 
Hepes AppliChem, Darmstadt 
Hydrochloric acid (HCl) Merck, Darmstadt 




Isopropanol J.T. Baker, Griesheim 
Leupeptin Sigma, Hamburg 
Lipofectamine 2000 Reagent Invitrogen, Karlsruhe 
Magnesium chloride (MgCl2) Bioline, Luckenwalde 
Magnesium sulphate (MgSO4) Roth, Karlsruhe 
Maleic acid AppliChem, Darmstadt 
Methanol Roth, Karlsruhe 
Milkpowder Roth, Karlsruhe 
Monosodium phosphate (NaH2PO4) Roth, Karlsruhe 
Nitro blue tetrazolium (NBT) Roche, Penzberg 
Mineral oil Sigma, Hamburg 
Nitrogen (liquid) Air Liquide, Kornwestheim 
Paraffin Roth, Karlsruhe 
Paraformaldehyde Roth, Karlsruhe 
Pepstatin Sigma, Hamburg 
 





product name company 
Peptone  Roth, Karlsruhe 
Phenol Biomol, Hamburg 
Phenylmethanesulfonylfluoride (PMSF) Sigma, Hamburg 
Polyvinylpyrollidone Sigma, Hamburg 
Ponceau S Sigma, Hamburg 
Potassium chloride (KCl) Roth, Karlsruhe 
Potassium ferricyanide (K3Fe(CN)6) Sigma, Hamburg 
Potassium ferrocyanide (K4Fe(CN)6) Sigma, Hamburg 
Potassium nitrate (KNO3) Merck, Darmstadt, 
Proteinase K Roche, Penzberg 
Roti-Nanoquant Roth, Karlsruhe 
Roti Safe Roth, Karlsruhe 
Salmon sperm DNA Sigma, Hamburg 
Sodium azide Roth, Karlsruhe 
Sodium bicarbonate (NaHCO3) Roth, Karlsruhe 
Sodium chloride (NaCl) AppliChem, Darmstadt 
Sodium citrate Roth, Karlsruhe 
Sodium dodecyl sulfate (SDS) Serva, Heidelberg 
Sodium hydroxide solution (NaOH) Merck, Darmstadt 
Torula RNA Sigma, Hamburg 
Triethanolamine Roth, Karlsruhe 
Tris(hydroxymethyl)-aminomethan (TRIS) AppliChem, Darmstadt 
Triton-X-100 Serva, Heidelberg 
TRIZOL
 
Reagent Invitrogen, Karlsruhe 
Tween 20 AppliChem, Darmstadt 
Vectashield with 4′,6-Diamidin-2-phenylindol 
(DAPI) 
Vector, Burlingame (USA) 
Yeast extract Roth, Karlsruhe 
X-Gal Biomol, Hamburg 
 





2.1.6 Buffers and solutions 
The following tables show how to prepare the buffers needed for different 
experiments. 
Table 7: Agarose gel electrophorese 
Buffer/solution Ingredients  
Loading Buffer (50 ml) 50 % (v/v) 
0.1 M 
0.02 % (w/v) 
0.02 % (w/v) 
0.02 % (w/v) 




Bromphenol Blue  
SDS 
 
1 x TAE  40 mM 
2 mM 
Tris-Acetate (pH 8.5) 
0.5 M  EDTA  
5 x TBE 450 mM  
450 mM  
20 mM  









Table 8: Co-immunoprecipitation (Co-IP) 
Buffer/solution Ingredients  








ad 25 ml ddH2O 
250 mM Tris-HCl (pH 7.5) 
1 M NaCl 
Detergent mix (10 mM 
Tris-HCl, 10 % Nonidet 
P40, 5 % sodiumdeoxy-
cholate) 
Protease inhibitor cocktail 
tablet 






ad 50 ml ddH2O 
250 mM Tris-HCl (pH 7.5) 
1 M NaCl 
Detergent mix (10 mM 
Tris-HCl, 10 % Nonidet 
P40, 5 % sodiumdeoxy-
cholate) 





ad 25 ml ddH2O 
250 mM Tris-HCl (pH 7.5) 
Detergent mix (10 mM 
Tris-HCl, 10 % Nonidet 
P40, 5 % sodiumdeoxy-
cholate) 
 
Table 9: DAB staining 
Buffer/solution Ingredients  







adjust pH to 6.2 
500 µl 










Table 10: Duolink 
Buffer/solution Ingredients  








ad 0.8 L ddH2O 
adjust pH to 7.4 
ad 1 L ddH2O 











ad 0.5 L ddH2O 
adjust pH to 7.5 
ad 1 L ddH2O 




Table 11: Polymerase chain reaction (PCR) 













Table 12: RNA isolation 
Buffer/solution Ingredients  
DEPC 1 ml 
ad 1 L ddH2O 
Diethylpyrocarbonate 









Table 13: Western blots 
Buffer/solution Ingredients  
Antibody Diluent 2 % 
in TBST 
BSA or milkpouder 
 
Blocking Buffer 5 % 
in TBST 
BSA or milkpouder 
Stripping Buffer (1 L, pH 









TBST (1 L) 10 ml 
9 g 
1 ml 
ad 1 L ddH2O 









ad 100 ml ddH2O 








0.1 %  
20 % 





Wash Buffer 2 % 
in TBST 
milkpouder 





Table 14: Whole mount in situ hybridisation 
Buffer/solution Ingredients  




adjust pH 9 
ad 100 ml ddH2O 
Tris (1 M) 
MgCl2 (1 M) 
NaCl (5 M)  
Tween 20 (20 %) 
Boehringer Mannheim 
Blocking Reagent (BMB) 
10 %  
ad MAB 
BMB 
Denhardts (100 x) 1 g  
1 g  
1 g  












ad 500 ml ddH2O 
Formamide 
SSC (20 x) 
Torula RNA (10 mg/ml) 
Heparin 
Denhardts (100 x) 
Tween 20 
CHAPS 
EDTA (2 M) 
MAB (5 x) 100 mM 
150 mM 













Buffer/solution Ingredients  






















PBS (10 x) 3.5 M 
37 mM 
150 mM 








ad 100 ml ddH2O 
Tris-Cl (1 M, pH 9.5) 
MgCl2 (1 M) 
NaCl (5 M) 
Tween 20 
 




SSC (20 x) 0.3 M 
3 M 
adjust pH 7 
Sodium citrate 
NaCl 






ad 10 ml PBS (1 x) 
X-Gal (40 mg/ml) 
K3Fe(CN)6 
K4Fe(CN)6 
MgCl2 (1 M) 





Table 15: Yeast two-hybrid 
Buffer/solution Ingredients  
Glucose (40 %) 200 g  
ad 500 ml ddH2O 
autoclave and filtrate 
Glucose 
PEG (50 %) 50 g  
ad 100 ml ddH2O 
autoclave 
PEG 4000 
LiAc (10 x) 6.598 g  
ad 100 ml ddH2O 
autoclave 
LiAc 
TE (10 x) 10 ml  
2 ml 
ad 100 ml ddH2O 
autoclave 
1 M Tris-HCl (pH 7.4 - 8) 
0.5 M EDTA (pH 8) 
2.1.7 Media and plates  
In table 16 the instructions for the preparation of media and plates for culturing 
bacteria, yeast and other cells are given. 
Table 16: Media and plates 
Charge /solution Ingredients  





















   





Charge /solution Ingredients  
LB plates 




15 g  











ad 475 ml ddH2O 
adjust pH 5.8 







 autoclave at 120 °C for 15 minutes  




40 % Glucose (autoclaved, 
filtrated) 
Streptomycin (100 mg/ml) 
Kanamycin (50 mg/ml) 





ad 475 ml ddH2O 
adjust pH 5.8 







 autoclave at 120 °C for 15 minutes  






40 % Glucose (autoclaved, 
filtrated) 
Streptomycin (100 mg/ml) 
Kanamycin (50 mg/ml) 
Adenine (20 mg/ml) 
Histidine (10 mg/ml) 





Charge /solution Ingredients Charge /solution 





ad 475 ml ddH2O 
adjust pH 5.8 







 autoclave at 120 °C for 15 minutes  





40 % Glucose (autoclaved, 
filtrated) 
Streptomycin (100 mg/ml) 
Kanamycin (50 mg/ml) 
Aureobasidin 
2.1.8 Sterilisation 
If not indicated differently, sterilisation of solutions and buffers was performed for 
20 minutes in the vapour pressure autoclave (Webeco) at 120 °C at 10
5
 Pa. Heat 
sensitive solutions were sterile filtrated using filtration units of 0.2-0.45 µm pore 
size. Objects of utility were either autoclaved or heat sterilised for 8-12 hours at 
180 °C. 
2.1.9 Antibiotics 
Ampicillin (50 mg/ml)  AppliChem, Darmstadt  
Aureobasidin A  Clontech, Heidelberg  
Kanamycin   Roth, Karlsruhe  
Penicillin/Streptomycin (100 x)  PAN Biotech, Nuremberg  
Streptomycin (100 mg/ml)  ns  
2.1.10 Antibodies 
All antibodies used in this work are listed in the tables below. Table 17 shows the 
primary antibodies and table 18 the secondary antibodies. 
 





Table 17: Primary antibodies 
antibody origin dilution company 
Anti-HA tag rat monoclonal 1:1,000 Roche, Penzberg 
ASH2L rabbit polyclonal 1:100/1:1,000 Abcam, Cambridge (UK) 
CHD7 goat polyclonal 1:100/1: 7,500 Abcam, Cambridge (UK) 
CHD8 rabbit polyclonal 1:100/1:8,500 Abcam, Cambridge (UK) 
HSC-70 mouse monoclonal 1:10,000 Santa Cruz, Heidelberg 
RBBP5 rabbit polyclonal 1:100/1:1,000 Abcam, Cambridge (UK) 
SEMA3D rabbit polyclonal 1:100 Santa Cruz, Heidelberg 
WDR5 rabbit polyclonal 1:100/1:1,000 Abcam, Cambridge (UK) 
Table 18: Secondary antibodies 
antibody origin dilution company 
Anti-goat IgG-H&L (Cy3) donkey polyclonal 1:200 
Abcam, 
Cambridge (UK) 
Anti-rabbit IgG (whole 
molecule), F(ab′)2 
fragment–Cy3 
sheep polyclonal 1:200 
Sigma, 
Deisenhofen 










goat polyclonal 1:10,0000 
Dianova, 
Hamburg 





The sequence of the Morpholinos used for injections to knockdown gene expression 
in Xenopus laevis are listed in table 19. 
Table 19: Morpholinos 
name purpose sequence 
Sema3a blocking of mRNA ATGCAATCCAGGTCAGAGAGCCCAT 
Sema3d blocking of mRNA GACATTTTTGATGCTTCTCTTTCAT 






The oligonucleotides were purchased from Eurofins Genomics. In table 20 the 
sequences of the oligonucleotides and their purpose of use are given. 
Table 20: Oligonucleotides 
name purpose sequence 
ASH2LhY2HF Y2H construct 
CCAGATTACGCTCATATGCGCGCGAGAG
AAGAGAGTATT 
ASH2LhY2HR Y2H construct 
GGCCTCCATGGCCATATGTTCCCAGAAA
GTCCTTGACAGA 
ASH2L_InFusion_1Rneu Y2H construct 
GGCCTCCATGGCCATATGGCATCTTTGG
GAGAACATTTGA 
ASH2L_InFusion_2Rneu Y2H construct 
GGCCTCCATGGCCATATGCGGTTGTTGG
CTTATGGTACAC 
DelSema3a1F patient screen TGGGCTGGTTAACTAGGATTGTCTGT 
DelSema3a1R patient screen GTTGGGAGGGAGTTCAAGGAATTAAG 
DelSema3a2F patient screen CAATGTTTTGCTTTGTTACCTTGCAG 
DelSema3a2R patient screen ACATACAGCCTACTCCGTTCCTCATC 
DelSema3a3F patient screen CTTTCTTTACTTCAGTTGCCCCAATG 
DelSema3a3R patient screen TCTTCTGGTGTAAGATACTGGCCACA 
DelSema3a4F patient screen CAGTCATGCTGATTGCTGAAACTCTT 
DelSema3a4R patient screen GTTCCACAGGCGTACAAGTGAGTCT 
DelSema3a5F patient screen CCACAGGACAATATTTTTAAGCTGGAG 
DelSema3a5R patient screen GCACCTATTAAAAGGGATGCTGTCA 
DelSema3a6F patient screen GACTTTGCTATCTTCCGAACTCTTGG 
DelSema3a6R patient screen CATCATGAAGTCACCACCATTAGCTT 
DelSema3a7F patient screen AAGTTCATTAGTGCCCACCTCATCTC 
DelSema3a7R patient screen AGCGTGAGTAGCTTTTCCAGAGTGTT 
DelSema3a8F patient screen TCCCTTCTTTCAGAATGACTTTGGAG 
DelSema3a8R patient screen ACGCAGTTCATCAAAATGAGTGTCA 
DelSema3a9F patient screen TGTTCAGACTTTGCCATTCCATAAAA 
DelSema3a9R patient screen CCAAGAGTACACAACAGCTCAAAGGTT 
DelSema3a10F patient screen AGGGATCAGCCGTGTGTATGTATAGC 
DelSema3a10R patient screen CTTCCTTGATAAGGCACCCATTGATA 
DelSema3a11F patient screen GAAGTCATCCAGCCATGTACAATCC 





name purpose sequence 
DelSema3a11R patient screen CATCATACTGTCCATCTTCTGCATCC 
DelSema3a12F patient screen TAACTTGTGGTCTTCTCCCCACTTTC 
DelSema3a12R patient screen AAACTGTCATTTCTTCCAGCAGAACC 
DelSema3a13F patient screen TGTGTCTTATTTCCCAGTCACATTGC 
DelSema3a13R patient screen AAAGCTCCATTGCTGAAATAGCAGTC 
DelSema3a14F patient screen TGTCACAGCAGTAAACTCTTTCCACAG 
DelSema3a14R patient screen TCCTACCTCTTTGCAGTGGGAAAATA 
DelSema3a15F patient screen TTCAGACGCACAAGACGACAAGATA 
DelSema3a15R patient screen TTAGCCTGGTCTTAGCAGGTTGAAAG 
DelSema3a16F patient screen AGCCCTGAAGAGAGAATCATCTATGG 
DelSema3a16R patient screen TCCTGTACCTCTTCTTTTCGCTCTTC 
DelSema3a17F patient screen CTGGAAGTCATTGACACAGAGCATTT 
DelSema3a17R patient screen GAACTCATCCATTGTGTTGAGATTGG 
Del_SEMA3A_1Fn patient screen GACTAAAGCAGCAAAGGGACCTACAG 
Del_SEMA3A_1Rn patient screen GTAGGATAATTTCAGCCTTGGCACAT 
Del_SEMA3A_9Fn patient screen TGTTCAGACTTTGCCATTCCAT 
Del_SEMA3A_9Rn patient screen CAGCTCAAAGGTTAAAGCAACACTT 
Del_SEMA3A_12Fn patient screen TTCAAAGATGTTGGGACCGTTCTTA 
Del_SEMA3A_12Rn patient screen ACTTGTCCATACCAAGTTCAGTGTGC 
DelSema3d1F patient screen CTAAGCATGACCATGTTGTTTCTTCC 
DelSema3d1R patient screen CTGATGCCAAAACATTTCACAGAAG 
DelSema3d2F patient screen GGGTTCATCAGAAGGACTGGATTTT 
DelSema3d2R patient screen ACAAAACGGGAGAAGAAGAGAGATGA 
DelSema3d3F patient screen ATTCACTCTCTGAGCAGAATTGCAGA 
DelSema3d3R patient screen ACTTACATTGGCATCTTTCCCAGCTA 
DelSema3d4F patient screen TGATCTACTTGGAAAACAGGTGGCATA 
DelSema3d4R patient screen CATATTGGATGAAATGCTCCAGTTCC 
DelSema3d5F patient screen AGACTGAAATGTCCTTTCGATCCTCA 
DelSema3d5R patient screen CAATAGGAAAATGCGGTTCAGTCAA 
DelSema3d6F patient screen CATCTTTGGTGTCATGCTGTGAAAT 
DelSema3d6R patient screen TCTGATGTAGTGGTGGTCATGAGTAGG 
DelSema3d7F patient screen TTGGAACTTTCTTCATACCAGACACCT 
DelSema3d7R patient screen CAAACTCTTCCAACTCGAGAAAGGAT 





name purpose sequence 
DelSema3d8F patient screen TGGAAGTGATGGGGCAGATACTTACT 
DelSema3d8R patient screen CCGTGTACTTTGCGTGTGAATTTTAG 
DelSema3d9F patient screen ACTCCCCACAAGAGATGAAAGAAATC 
DelSema3d9R patient screen ATATGCTACTACAAACGCAGGGACAA 
DelSema3d10F patient screen ATCTTCAAAGGCTCTGCTGTTTGTGT 
DelSema3d10R patient screen CGTGGATAAGGAATTCTCCCATCATA 
DelSema3d11F patient screen ATCAGTTTCATAAAGCGGCACTCTGT 
DelSema3d11R patient screen CATTACATCGTACTGGCCATCTTCTG 
DelSema3d12F patient screen AAGAGAAGTGAGGGGAATGATTTGC 
DelSema3d12R patient screen ACTCCTCCAGCACTACCTCTTCCATA 
DelSema3d13F patient screen CTTGAACATGGAATTGTCTCTGAAGC 
DelSema3d13R patient screen GCAAGGCTGAAACAATGGTCTCTAAT 
DelSema3d14F patient screen ATTGTACATTGGTTCCCGAGATGGAT 
DelSema3d14R patient screen AGTAGGGGTCTCTGGCAAGACAACAG 
DelSema3d15F patient screen GGAGAGCTAGACGCCAAGATGTAAAA 
DelSema3d15R patient screen AATTTCCTGTTGCTCTTCCAGAACAC 
DelSema3d16F patient screen GCTTTCCAGGCATTAGTCATGAAACT 
DelSema3d16R patient screen ATGACAACAGCTTACCTCCTCTCGAT 
DelSema3d17F patient screen CAAAACGGAATATGGGCTACTGATTC 
DelSema3d17R patient screen TATCTCAACCGTGACTCAGCCAATAG 
Del_SEMA3D_1Fn patient screen GACTTAAAGCCAGAAGCCAAGATTTTC 
Del_SEMA3D_1Rn patient screen CCTTTGTAGGTTAGCTTGAGTCTTGGA 
hCHD7_F1 Y2H construct 
GAGGACCTGCATATGAAGATGGCAGATC
CAGGAATGA 
EphA3mF1 RT-qPCR AAAGAGGAGGACCCTCCCAGGATGTA 
EphA3mR1 RT-qPCR ATCGGAAGCCTTGTAGAAGCCTGGTC 
Gfra2mF1 RT-qPCR AAACCATCCTGCCCAGCTGTTCCTAT 
Gfra2mR1 RT-qPCR ATTGTCCGGTAGGAGGCTCGACAGTT 
hCHD7_R1 Y2H construct 
CTCCATGGCCATATGCCTTCTGCATCAAC
AGATTCCT 
hCHD7_F2 Y2H construct 
AATTCCCGGGGATCCCACCATCTCCTCCT
CCTGAAGAAG 
hCHD7_R2 Y2H construct 
CAGGTCGACGGATCCCACTGTAGAGCCT
GGTCTGCTT 
hCHD7_F3 Y2H construct 
GAGGACCTGCATATGAAGTGGGCTAAGA
AGGCTGAAT 
hCHD7_R3 Y2H construct 
CTCCATGGCCATATGTGTCCTCACTCCCA
CTAATGCT 





name purpose sequence 
hCHD7_F4 Y2H construct 
GAGGACCTGCATATGGAAGCAGTGTTGA
AAGGCAAAT 




















































SEMA3A1F Sequencing TCACCTGTTACCTCCAGTTTCC 
SEMA3A1R Sequencing GGTTTGATGATTTGGGGTTG 
SEMA3A2F Sequencing TCAGGTTACCATGTACCAACAGTC 
SEMA3A2R Sequencing TGCATCCATTGATTCATTACTGTC 
SEMA3A3F Sequencing ACTTCAGTTGCCCCAATGTC 
SEMA3A3R Sequencing CACATGACCCACAAGTGGAA 
SEMA3A4F Sequencing CAGTCATGCTGATTGCTGAAA 
SEMA3A4R Sequencing TGAACCACAAGCAAAATAAACTG 
SEMA3A5F Sequencing TCTCTGATTAACTGATGTGTTGAAA 
SEMA3A5R Sequencing TTATTTCATAATGGAAAATCTTGGT 
SEMA3A6F Sequencing CATGGTCATAACATGAAACTTGC 
SEMA3A6R Sequencing CCATCATGAAGTCACCACCA 
SEMA3A7F Sequencing TGGACTGTTCAGAATGGTATTATTT 
SEMA3A7R Sequencing CCTGTACCTGTATATTTGACTGCG 
SEMA3A8/9F Sequencing GGAACGATTCGACCACAAAT 
SEMA3A8/9R Sequencing TGCAAATTATGAGTACTTGGATAGC 
SEMA3A10F Sequencing GCCATTTTCACCTATGCCTT 
SEMA3A10R Sequencing TCTGTCTGTAGCTGCATTGTTTT 





name purpose sequence 
SEMA3A11F Sequencing GAACCATTGAGGCCATGTGT 
SEMA3A11R Sequencing CCAACCCCTGAGATGTTCAA 
SEMA3A12F Sequencing AAAAGGAAGACCGATATCAAAGG 
SEMA3A12R Sequencing TGAGAAAACAAAATATGAGCCAAA 
SEMA3A13F Sequencing AGCAATAACCCCAACTTGGTC 
SEMA3A13R Sequencing ATCAAAAACATGAGGGCAATG 
SEMA3A14F Sequencing AGAAGGCCTTTAAAGAAATTAGCA 
SEMA3A14R Sequencing TTGATGCACTTATTTGAAGAAAGC 
SEMA3A15F Sequencing TCTGGTAGTGAAAAAGCCATGA 
SEMA3A15R Sequencing TCTCTTCGGCTGCATTTCTT 
SEMA3A16F Sequencing TGGCAATAACTTGTCTCCTGAA 
SEMA3A16R Sequencing TGAATGAGCGATTGATTGGT 
SEMA3A17F Sequencing ACAGACACGGAGTTTCAGAGC 
SEMA3A17R1 Sequencing AGATTGGGGTGGTTGATGAG 
SEMA3A17R2 Sequencing CCCACCATTGTAAACATCCA 
SEMA3D1F Sequencing AACACCATTTGAAAGAGAACATTG 
SEMA3D1R Sequencing AATGAGTAATTGGGCTTCGTGT 
SEMA3D2F Sequencing TTGGCCCTTTTATGCTGTATG 
SEMA3D2R Sequencing CCAGAATGTGTATCAGAGGCAAT 
SEMA3D3F Sequencing TCTGAGCAGAATTGCAGAGTG 
SEMA3D3R Sequencing CCATTAATTCAGTAAAGCCCAAT 
SEMA3D4F Sequencing ATTTGTCTTGCCTCGTTTGC 
SEMA3D4R Sequencing TCAAATCTGCCTGTTTTATGTCA 
SEMA3D5F Sequencing GGAATTTAGTTTGTATCTCCCACA 
SEMA3D5R Sequencing AATAATGGAAACAAATCGCTTG 
SEMA3D6F Sequencing GGTGTCATGCTGTGAAATTTGT 
SEMA3D6R Sequencing TTAAACCAAAGCAAGACAATCAAA 
SEMA3D7F Sequencing CCCACATCTGGCTTATAGTTCA 
SEMA3D7R Sequencing AGCATTAACTTTGGCTTAAACCTT 
SEMA3D8Fa Sequencing TGATGGTAGTGGTGCGTGTATT 
SEMA3D8Ra Sequencing TGCATTGTTCAAATCATTTATGC 
SEMA3D8Fb Sequencing AGACACTACCTGTAATAGCCACCA 
SEMA3D8Rb Sequencing TGGAGCCAAAGGGAAATAAA 
i 





name purpose sequence 
SEMA3D9F Sequencing GCATAATATAGTGCCTCTGTTAATCG 
SEMA3D9R Sequencing CTACTACAAACGCAGGGACAAA 
SEMA3D10F Sequencing TGAATGATTGAATGATGATGCT 
SEMA3D10R Sequencing GTGGCTCTGGTGAATAGCAG 
SEMA3D11F Sequencing TTCCATATTGACTCTGTTGTCCA 
SEMA3D11R Sequencing TTTTAAGAAATGCTGACAAGGTTTT 
SEMA3D12F Sequencing GAGAAGTGAGGGGAATGATTTG 
SEMA3D12R Sequencing AAACAAGGGTGCCCTATAACAA 
SEMA3D13F Sequencing TTTACTTCAGTGATATATGGCATCAG 
SEMA3D13R Sequencing TTTAACTCCCAATTTCAATGGAT 
SEMA3D14F Sequencing GTCTGAAAGATGCTTCTAATTCATTT 
SEMA3D14R Sequencing TTCCTTCCATAGGACATGTTAGTAAT 
SEMA3D15F Sequencing CATAGTACTGCATCTGCCACTGT 
SEMA3D15R Sequencing CCAGAACACATGCATTACACAA 
SEMA3D16F Sequencing TGGCATCTGTTCTGAATCAGTC 
SEMA3D16R Sequencing TCAATCGTACACTATTTCCCTCAA 
SEMA3D17F1 Sequencing CATTTGCTCTTAGCTCTCTCTGTG 
SEMA3D17R1 Sequencing TCATCCAGGTCTCTGTGATGTC 
SEMA3D17F2 Sequencing AAATCCTTAGCAGCCCAAACTT 
SEMA3D17R2 Sequencing ACTCCATGGGAAGCATTTATGA 
SeqhASH2L1F Sequencing GGTCGCAAATGCAACAGG 
SeqhASH2L1R Sequencing GCTTACATCGACCAAGTTTGC 
SeqhASH2L2F Sequencing ACAGGGACCACCAAGAAGG 
SeqhASH2L2R Sequencing CCATCTTTGTTAAACGGGTGTT 
SeqhASH2L3F Sequencing CCATTAACTTTGGACCATGCTT 
SeqhASH2L3R Sequencing ATGTCACTCATAGGGCGGTAAG 
SeqCHD71.1R Sequencing ACTGTCTGGCTCCGAGAACTAA 
SeqCHD71.2F Sequencing GCCTCAATCAGGGAAATCCT 
SeqCHD71.2R Sequencing CAGGTATCAGTCGTTCCTGGAT 
SeqCHD71.3F Sequencing ATCCTCAGCCATCTCACCAG 
SeqCHD71.4F Sequencing TAGCAGAGGATCCCAGTAAAGG 
SeqCHD72.1R Sequencing CTGGAGACTCTGCATTGTGTGT 
SeqCHD72.2F Sequencing GGTGGTCAAGCTAACGTACCTAAC 
i 





name purpose sequence 
SeqCHD73.1R Sequencing CTCTCACTGTGCTTACCTGTGG 
SeqCHD73.2F Sequencing GAACAGACATGCTAGCAGATGG 
SeqCHD73.2R Sequencing GGATAACTCAGGGTCATTGAGG 
SeqCHD74.1R Sequencing GGCCTTCTTCCTCTTCTGCT 
SeqCHD74.2F Sequencing CAATGAAGGATCTACCCAGGTG 
seqCHD7_1vectR Sequencing GCTGACCCATAGGATTTACTGG 
seqCHD7_2vectR Sequencing TCCAACTGGTATTCCCTGAGTT 
seqCHD7_3vectR Sequencing GATGGTTCTGCAGATGGTTTCT 
seqCHD7_4vectR Sequencing CCTCTCTTGAGGCCTTTGATAA 
SeqCHD7F1new Sequencing ATGGCAGATCCAGGAATGAT 
SeqCHD7F2new Sequencing AGATCAAGCAAAGATCGAGGAG 
SeqCHD7F3new Sequencing AACCTCACTGCTGCTGATACCT 
SeqCHD7F4new Sequencing AATGTTTCAGGGTGGAGAAGAA 
SeqCHD7F5new Sequencing CTTGGATCTGCCAGAGTGGT 
SeqCHD7F6new Sequencing CAAGAGGCGAAATCTCATGG 
SeqCHD7F7new Sequencing CTAGTCAAGGAGAACCGGAAGA 
seqRbBP5h.F4 Sequencing GACCCTATTGCTGCCTTCTGTA 
SeqxSema3a1F Sequencing CTGACCTGGATTGCATTTCTTT 
SeqxSema3a1R Sequencing TTGTAGGACAATCTGAGCCTTG 
SeqxSema3a2F Sequencing GGTGGCCACAGAAGCTTAGTTA 
SeqxSema3a2R Sequencing ACATTCTGACAGTTGAGCCTTG 
SeqxSema3a3F Sequencing AGCTGAGGATGGTCAATACGAT 
SeqxSema3a3R Sequencing TGTATCAATGCCATTAGGACCA 
SeqxSema3a4F Sequencing AATGTCCAGGTTAGCAACACAA 
SeqxSema3a4R Sequencing CTCAAATTCATGGGTCCTCCTA 
seqSEMA3A_F3new Sequencing AGACGCACAAGACGACAAGATA 
seqSEMA3A_R3new Sequencing ATTCTCTCTTCAGGGCTGTGG 
SeqSema3d_1F Sequencing TTAAACCGCAGCATTCCTCTAC 
SeqSema3d_1R Sequencing CCGAGGAATATTCTGTTTCAGG 
SeqSema3d_2F Sequencing TGTTCAATTCCTGGACAAGATG 
SeqSema3d_2R Sequencing GGATTTCTTTCGTCCTTTGTTG 
SeqSema3d_3F Sequencing CAATCAGGTGGTTTATTCAGCA 
SeqSema3d_3R Sequencing GAATCAGAAGCCCGTAGTCTGT 
i 





name purpose sequence 
Sema3AmF1 RT-qPCR CGGGACTTCGCTATCTTCAGAACACT 
Sema3AmR1 RT-qPCR TCATCTTCAGGGTTGTCACTCTCTGG 
Sema3DmF1 RT-qPCR TTACGTGTGTGGAACTGGAGCGTTTC 
Sema3DmR1 RT-qPCR AGGCTGCTGAGGATCAAAGGGACAT 
SOX10mF1 RT-qPCR GCTCAGCAAGACACTAGGCAAGCTCT 
SOX10mR1 RT-qPCR CGAGGTTGGTACTTGTAGTCCGGATG 
SRY_F gender PCR AGCCTGTTGATATCCCCACTG 
SRY_R gender PCR ATGCTCACCAGTGTGTCAGC 
Trp53bp2mF1 RT-qPCR CCCAGTTGCTGATAACGAACGGATGT 
Trp53bp2mR1 RT-qPCR TCGGTCCACTCACAATGTCCCTGTTA 
WDR5hY2HF Y2H construct 
CCAGATTACGCTCATATGTCCACCCTTGT
CTCCTGTGC 
WDR5hY2HR Y2H construct 
GGCCTCCATGGCCATATGGGTCAACTTC
CCGACAGTCTCT 
2.1.13 DNA marker 
100 bp DNA ladder Invitrogen, Karlsruhe 
1 kb DNA ladder Invitrogen, Karlsruhe 
1 kb DNA ladder BioLabs, Frankfurt am Main 
2.1.14 Protein marker 
See Blue Plus 2 Pre-stained Standard Invitrogen, Karlsruhe 
Hi Mark Pre-Stained  Invitrogen, Karlsruhe 
2.1.15 Vectors 
pBluescript SK (-) Agilent Technologies, 
Boeblingen 
pcDNA3.1 (+) Flag-6xHis Invitrogen, Karlsruhe 
pCMV-HA Clontech, Heidelberg 
pCMV-Myc Clontech, Heidelberg 
pCS2+MT ns 
pGADT7 Clontech, Heidelberg 
pGBKT7 Clontech, Heidelberg 
pGEM-T Easy Promega, Mannheim 






Antarctisc Phosphortase BioLabs, Frankfurt am Main 
DNase I (1 U/µl) Thermo Scientific, Schwerte 
Proteinase K Roth, Karlsruhe 
SuperScript
®
 II Invitrogen, Karlsruhe 
T4 Ligase BioLabs, Frankfurt am Main 
2.1.17 Polymerases (Kits) 
IMMOLASE
TM 
DNA Polymerase Bioline, Luckenwalde 
In-Fusion
TM
 Advantage PCR Cloning Kit  Clontech, Heidelberg 
peqGOLD Pwo-DNA-Polymerase Peqlab, Erlangen 
PfuUltra
TM
 Hi-Fidelity DNA polymerase Stratagene, La Jolla (USA) 
Platinum
®
 Taq DNA Polymerase Invitrogen, Karlsruhe 
2.1.18 Restriction enzymes and Buffers 
BamHI Invitrogen, Karlsruhe 
EcoRI Invitrogen, Karlsruhe 
MscI BioLabs, Frankfurt am Main 
NdeI BioLabs, Frankfurt am Main 
NruI BioLabs, Frankfurt am Main 
SfiI BioLabs, Frankfurt am Main 
XhoI Invitrogen, Karlsruhe 
H Buffer Invitrogen, Karlsruhe 
NEBuffer 2 Invitrogen, Karlsruhe 
NEBuffer 3 BioLabs, Frankfurt am Main 
NEBuffer 4 BioLabs, Frankfurt am Main 
React3 Invitrogen, Karlsruhe 
2.1.19 Bacterial strains 
E. coli DH5α competent cells Invitrogen, Karlsruhe 
Stellar competent cells Clontech, Heidelberg 





2.1.20 Cell line 
HeLa cells (human) 
2.1.21 Yeast strain 
Saccharomyces cerevisiae AH109 Clontech, Heidelberg 
Y2HGold Yeast Strain Clontech, Heidelberg 
2.1.22 Model organisms 
The Whirligig mouse line was generated by ENU (N-ethyl-N-nitrosourea) 
mutagenesis (Bosman et al., 2005). It was kindly provided from K. P. Steel (Sanger 
Centre, Cambridge, United Kingdom) and the Helmholtz Zentrum Munich, 
Germany. 
African clawed frog Xenopus laevis. Adult frogs were purchased from Nasco (Ft. 
Atkinson, WI, USA).  
2.1.23 Software used 
Adobe Photoshop SC4 (compile figures) 
AlphaView (capturing and analysing images) 
Gen5™ (analysing data, determining protein concentration) 
Microsoft Office Excel 2007 (analysing data) 
Microsoft Office PowerPoint 2007 (compile figures/tables) 
Microsoft Office Word 2007 (compile documents) 
Paint (Erstellen und Bearbeiten von Zeichnungen) 
SDS Version 2.1, PE Applied Biosystems (analysing RT-qPCR) 
4D Tierbase (administration of mice) 
Cellsens Dimension (microscopy imaging applications) 
2.1.24 Internet platforms used 
BLAST (Analysis of DNA sequences) 
http://blast.ncbi.nlm.nih.gov/Blast.cgi 
dbSNP (information about mutations) 
http://www.ncbi.nlm.nih.gov/projects/SNP/ 





Ensembl (genetic information) 
http://www.ensembl.org/index.html 
Mutation taster (prediction program) 
http://www.mutationtaster.org/ 
NCBI, National Center for Biotechnology Information (biomedical and genetic 
information) 
http://www.ncbi.nlm.nih.gov/ 
NEBcutter V2.0 (recognition sites for restriction enzymes) 
http://tools.neb.com/NEBcutter2/index.php 
OMIM (information about genes and diseases) 
http://www.ncbi.nlm.nih.gov/omim 
PolyPhen2 (prediction program) 
http://genetics.bwh.harvard.edu/pph2/ 
Primer3 Input (version 0.4.0) (searching for oligonucleotides) 
http://frodo.wi.mit.edu/primer3/ 
Pubmed (searching for publications) 
http://www.ncbi.nlm.nih.gov/pubmed/  
RepeatMasker Web Server (checking for repetitive sequences within genes) 
http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker 
SIFT (prediction program) 
http://sift.jcvi.org/ 
 






2.2.1 Isolation of nucleic acids 
2.2.1.1 Isolation of genomic DNA for genotyping of mice 
To determine the genotype of mouse litters, a tail biopsy was taken at the age of three 
weeks. To isolate genomic DNA from mouse tail, it was proceded according to 
Wieczerzak (2012) with a modified centrifugation step. Therefore, 150 µl of direct 
lysis buffer (Peqlab) and 5 µl Proteinase K (10 µg/ml) were added and incubated 
overnight at 55 °C under shaking. Inactivation of proteinase K took place at 85 °C 
for 50 minutes and the samples were centrifuged at 13,000 rpm for 1 minute. Probes 
were kept at 8 °C until proceeding with the genotyping PCR using Immolase
TM
 DNA 
polymerase (compare 2.2.7). 
2.2.1.2 Isolation of plasmid DNA from bacteria 
The plasmid preparation is a procedure to isolate and purify plasmid DNA from 
bacteria. Three basic steps can be mentioned: 
 preparation of a bacterial culture 
 lyse the bacteria to extract plasmid DNA 
 purification of plasmid DNA 
a) Mini-preparation 
To extract and purify moderate yields of plasmid DNA from bacteria, the QIAprep
®
 
Miniprep from Qiagen was used following the company’s instructions with some 
modifications regarding the amount of the buffers and incubation times. The 
principle of this procedure is based on a modified alkaline lysis method of Birnboim 
and Doly (1979). Starting material is a 5 ml overnight culture of E. coli in LB 
(Lysogeny Broth) medium with 5 µl of an appropriate antibiotic (50 mg/ml). First, 
the bacterial cells were pelleted by centrifugation at 4,000 rpm for 10 minutes at 
8 °C. The supernatant was discarded and the pellet resuspended in 200 µl Buffer P1 
(Resuspension Buffer) with RNase A (Qiagen protocol: 250 µl). Next, 200 µl Buffer 
P2 (Lysis Buffer) was added and mixed thoroughly by inverting the tube 4-6 times 
(Qiagen protocol: 250 µl). After incubation for 5 minutes at room temperature, 
200 µl Buffer N3 (Neutralisation Buffer) was added (Qiagen protocol: 350 µl). The 





solution was immediately mixed by inverting the tubes 4-6 times. Samples were 
incubated for 5 minutes on ice then centrifuged at 13,000 rpm for 20 minutes at 4 °C 
(Qiagen protocol: no incubation before the 10 minutes centrifugation step at room 
temperature). In this protocol no column is utilised; instead, the plasmid DNA is 
precipitated with isopropanol. The supernatant was carefully transferred to a new 
tube without taking debris from the pellet. To precipitate the DNA, 420 µl 
isopropanol was added, mixed and samples incubated for 15 minutes at room 
temperature before centrifuging at 13,000 rpm for 30 minutes at 4 °C. The 
supernatant was discarded and the DNA pellet washed with 500 µl 70 % ethanol. 
After a final centrifugation step at 13,000 rpm for 5 minutes at 4 °C, the supernatant 
was discarded and the pellet air-dried. Depending on its size the DNA pellet was 
dissolved in 30-50 µl TE (Tris-EDTA) Buffer or ddH2O. The DNA concentration 
was measured with the photometer (Eppendorf) (compare 2.2.2) and stored at -20 °C. 
b) Midi-preparation 
This method is used to isolate and purify plasmid DNA from bacteria. Here, the 
PureLink
®
 HiPure Plasmid Filter Purification Kit (for midi and maxi preparation of 
plasmid DNA) from Invitrogen was used which employs a patented anion-exchange 
resin that ensures high yields of highly pure plasmid DNA. The midiprep was 
performed according to the manufacturer’s instructions with slightly modifications. 
First, the cell lysate was prepared. Departing from the manufacturer’s advice 30 ml 
instead of 15-25 ml of an overnight LB culture per sample was used for high copy 
number plasmids containing 30 µl of an appropriate antibiotic (50 mg/ml). The cells 
were harvested by centrifuging at 4,000 x g for 10 minutes at room temperature. 
Next, 4 ml Resuspension Buffer (R3) with RNase A was added to the cell pellet 
which was vortexed until cells were homogenously resuspended (Invitrogen 
protocol: 10 ml R3 buffer). After that 4 ml Lysis Buffer (L7) was added and tubes 
were inverted until the lysate composite was homogenously mixed (Invitrogen 
protocol: 10 ml L7 buffer). Next, the lysate was incubated at room temperature for 
exactly 5 minutes. Then, 4 ml Precipitation Buffer (N3) was added and tubes were 
homogeneously mixed by inverting (Invitrogen protocol: 10 ml N3 buffer). While 
probes were centrifuging at 12,000 x g for 10 minutes at room temperature (not listed 
in the manufacturer’s protocol), the columns were equilibrated by applying 10 ml 
Equilibration Buffer (EQ1) directly to the filtration cartridge of the column 





(Invitrogen protocol: 15 ml EQ1 buffer). After the solution drained by gravity flow, 
the precipitated lysate was transferred onto the column through a filter to prevent 
loading any protein remains. The column was washed twice with 10 ml Washing 
Buffer (W8). The buffer flew through the column by gravity flow until the flow 
stopped. The flow through was discarded and the DNA was eluted. Therefore, a 
sterile tube was placed under the column and 5 ml Elution Buffer (E4) was applied to 
the column. The solution was drained by gravity flow. Next, the DNA was 
precipitated by adding 3.5 ml isopropanol to the elution, then mixed well and 
incubated for 2 minutes at room temperature. A centrifugation step was performed at 
> 12,000 x g for 30 minutes at 4 °C. The supernatant was removed and the pellet 
washed with 3 ml 70 % ethanol. After centrifuging at > 12,000 x g for 5 minutes at 
4 °C, the supernatant was removed and the pellet was air-dried for about 10 minutes. 
Depending on the pellet size the DNA was resuspended in 100-200 µl TE Buffer or 
ddH2O. The concentration of the precipitated DNA was measured with a spectral 
photometer (Eppendorf) (compare 2.2.2) and stored at -20 °C. 
2.2.1.3 RNA isolation from mouse embryos 





) and homozygous (Chd7
Whi/Whi
)) were used according to the 
standard protocol of the Transcriptome Analysis Laboratory (TAL), Goettingen. 
Adding 1 ml TRizol Reagent (Invitrogen) the entire embryo was lysed in a rotor 
homogenisator for 5 minutes at 50 oscillations. Next, the homogenate was incubated 
for 5 minutes at room temperature. To remove insoluble material from the 
homogenate, samples were centrifuged at 12,000 x g for 10 minutes at 4 °C. The 
supernatant was transferred to a fresh tube and the sample incubated again for 
5 minutes at room temperature. 200 µl chloroform was added, tubes were vigorously 
shaken by hand for 15 seconds, then incubated 5 minutes at room temperature. After 
a 15 minute centrifugation step at 12,000 x g at 4 °C, the upper aqueous phase 
containing the RNA was transferred to a fresh 2 ml tube. Next, the RNA was 
precipitated by adding 500 µl isopropanol and 1 µl GlycoBlue. Samples were 
vortexed and incubated at -20 °C for 2 hours or overnight. The samples were 
centrifuged at 12,000 x g for 30 minutes at 4 °C. The supernatant was removed and 
the RNA pellet was washed with 1 ml 75 % ethanol. Samples were centrifuged at 
12,000 x g for 5 minutes at 4 °C and the supernatant discarded. In case of a DNase 





treatment a repetition of the wash step is not necessary. The RNA pellet was air-dried 
and dissolved in 25 µl DEPC. The concentration of the RNA was determined using a 
photo spectrometer (Eppendorf) (compare 2.2.2) and stored at 80 °C. 
2.2.2 Determination of nucleic acid concentration 
To measure the concentration of DNA or RNA, a spectral photometer (Eppendorf) 
was used as described by Nolte (2008). After determining the blank value (solvent, 
e.g., TE Buffer, DEPC or ddH2O) the concentration of the nucleic acid could be 
calculated by measuring the absorbance at 260 nm on the supposition that E260 of a 
50 ng/µl DNA solution (and 40 ng/µl of a RNA solution) equals 1. The additional 
quotients E260/E280 and E260/E230 reflect contaminations with proteins and salt, 
respectively. The values should be > 1.8 and > 2.0, respectively. Before the 
measurement the type of nucleic acid and the dilution factor of the sample were 
quoted and the concentration in µg/µl was determined. 
2.2.3 Reverse transcription 
This method was applied to transcribe RNA into complementary DNA (cDNA) using 
SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s 
instructions. In total, 5 µg RNA was used for a total reaction volume of 20 µl. Next, 
1 µl Oligo dT (500 µg/ml) and 1 µl dNTP mix (10 mM each) were added to the RNA 
and ddH2O was admitted up to 12 µl total. The mixture was incubated at 65 °C for 
5 minutes then 2 µl of 0.1 M DTT and 4 µl 5 x First-Strand Buffer were added and 
mixed gently. Next, samples were incubated at 42 °C for 2 minutes before adding 
1 µl of SuperScript II reverse transcriptase. The reaction sample was gently mixed 
and incubated at 42 °C for 50 minutes. By heating up to 70 °C for 15 minutes the 
reaction was inactivated. The cDNA was kept on ice for 5 minutes and stored at 
20 °C. To verify whether the transcription was successful, a PCR was performed 
(compare 2.2.7). 
2.2.4 Cloning 
Cloning is a method used to create copies of specific DNA fragments. The target 
DNA is brought into bacterial cells via plasmids. Through cell division (formation of 
bacterial colonies) the DNA is multiplied.  





2.2.4.1 Restriction digestion of plasmid DNA 
Restriction endonucleases are enzymes which naturally occur in bacteria and archaea 
where they have a protecting function against virus invasion (Arber and Linn, 1969; 
Pingoud et al., 1993). The restriction endonucleases used in this work belong to the 
type II restriction enzymes. They recognise a specific palindromic sequence of 
nucleotides and cleave the DNA at the same site (Pingoud and Jeltsch, 2001).  
Plasmid DNA was cleaved using restriction enzymes from different companies. In 
general 10 units (U) enzyme were used to cleave 1 µg DNA in 1-2 hours. The 
incubation temperature as well as the reaction Buffer depends on the enzyme. To 
some restriction enzymes 1 x Bovine Serum Albumin (BSA) was added to prevent 
unspecific bindings. To check whether the cleavage was complete, an aliquote of the 
reaction was put on an agarose gel (compare 2.2.10).  
2.2.4.2 Ligation of DNA fragments into plasmids 
For the ligation target DNA fragments (inserts) were amplified by PCR. Inserts and 
the desired plasmid were digested with appropriate restriction enzymes. For the 
ligation the T4 Ligase (BioLabs) was used according to the manufacturer’s 
instructions. A reaction volume of 10 µl contained a molar ratio of 1:3 vector to 
insert, 1 µl T4 ligase and 2 µl 5 x Ligation Buffer. If needed, ddH2O was supplied to 
a final volume of 10 µl. The ligation was incubated overnight at 4 °C. 
2.2.4.3 Transformation 
For the transformation of a ligation reaction, 50 µl competent E.coli DH5α-cells 
(Invitrogen) were defrozen on ice and proceeded according to Hanahan (1983) with 
some modifications. 10 µl of the ligation mix was carefully added to the DH5α-cells 
and incubated for 30 minutes on ice. To increase the rate of plasmids adsorbed by the 
cells, a heat shock was performed at 42 °C for 45 seconds instead of 90 seconds. 
After that, the samples were incubated on ice for 2 minutes. For proliferation of 
bacterial cells, 450 µl prewarmed S.O.C. (Super Optimal Broth) medium (Invitrogen) 
instead of 800 µl was supplied and the samples incubated under continuously 
shaking at 37 °C for 1 hour. 100 µl of the bacterial mixture was plated on LB plates 
with an appropriate antibiotic. The plates were incubated overnight at 37 °C. 





For a transformation of an In-Fusion
TM
 reaction in DH5α-cells, 2.5-3 µl of the 
reaction was used and proceeded as described previously.  
If an In-Fusion
TM
 reaction was transformed into Stella cells, 2.5-3 µl of the mixture 
was used, respectively and proceeded as described previously. After 1 hour 
incubation at 37 °C, 50 µl of the cell culture was mixed with 50 µl fresh S.O.C. 
medium and plated on an LB plate with an appropriate antibiotic. The other 400 µl 
S.O.C. medium was centrifuged at 6,000 rpm for 5 minutes at room temperature. The 
supernatant was discarded and the cell pellet resuspended in 100 µl fresh S.O.C. 
medium, then plated on an LB plate with an appropriate antibiotic and incubated 
overnight at 37 °C. 
2.2.5 Cloning by In-FusionTM 
In-Fusion
TM
 is a PCR cloning method typically used to clone PCR products into 
vectors. In this work the In-Fusion
TM 
Advantage PCR Cloning Kit (Clontech) was 
used according to the company’s manual. First, gene-specific In-Fusion primers were 
designed with 15 bases extensions homologous to the ends of the linearised cloning 
vector. These primers are used to amplify the gene of interest by PCR. The target 
fragment was isolated by gel extraction. Then, the In-Fusion
TM
 cloning reaction was 
set up. For a total reaction volume of 10 µl, 2 µl of 5 x In-Fusion
TM
 Reaction Buffer, 
1 µl In-Fusion
TM
 Enzyme, a 2 : 1 molar ratio of insert : vector and the appropriate 
amount of ddH2O were used. The cloning reaction was incubated for 15 minutes at 
37 °C followed by additional 15 minutes at 50 °C. After that the reaction volume was 
brought up to 50 µl with TE buffer (pH 8). Next, the constructs were transformed 
into either DH5α or Stella cells (compare 2.2.4.3). 
2.2.6 Preparation of glycerin stocks 
Every construct has to be maintained as a glycerin stock. Glycerin stocks were 
prepared according to Wieczerzak (2012). Therefore, a single bacterial colony was 
picked from an LB plate and inoculated in 5 ml LB medium with 5 µl of an 
appropriate antibiotic (50 mg/ml). Inoculated samples were incubated overnight at 
37 °C continuously shaking at 120 rpm. 700 µl of the bacterial culture was mixed 
with 300 µl 50 % glycerin and stored at -80 °C. 





2.2.7 PCR  
The PCR is a method where a polymerase is used to exponentially amplify a desired 
DNA sequence in vitro (Kleppe et al., 1971; Mullis et al., 1986). As a template a 
double strand DNA is used which is denaturised by heating up to 94 °C. At a lower 
temperature the primer hybridisation takes place. Primers are short oligonucleotides 
which are complementary to a specific region of the template and mark the starting 
point of the DNA synthesis. An increase of the temperature leads to the activation of 
the polymerase which binds to the primers and synthesises a new DNA strand 
complementary to the DNA template strand by using deoxynucleotide triphosphates 




 DNA Polymerase (Bioline) is a thermostable DNA polymerase 
isolated from a novel organism (Bioline, n.d.). This polymerase is characterised by 
excellent specificity and robust performance and it is able to eliminate primer-dimers 
or mis-primed products (Bioline, n.d.). In this work the Immolase
TM
 DNA 
ploymerase was used to perform genotyping of mice. Furthermore, this DNA 
polymerase was used to test the oligonucleotides for RT-qPCR and check transcribed 
cDNA. The PCR reactions were assembled according to the manufacturer’s 
recommendations. Considering the PCR program the activation conditions were 
optimised. 
Table 21: PCR reaction conditions (Immolase
TM
) 
component volume (µl) 
10 x Immo-Puffer 2.5 
MgCl2 (50 mM) 0.75 
dNTPs (je 2,5 mM) 0.5 
forward primer (10 pmol/µl) 0.5 
reverse primer (10 pmol/µl) 0.5 
IMMOLASE
TM
 DNA Polymerase (5 U/µl) 0.2 
template DNA 1 
ddH2O to 25 
 





Table 22: PCR program (Immolase
TM
) 
step temperature (°C) time cycle 
Activation 94 5 min 1 
Denaturation 94 30 sec  
Annealing 60/67 45-60 sec 30-35 
Extension 72 1 min  
Final extension 72 5-7 min 1 
Cooling 4 ∞ 1 
b) peqGOLD Pwo-DNA-Polymerase 
The peqGOLD Pwo-DNA-Polymerase (Peqlab) was originally isolated form the 
thermophilic archaebacterium Pyrococcus woesei and is thermal stable (Peqlab, n.d.). 
It works highly processive and has a proof-reading function by 3'→5' exonuclease 
activity (Peqlab, n.d.). This polymerase was used to amplify products which are used 
to generate constructs for Co-IP and Y2H experiments. Based on the 3'→5' 
exonuclease activity of the Pwo-DNA-Polymerase it is possible that primers and 
template are destroyed. Therefore, two master mixes are prepared and right before 
starting the PCR combined according to the company’s instructions. 
Table 23: PCR reaction conditions (peqGOLD Pwo) 
component volume (µl) 
Master mix I (25 µl):  
dNTPs (Invitrogen) 4 
forward primer (10 pmol/µl) 2 
reverse primer (10 pmol/µl) 2 
template DNA 1 
ddH2O to 25 
Master mix II (25 µl):  
10 x reaction Buffer complete 5 
Pwo-DNA-Polymerase (1 U/µl) 3 
ddH2O to 25 
 





Table 24: PCR program (peqGOLD Pwo) 
step temperature (°C) time cycle 
Activation 94 2 min 1 
Denaturation 94 15 sec  
Annealing 54/64 30 sec 40 
Extension 68 2 min  
Final extension 68 7 min 1 
Cooling 4 ∞ 1 
c) PfuUltraTM High-Fidelity DNA Polymerase 
The Pfu polymerase is found in the hyperthermophilic archaeon Pyrococcus furiosus. 
PfuUltra™ High-Fidelity DNA Polymerase is formulated with the ArchaeMaxx
®
 
polymerase enhancing factor, resulting in improved overall PCR performance 
(AgilentTechnologies, n.d.). The PfuUltra™ High-Fidelity DNA Polymerase 
(Stratagene) was used to amplify products for engineering constructs for Y2H. PCR 
reaction conditions recommended by the company were optimised by adding 1 µl of 
MgSO4 and modifying the concentration of dNTPs and the polymerase. The 
annealing and the denaturation cycle were extended from 30 seconds to 45 seconds 
and the temperature of the extension cycles were set at 72 °C instead of 68 °C. 





Table 25: PCR reaction conditions (PfuUltra
TM
 High-Fidelity) 
component volume (µl) 
10 x PfuUltra HF reaction buffer 2.5 
MgSO4 (50 mM) 1 
dNTPs (2,5 mM each) 0.8 
forward primer (10 pmol/µl) 0.5  
reverse primer (10 pmol/µl) 0.5  
PfuUltra
TM
 high-fidelity DNA polymerase (5 U/µl) 1 
template DNA 1 
ddH2O to 25  
Table 26: PCR program (PfuUltra
TM
 High-Fidelity) 
step temperature (°C) time cycle 
Activation 95 2 min 1 
Denaturation 95 45 sec  
Annealing 60 45 sec 35 
Extension 68 2 min  
Final extension 68 10 min 1 
Cooling 4 ∞ 1 
d) Platinum® Taq DNA polymerase 
The Platinum
®
 Taq DNA Polymerase is found in the thermophilic bacterium 
Thermus aquaticus and it has a 5'→3' polymerase and a 5'→3' exonuclease activity 
(Invitrogen, 2010). The polymerase is complexed with a proprietary antibody that 
blocks polymerase activity at low temperatures (Invitrogen, 2010). A “hotstart” at 
94 °C restores the activity (Invitrogen, 2010). In this work the Platinum
®
 Taq DNA 
Polymerase (Invitrogen) was also used to amplify products for engineering 
constructs for Y2H. Furthermore, it was applied to distinguish the gender of mouse 
embryos. The PCR reaction was set up according the company’s recommendations. 





The activation, denaturation and annealing cycles were optimised and a final 
extension step included. 
Table 27: PCR reaction conditions (Platinum
®
 Taq) 
component volume (µl) 
10 x PCR buffer 2.5 
MgCl2 (50 mM) 0.75 
dNTPs (2,5 mM each) 0.5 
forward primer (10 pmol/µl) 0.5 
reverse primer (10 pmol/µl) 0.5 
Platinum
®
 Taq DNA polymerase (5 U/µl) 0.2 
template DNA 1 
ddH2O to 25 
Table 28: PCR grogram (Platinum
®
 Taq) 
step temperature (°C) time cycle 
Activation 94/95 5 min 1 
Denaturation 94/95 45 sec  
Annealing 59/61 45 sec 35/40 
Extension 72 1.5/2 min  
Final extension 72 5/7 min 1 
Cooling 4 ∞ 1 
2.2.7.1 Touchdown PCR 
The touchdown PCR is a method to avoid amplifying nonspecific sequences by 
unspecific primer binding. Different annealing temperatures are used starting with 
high temperatures. The upper limit of the annealing temperature is set by the melting 
point of the primers used. The increments of annealing temperature decrease as well 
as the number of cycles can be chosen individually. At temperatures just below the 
melting point the annealing of primers to the template is most specific while at lower 
temperatures primers bind less specifically. By the exponential nature of the 
polymerase amplification the specific sequences amplified in early steps will 





overwhelm the nonspecific sequences amplified later (Korbie and Mattick, 2008). 
For the touchdown PCR applied for mutation screens with human samples the 
Immolase
TM
 DNA polymerase was used. 
Table 29: PCR reaction conditions (Touchdown) 
component volume (µl) 
10 x Immo-Puffer 2.5 
MgCl2 (50 mM) 0.75 
dNTPs (2,5 mM each) 0.5 
forward primer (10 pmol/µl) 0.65 
reverse primer (10 pmol/µl) 0.65 
IMMOLASE
TM
 DNA Polymerase (5 U/µl) 0.2 
template DNA 1 
ddH2O to 25 
Table 30: PCR program (Touchdown) 
step temperature (°C) time cycle 
Activation 95 7 min 1 
Denaturation 95 30 sec  
Annealing 65 -1 until 60 1 min 5 
Extension 72 1 min  
Denaturation 95 30 sec  
Extension 72 1 min 30 
Final extension 72 5 min  
Cooling 4 ∞ 1 
2.2.7.2 Sequencing PCR 
The sequence analysis used in this work is modified from the chain determination 
method by Sanger and Coulson (Sanger and Coulson, 1975). This variation of a PCR 
uses only one primer. Besides from all four standard deoxynucleotide triphosphates 
(dNTPs) modified dideoxynucleotide triphosphates (ddNTPs) are used. The four 
ddNTPs are differently labeled with fluorescent dye and lack a 3'-hydroxy (OH-) 





group that is required for the formation of a phosphodiester bond between two 
nucleotides which causes termination of DNA strand elongation (Atkinson et al., 
1969). The consequences are DNA fragments of different lengths that are separated 
by size using a capillary electrophorese (MegaBACE
TM
1000, Amersham). 
Stimulated by laser the fluorescently labeled ddNTPs emit light at different 
wavelengths. The sequence is visualised as peaks of different height and shape 
(chromatogram). 
Table 31: PCR reaction conditions (sequencing) 
component volume (µl) 




forward primer or reverse primer (10 pmol/µl) 1 
template DNA 1-6 
ddH2O to 10 
Table 32: PCR program (sequencing) 
step temperature (°C) time cycle 
Activation 95 1 min 1 
Denaturation 95 30 sec  
Annealing/Extension 60 2.5 min 30 
Final extension 60 5 min 1 
Cooling 8 ∞ 1 
After the PCR run, 10 µl ddH2O was added to each sample. 
2.2.8 Quantitative real-time PCR and data analysis 
The RT-qPCR is used to amplify and simultaneously quantify cDNA samples reverse 
transcribed from mRNA (messenger RNA). Therefore, SYBR Green I, an 
asymmetrical cyanine dye that intercalates with double stranded DNA is used 
(Zipper et al., 2004). In this complex SYBR Green I absorbs blue light. The excitation 
maximum is about 490 nm and it has an emission maximum of approximately 





520 nm. This fluorescent signal can be detected by a detection system during qPCR 
(quantitative real-time PCR) and is proportional to the amplified DNA. 
Absolute and relative quantification of nucleic acids are possible by using this 
method. In this work the relative quantification of gene expression was used. 
Thereby, an internal reference gene (housekeeping gene) is needed to determine the 
fold change in expression. ROX (6-Carboxyl-X-Rho-damine) is used as a passive 
reference dye to normalise the fluorescence signal of SYBR Green I (Illumina, 2011). 
Unspecific influences such as variations caused by pipetting errors can be 
compensated.  
For the RT-qPCR RNA of mouse embryos were reverse transcribed into cDNA. 
Serial 1:5 dilutions of the cDNA were prepared for each analysed gene which should 
be analysed to determine the standard curve. To exclude contamination, ddH2O was 
used as a blank value for each gene. A triple measurement was performed for all 
analysed genes, respectively. Samples were applied onto a 384 well plate and 
analysed with “ABI PRISM
®
 7900HT Sequence Detection System”. Below the RT-
qPCR/qPCR program and the reaction conditions are listed. 
Table 33: RT-qPCR/qPCR program 
step temperature (°C) time cycle 
 50 2 min 1 
Activation 95 15 min 1 
Denaturation 94 15 sec  
Annealing 60 30 sec 40 
Extension 72 1 min  
 95 15 sec  
Dissociation 60 15 sec 1 
 95 15 sec  





Table 34: reaction conditions (RT-qPCR/qPCR) 
component volume (µl) 
SYBR Green I 5 
cDNA or human genomic DNA 2.5 
forward primer (1 pmol/µl) 1.25 
reverse primer (1 pmol/µl) 1.25 
The raw data were evaluated using the sequence-detection software (SDS Version 
2.1, PE Applied Biosystems). The SDS software displays the results of the RT-
qPCR/qPCR run and plots them in a graph of normalised reporter fluorescence (Rn) 
versus cycle number (Fig. 4). In table 35 is the definition of terms listed which are 
used in quantification analysis. 
Table 35: Terms used in Allelic Discrimination Analysis.  
Term Definition 
Baseline 
A line fit to fluorescence intensity values during 
the initial cycles of PCR, in which there is little 
change in fluorescence signal. 
Threshold cycle (CT) 
The fractional cycle number at which the 
fluorescence intensity exceeds the threshold 
intensity. 
Passive reference 
A dye that provides an internal fluorescence 
reference to which the reporter dye signal can be 
normalized during data analysis. Normalization is 
necessary to correct for fluorescence fluctuations 
caused by changes in concentration or volume. 
Reporter dye The dye (SYBR Green I) provides a signal that 
indicates specific amplification. 
Normalised reporter (Rn) 
The ratio of the fluorescence intensity of the 
reporter dye signal to the fluorescence intensity of 
the passive reference dye signal. 
Delta Rn (Rn) The magnitude of the signal generated by a set of 
PCR conditions. (Rn= Rn baseline) 
Table modified after AppliedBiosystems (n.d.). 






Figure 4: Results after RT-qPCR/qPCR run. 
The graph shows the normalised reporter fluorescence (Rn) (ordinate) versus cycle number (abscissa). 
The threshold is set at a certain Rn value during the exponential amplification phase (geometric phase) 
slightly above background. Within this phase optimal PCR conditions exists, whereas in the linear and 
plateau phase the PCR reaction is inhibited due to limited availability of substrates or starting 
destruction of the polymerase or nucleotides. The number of cycles at which the fluorescence intensity 
exceeds the threshold intensity is called the threshold cycle (Ct). With the Ct values the quantification 
of the DNA samples can be determined. Figure modified after AppliedBiosystems (n.d.). 
Data were exported to Microsoft Excel and further processed according to Dr. Arne 
Zibat’s instructions. By using the serial 1:5 dilution of the DNA template a standard 
curve for each target gene was determined. Therefore, the initial concentration of the 
template DNA has to be known. By plotting the logarithms of the initial 
concentrations (ordinate) versus the median Ct values (abscissa) the linear equation 
y = mx + b were achieved for the computation of a standard curve. The constant m is 
the slope of the straight line, constant b indicates were the straight line intercepts the 
y-axis and x is the independent variable. Next, the efficiency (E) was determined: E 
= 10 
(− 1 / m)
 − 1. A slope (m) of -3.32 results in an efficiency of 100 %. To analyse 
the data, the efficiency should be between 85 % and 105 %. Values above 100 % 
indicate an inhibition of the qPCR. R
2
 displays the scattering around the straight line 
and indicates the reliability of the data. R
2 
should be at the minimum of 95 %. Next, 
the target genes were normalised against three reference genes (housekeeping genes) 














its expression should be stable in different cell types, during the cell cycle or during 
certain outer influences (Bustin et al., 2009). For the normalisation the logarithms of 
the initial concentrations of the reference genes were determined by using the 
formula: log (initial concentration) = (Ct − b) / m. Next, the logarithms were 
countermanded and the mean as well as the standard deviation of the initial 
concentration were determined. Now, the target genes were normalised against the 
three reference genes. Therefore, the logarithms of the initial concentrations of the 
target genes were determined and the logarithms countermanded as for the reference 
genes before. After that, the initial concentration were used for the normalisation 
(N): N = initial concentration/mean of the initial concentration of the reference 
genes. The mean and the standard deviation of the normalisation were determined. 
Further, the relative change in expression of the target genes was compared to the 
calibrator (pooled wild-type samples): N/mean of the initial concentration of the 
calibrator. The mean and the standard deviation of the relative change in expression 
were determined. Finally, the mean of the relative change in expression of each 
target gene against the three reference genes were determined and results were 
represented in a diagram.  
For the patient screen to check for duplications and deletions within exons of certain 
genes, qPCR was performed under adherence of diagnostic standards. Based on the 
determined concentrations of the DNA samples, patient probes and the wild-type 
control were brought to a concentration of 1.25 ng/µl using ddH2O. Using standard 
DNA (Human DNA Male, ABI) four different concentrations (2.5 ng/µl, 1.25 ng/µl, 
0625 ng/µl and 0.3125 ng/µl) were adjusted. Two reference genes were used and for 
each analysed probe a no template control (NTC) (DNA volume was replaced by the 
same volume of ddH2O) was carried along to check for contaminations. For each 
probe a double parallel measurement was performed.  
A total reaction volume of 10 µl (Tab. 34) was supplied on a 384 well plate. First, 
2.5 µl of primer-mix were placed into the wells of a 384 well plate which was then 
centrifuged for 2 minutes at 1,500 rpm. Next, 7.5 µl of a mixture containing the 
DNA probe and SYBR Green I was added to the wells. To eliminate air bubbles, the 
plate was centrifuged for 10 minutes at 3,000 rpm and then placed into the “ABI 
PRISM
TM
 7900HT Fast Real-Time PCR System” to record the data. 
The data were analysed using the software SDS2.3 according to the operating 
instructions (2012) of the diagnostic department of the Human Genetic Institute, 





Goettingen. First, the data were checked for contaminations by using the NTCs. 
Clear signals indicate a possible contamination and the analysis of this probe has to 
be repeated. Next, the dissociation curve should show a single peak, which indicates 
a unified product. If double peaks are present (unspecific side product), the analysis 
has to be repeated. For each primer pair a standard curve and R
2
 value were 
determined by the SDS software. For R
2
, values should be between 0.99 and 0.98. 
Next, data were exported and analysed using Microsoft Excel. The multiple of the 
median (MOM) was determined: MOM = quantity/mean quantity of all references. 
For each double measured probe the median of the MOM and the standard deviation 
were determined and the values rounded to two decimal places after the decimal 
point. The mean MOM values were presented for each analysed probe in a column 
diagram. A deletion reveals in the calculation a theoretical value of MOM 0.4-0.6 
and duplication a theoretical value of MOM 1.4. The theoretical value of MOM for 
wild-type is 1.0. Since the qPCR is a sensitive method, the determined values are 
subjected to variation, so they are often present below or above these theoretical 
values. Therefore, values below MOM 0.8 and above MOM 1.2 are classified to be 
suspicious. The reactions have to be repeated. 
2.2.9 Purification of DNA 
The MSB
®
 Spin PCRapace Kit (Invitek) was used for fast and efficient direct 
purification of PCR products, digested samples and mini preparations according to 
the manufacturer’s instructions with an additional centrifugation step. All 
centrifugation steps were carried out at room temperature. Up to 50 µl PCR samples 
250 µl Binding Buffer was added to the PCR mixture. The sample was mixed 
vigorously by pipetting, then transferred onto a Spin Filter to bind the PCR 
fragments. Next, samples were centrifuged at 12,000 rpm for 3 minutes and the flow-
through was discarded. An additional centrifugation step at 13,000 rpm for 1 minute 
was performed to fully remove all ethanol. The flow-through was discarded and the 
Spin Filter was placed into a new tube. To elute the PCR fragments, at least 10 µl 
ddH2O was supplied directly onto the center of the Spin Filter. After 1 minute 
incubation at room temperature, the samples were centrifuged at 10,000 rpm for 
1 minute. Purified samples were stored at -20 °C. 





2.2.10 Agarose gel electrophoresis 
To separate DNA fragments according to their length after PCR amplification, 
restriction digestion and ligation reaction, standard agarose gel elelectrophoresis was 
used (Fisher and Dingman, 1971; Helling et al., 1974). Depending on the DNA 
fragment length, 0.5-2 % agarose gels were prepared using agarose (Bio-Budget) and 
1 x Tris/Acetate/EDTA (TAE) buffer or 0.5 x Tris/Borate/EDTA (TBE) buffer 
(Tab. 7). The mixture was boiled in the microwave until the agarose was completely 
dissolved. As running buffer 1 x TAE buffer or 0.5 x TBE buffer were used. To 
visualise the DNA under UV light, one drop of Ethidium bromide (AppliChem) 
(Sharp et al., 1973) or Roti Safe (Roth) was added to the agarose mixture. Gels were 
placed in horizontal gel chambers (Owl Scientific). Gels were loaded according to 
Lee et al. (2012). 
2.2.11 Gel extraction  
The QIAquick Gel Extraction Kit (Qiagen) is used to extract and purify DNA (70 bp-
10 kb) from agarose gels in TAE or TBE buffer according to the manufacturer’s 
instructions. All centrifugation steps were carried out at 13,000 rpm at room 
temperature. The desired DNA fragment was excised from the agarose gel using a 
clean scalpel. If possible, extra agarose was removed before the gel slice was scaled 
in a colourless tube. To 1 volume of gel (1 mg is equivalent to 100 µl) 3 volumes of 
Buffer QG were added to the gel slice. In case of > 2 % agarose gels, 6 volumes 
Buffer QG were needed. Next, the tube with the gel slice was incubated 10 minutes 
at 50 °C until the gel slice was completely dissolved. Every 2-3 minutes the tubes 
were vortexed during incubation to support dissolution. Since the adsorption of DNA 
to the QIAquick membrane is efficient only at pH ≤ 7.5, it is necessary that the 
colour of the mixture stays yellow indicating the required pH. In case the mixture is 
orange or violet after the gel has dissolved, 10 µl of 3 M sodium acetate (pH 5) had 
to be added. To DNA fragments < 500 bp and > 4 kb 1 gel volume of isopropanol 
was added which increases the yield of DNA fragments. Next, a QIAquick spin 
column was placed in the provided 2 ml collection tube before the sample was 
applied to the column to bind DNA. The probes were centrifuged for 1 minute. The 
column reservoir is 800 µl. For sample volumes > 800 µl, the column was simply 
loaded and centrifuged again. The flow-through was discarded and the column 





placed back in the same collection tube. 500 µl Buffer QG was added to the column 
and centrifuged for 1 minute. The flow-throw was discarded and 750 µl of Buffer PE 
was added to the column for washing. After 2-5 minutes incubation, the column was 
centrifuged for 1 minute. The flow-through was removed and the column centrifuged 
again for 1 minute to completely remove the ethanol from the Buffer PE. To elute the 
DNA, the column was placed into a new 1.5 ml e-cup and 30-50 µl ddH2O was 
added to the center of the QIAquick membrane. After 1 minute incubation the 
column was centrifuged for 1 minute. The DNA samples were stored at -20 °C 
2.2.12 Mouse preparation 
One-to-one matings of heterozygous Whirligig (Chd7
Whi/+
) females and males were 
set up. To determine the age of the embryos, a daily check for a vaginal plug (VP 
check) was performed on female Whirligig mice. The day when the copulation plug 
was observed, was counted as embryonic stage 0.5 (E0.5). At the required day the 
pregnant Whirligig mice were sacrificed by cervical dislocation and the uterus was 
removed. The embryos were dissected from the yolk sacs and washed with PBS. To 
determine the gender of the embryos, a tail biopsy was performed. For protein and 
RNA isolation the embryos were flash frozen on liquid nitrogen and stored at -80 °C. 
For paraffin sections the embryos were fixed overnight at 4 °C in 4 % 
paraformaldehyde.   
2.2.13 Fixation and dehydration of embryos for paraffin embedding 
Fixation and dehydration of mouse embryos have been carried out according to 
Luxan et al. (2013) with some modifications, such as additional incubation steps and 
longer incubation times. Mouse embryos isolated from the uterus were fixated 
overnight in 4 % paraformaldehyde in PBS at 4 °C. The next day embryos were 
washed for 10 minutes in PBS. If not indicated differently, all steps were carried out 
at room temperature. By an increasing ethanol row (50 %, 70 %, 80 %, 90 % 
ethanol/PBS and 100 % ethanol) embryos were dehydrated. In contrast to the 
procedure performed by Luxan et al. (2013) an additional 50 % ethanol/PBS 
incubation step was carried out and each concentration step was performed twice for 
1 hour. After the dehydration, embryos were incubated overnight instead of 
30 minutes in 100 % xylene. Additionally, embryos were incubated in 50 % 





paraffin/xylene for 2-6 hours at 65 °C. Embryos were transferred into 100 % paraffin 
and incubated for 2 days instead of 3 hours at 65 °C. During that time the paraffin 
was exchanged at least six times. The embryos were ready to be placed into forms to 
make paraffin blocks for the preparation of sections.  
2.2.14 Preparation of paraffin sections of mouse embryos 
To prepare paraffin sections, the microtome (JUNG RM 2035, Leica) were used. 
First, the paraffin block with the fixed embryo was cut to the size needed and 
clamped onto the microtome. Sections of 6-8 µm thickness were made which were 
carefully transferred to the surface of water (58 °C) from where they were placed on 
slides (Thermo Scientific). After the sections were dried, they were stored at 4 °C or 
room temperature until needed. 
2.2.15 Microarray and data analysis 
Microarrays are used to measure the expression of a large number of genes (Schena 
et al., 1995). In this work the microarrays were performed by the TAL in Goettingen 
as described by Schulz et al. (2014b) using the "Low RNA Input linear Amplification 
Kit Plus, One Color" protocol (Agilent Technologies, Inc. 2007; Cat. N°: 5188-5339) 
and the RNA Spike-In Kit for One color (Agilent Technologies, Inc. 2007; Cat. N°: 
5188-5282) following the manufacturer's instructions. For the analysis of global gene 
expression the Mice 4 x 44 K design array from Agilent Technologies (G4846A) was 
used following the manufacturer’s standard protocol. 200 ng of total RNA was used 
for reverse transcription into cDNA following the company’s recommendation. The 
in vitro transcription was done according to the manufacturer’s instructions. To 
determine the quantity and efficiency of the amplified cRNA that was labeled, the 
NanoDrop ND-1000 UV-VIS Spectrophotometer version 3.2.1 was used. The 
hybridisation procedure took place in the Hybridisation Oven (Agilent). Probes were 
incubated for 17 hours at 10 rpm at 65 °C. The following washing and staining were 
performed according to the manufacturer’s standard protocol. All together the 
microarray data were generated according to the Minimum Information About a 
Microarray Experiment (MIAME) guidelines (compare NCBI's Gene Expression 
Omnibus (GSE46591). The Agilent DNA microarray scanner (G2505B) was used at 
5 micron resolution to detect the Cy3 intensities by one-color scanning. Next, the 





scanned image files were screened for artefacts and further analysed conforming to 
Opitz et al. (2010). The Feature Extraction Software Version was changed to 
10.7.3.1. DAVID was used to find over-represented functions (Huang da et al., 
2009b, a) 
2.2.16 Cell biological methods 
2.2.16.1 Culturing of eukaryotic cells 
In this work human HeLa cells derived from cervical cancer cells were used (Scherer 
et al., 1953). The adherent cells were cultured in 25 cm
2
 and 75 cm
2
 culture flasks 
(Sarstedt) in 5 ml and 10 ml medium, respectively. The medium consists of 
Dulbecco’s modified Eagle’s media (DMEM) (PAN BIOTECH), 10 % foetal calf 
serum (PAN BIOTECH) and 1 % penicillin/streptomycin (PAN BIOTECH). Cells 
were cultured at 37 °C at a humidity of 98 % and CO2 content of 5 %. Every two 
days the medium was exchanged.  
To split cells, TrypLE Express (Invitrogen) was used to detach cells from the culture 
flask. First, cells cultured in a 25 cm
2
 flask were washed once or twice with 5 ml 
DPBS. DPBS was removed completely before adding 1.5 ml TrypLE Express. Cells 
were incubated at 37 °C for 3 minutes. Then, 3.5 ml medium was added and cells 
were resuspended and transferred to a 13 ml centrifugation tube and centrifuged at 
1,000 rpm for 5 minutes at room temperature. Supernatant was removed and the cell 
pellet was washed by resuspending in 5 ml DPBS. Tubes were centrifuged again at 
1,000 rpm for 5 minutes at room temperature. The supernatant was discarded and the 
cell pellet was resuspended in medium. A few drops were added to a new 25 cm
2
 
culturing flask with 5 ml fresh medium. Cells were equally distributed and incubated 
at 37 °C. 
2.2.16.2 Cryopreservation and revitalisation of eukaryotic cells 
For a permanently storage, cells were cultured in 75 cm
2
 flask (Sarstedt) until they 
reached a confluence of 80 %. They were washed with DPBS and then trypsinised 
(2.2.16.1). Cells were resuspended in 1.5 ml DMEM, and 1.5 ml of the Cryo-medium 
consisting of 50 % FKS, 30 % DMEM and 20 % DMSO was added. Cell mixture 
was transferred in Cryo-tubes and temporarily incubated at -20 °C. Then, cells were 
kept at -80 °C or liquid nitrogen. For revitalisation, cells were quickly unfrozen at 





room temperature and resuspended in 9 ml prewarmed culturing medium. Cells were 
pelleted twice, washed with culturing medium and cultured in a 25 cm
2
 flask 
(Sarstedt) with fresh medium (2.2.16.1). After 24 hours the medium was exchanged.  
2.2.16.3 Transfection of eukaryotic cells with plasmids 
Transfection is the introduction of nucleic acids (DNA or RNA) into cells. In this 
work HeLa cells were transfected with plasmids containing either a complete gene 
sequence or certain segments of a gene sequence to overexpress the appropriate 
DNA sequence in vivo. As transfection reagent lipofectamine 2000 (Invitrogen) was 
used according to the manufacturer’s instructions. Lipofectamine reagent forms 
cationic liposomes in an aqueous environment which entrap the negatively charged 
transfection material by forming complexes (Dalby et al., 2004). The cationic lipid 
molecules are formulated with a neutral lipid that ensures the introduction of the 
transfection material into the cells (Dalby et al., 2004). HeLa cells were cultured 
24 hours before transfection in 75 cm
2
 flasks (Sarstedt) so they have a confluence of 
70-90 % at the time of transfection. 30 µg of plasmid DNA was mixed with 1.875 ml 
Opti MEM (Invitrogen) and incubated for 5 minutes at room temperature. 75 µl 
lipofectamine 2000 was also mixed with 1.875 ml Opti MEM and incubated for 
5 minutes at room temperature. The plasmid DNA and the the lipofectamine mixture 
were combined and incubated for 25 minutes at room temperature. In the meanwhile 
cells were washed with DPBS and 9 ml DMEM with 1 x NEAA (Gibco) was added. 
The transfection mixture was added to the cells trop by trop and then incubated at 
37 °C. After 4-5 hours, 9 ml DMEM with 20 % FKS and 1 x NEAA was added to 
the medium. After transfection, cells were incubated at 37 °C for 24 hours total.   
2.2.17 Protein chemical methods 
2.2.17.1 Protein isolation from HeLa cells 
Nuclear proteins from HeLa cells were specifically isolated using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to the 
manufacturer’s instruction. First, the medium were removed and cells were washed 
twice with DPBS and then harvested using TrypLE Express (Invitrogen). To 
neutralise the trypsin, DMEM medium was added instead of DPBS and the cell 
suspension was centrifuged at 500 x g for 5 minutes. The supernatant was removed 





and the cell pellet washed by suspending in DPBS. The cell suspension was 
centrifuged again at 500 x g for 5 minutes. The supernatant was discarded and the 
cell pellet suspended in 1.5 ml DPBS and then transferred into a 1.5 ml e-cup. 
Following centrifugation steps were performed at 4 °C, cell samples and extracts 
were kept on ice. Next, the cells were centrifuged at 500 x g for 2-3 minutes. The 
supernatant was carefully removed to leave the cell pellet as dry as possible. 
Depending on the cell volume the reagent volume was determined as shown below. 
Table 36: Reagent volumes for different packed cell volume 
Packed Cell Volume (µl) CER I (µl) CER II (µl) NER (µl) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
100 1,000 55 500 
Right before using CER I and NER protease inhibitors (100 x stock) were added to 
maintain extract integrity and function. First, ice-cold CER I was added to the cell 
pellet which was then fully suspended by vortexing on the highest setting for 
15 seconds. After 10 minutes incubation, the appropriate amount on ice-cold CER II 
was added. The tube was vortexed for 5 seconds on the highest setting, then 
incubated for 10 minutes and vortexed again for 5 seconds on the highest setting. 
Samples were centrifuged for 5 minutes at maximum speed (~ 16,000 x g). The 
supernatant consisting of the cytoplasmic extract was transferred to a new prechilled 
tube. To the pellet which contains the nuclei, the appropriate amount on ice-cold 
NER was added. For a total of 40 minutes the tube was vortexed every 10 minutes 
for 15 seconds on the highest setting and then centrifuged for 10 minutes at 
maximum speed (~ 16,000 x g). The supernatant which contains the nuclear extract 
was transferred to a new prechilled tube. The protein concentration was determined 
by Synergy Mx spectrophotometer (BioTek). Extracts were aliquoted and stored at 
80 °C. 
2.2.17.2 Measurement of protein concentration 
After the principle according to Bradford (1976), the concentration of proteins was 
measured. Therefore, Roti
®
-Nanoquant (Roth) was employed as described by Witt 





(2013). This solution contains Coomassie Brilliant Blue that binds under acidic 
conditions to proteins which leads to a conversion of the red form to the blue form of 
the dye causing a shift in the absorption spectrum maximum from 365 nm to 595 nm 
(Bradford, 1976). A standard protein, namely BSA (0-6.7 µg BSA/ml), was used for 
calibration. Based on the standard curve the protein concentration could be 
extrapolated. A triple measurement of each sample was performed and the average of 
the values was determined. First, a 1:100 dilution of the desired protein extract was 
prepared. 50 µl of the diluted protein extract and 50 µl of ddH2O as a reference were 
put in a 96 well plate and 200 µl of the Roti
®
-Nanoquant solution was added. After 
5 minute incubation at room temperature, the absorption was measured at 590 and 
450 nm by Synergy Mx spectrophotometer.  
2.2.17.3 Co-IP 
The Co-IP is a technique used to analyse protein-protein interactions. With an 
antibody a known protein is targeted which is believed to be a member of a protein 
complex, the protein antigen is precipitated as well as proteins that are bound to it. 
By western blot analysis and further protein detection methods it might be possible to 
identify unknown complex members. For Co-IP nuclear cell extract was used and the 
immunoprecipitation of the target protein was carried out using the 
Immunoprecipitation Kit (Protein G) from Roche according to the manufacturer’s 
instructions with modifications regarding incubation times, number of washing steps 
and during centrifugation steps. Depending on the amount of nuclear cell extract, an 
appropriate amount of the specific antibody was added and the sample incubated on a 
rotating platform overnight at 4 °C (Roche protocol: 1 hour). The next day 45 µl of 
the protein G was added to a new tube and centrifuged for 1 minute at 13,000 rpm at 
room temperature (Roche protocol: 50 µl). The supernatant was removed and the 
overnight protein solution was added to the remaining protein G. Next, the mixture 
was incubated on a rotating platform for 2 hours at 4 °C (Roche protocol: 3 hours). 
Complexes were collected by 3 minutes centrifugation at 3,000 rpm at 4 °C (Roche 
protocol: 12,000 x g for 20 sec). After the supernatant was removed, the beads were 
washed using 500 µl of the lysis buffer (Roche protocol: 2 times 1 ml lysis buffer 
and 20 minutes incubation). The samples were centrifuged again for 3 minutes at 
3,000 rpm at 4 °C (Roche protocol: 12,000 x g for 20 sec). The beads were 
resuspended in 1 ml wash buffer 2 and centrifuged under the same conditions as 





before (Roche protocol: centrifugation at 12,000 x g for 20 sec after 20 minutes 
incubation). After the supernatant was removed, a final washing step using 1 ml 
wash buffer 3 was performed (Roche protocol: 2 times 1 ml wash buffer 3 and 
20 minutes incubation). The following preparation to load the sample on an SDS gel 
was performed differently. The supernatant was removed after centrifugation and 
18 µl DPBS (PAN), 18 µl LDS (Invitrogen) and 4 µl 1M DTT were added to the 
beads. To denaturise proteins and separate them from the protein G beads, the 
mixture was incubated for 5 minutes at 95 °C. Beads were centrifuged down and the 
supernatant was loaded on an SDS gel and further analysed by western blot 
(2.2.17.5). 
2.2.17.4 SDS polyacrylamide gel electrophoresis 
By SDS polyacrylamide gel electrophoresis (SDS PAGE) proteins are denaturised 
and can be separated according to their molecular weight in a polyacrylamide gel by 
an electric field (Shapiro et al., 1967; Laemmli, 1970). In this work 4-12 % Bis-Tris 
Gels (Invitrogen) and 3-8 % Tris-Acetate Gels 3-8 % Tris-Acetate Gels (Invitrogen) 
were used for protein separation (2.2.17.5). 
2.2.17.5 Western blot 
The western blot is an analytical technique and this method was used to transfer 
proteins from an SDS gel to a nitrocellulose membrane where the proteins can be 
detected by different reactions (Towbin et al., 1979; Towbin and Gordon, 1984; 
Towbin et al., 1992). 
Protein extracts used for Co-IP were incubated with 18 µl DPBS (PAN), 18 µl LDS 
(Invitrogen) and 4 µl 1M DTT for 5 minutes at 95 °C. After spinning down the 
Protein-G-agarose beads, 30 µl of the supernatant which contains the precipitated 
protein along with other proteins bound to it in a denaturised form was loaded on an 
SDS gel. Two different transfer methods were used in this work. 
a) semidry 
With this transfer variant proteins < 100 kDa were transferred from an SDS gel to a 
membrane. Using MES SDS Running Buffer (Invitrogen) and a 4-12 % Bis-Tris Gel 
(Invitrogen), proteins were separated according to their molecular weight. For 
approximately 2.5-3 hours the gel was running at 100 V. The protein transfer was 





performed according to Wieczerzak (2012). The blotting condition was changed to 
220 mA instead of 230 mA. 4 Whatman Papers which were soaked in transfer buffer 
were placed on the Turboblotter
TM
 (Schleicher & Schuell). A nitrocellulose 
membrane which was wetted in ddH2O and transfer buffer was put on top of it 
followed by the SDS gel and another 4 prewetted Whatman Papers. Approximately 
50 ml transfer buffer were needed. The blotting was performed at constant 150 mA 
for 15 minutes followed by 45 minutes at 220 mA. 
b) wet blot 
 
This transfer method is appropriate for larger proteins (> 100 kDa). First proteins 
were separated according to their molecular weight using gel electrophoresis. 
Therefore, Acetate SDS Running Buffer (Invitrogen) and 3-8 % Tris-Acetate Gels 
(Invitrogen) were used. The running time of the gel amounted 3-3.5 hours at 100 V. 
To prevent heating of the buffer, the gel chamber was placed in an ice box. Once the 
proteins were separated, the “gel-sandwich” was assembled in transfer buffer to 
avoid bubbles according to BIO-RAD (n.d.). On the grey coloured side of the 
cassette (Bio-Rad) a foam pad was placed followed by 2 Whatman Papers, a 
nitrocellulose membrane and the SDS gel. Finally, 2 Whatman Papers and another 
foam pad were placed on top. The cassette was closed and placed vertically between 
parallel electrodes in the buffer tank (Bio-Rad) containing a frozen blue cooling unit 
and the transfer buffer (Tab. 13). To avoid the formation of an ion gradient and to 
insure the temperature homogeneity, a magnetic stir bar was placed in the buffer tank 
which was put in a box filled with ice on a magnetic stirrer. For the blotting at 4 °C, 
the voltage was set on 60 V constant for 2.5 hours. 
2.2.17.6 Protein detection using antibodies 
Once the protein transfer from the SDS gel to the membrane was completed, the 
membrane was transferred into a falcon tube (CellSTAR) and unspecific binding 
sites were blocked by incubating the membrane in TBST with 5 % milk or 5 % BSA 
for 1-2 hours at room temperature. During incubation steps membranes were placed 
on a rolling platform. The membrane was then incubated overnight at 4 °C with the 
appropriate primary antibody. Antibodies were diluted 1:1,000 to 1:2,000 in TBST 
with 2 % milk or 2 % BSA. Next day the membrane was washed three times for 
10 minutes in 20 ml TBST with 2 % milk or TBST if BSA was used. The membrane 





was then incubated for 2 hours at room temperature or at 4 °C with a secondary 
antibody conjugated to horseradish peroxidase (HRP). The antibodies were 1:7,000 
to 1:10,000 diluted in TBST with 2 % milk (incubation at room temperature) or 2 % 
BSA (incubation at 4 °C). After that, the membrane was washed three times for 
10 minutes in TBST with 2 % milk and once with TBST for 5 minutes or three times 
for 10 minutes with TBST at room temperature. To visualise proteins, SuperSignal
TM 
West Pico Chemiluminescent Substrate (Thermo Scientific) was used according to 
the company’s instructions. To prepare the substrate working solution, the two 
substrate components were mixed in a 1:1 ratio (light sensitive). The membrane was 
placed between a clear plastic wrap and incubated 5 minutes in the dark with 
SuperSignal West Pico Substrate Working Solution. HRP produces a detectable light 
signal in the presence of a substrate which can be either detect on X-ray films or by 
the detecting system FlourChem
®
 Q (Alpha Innotech).    
2.2.18 Direct yeast two-hybrid  
The direct Y2H assay is used to identify and investigate protein-protein interactions 
in vivo using yeast cells. Two proteins of interest are expressed separately. The 
protein functioning as a bait protein is fused to the Gal4 DNA-binding domain (e.g. 
pGBKT7 plasmid) while the other one functions as the prey protein which is fused to 
the Gal4 transcriptional activation domain (e.g. pGADT7 plasmid) (Fields and Song, 
1989). Only if a cell contains both proteins that interact with each other, the Gal4 
DNA activator is able to bind to the GAL4 DNA binding domain and activates the 
Gal4-responsive reporters ADE2 and HIS3 (Clontech_Laboratories, 2009a). That 
means the amino acids adenine and histidine are expressed. Furthermore, the bait 
plasmid encodes tryptophan (TRP1) (Clontech_Laboratories, 2008) and the prey 
plasmid encodes leucine (LEU2) (Clontech_Laboratories, 2012). By plating yeast 
cells on an appropriate synthetic dropout (SD) medium, transformants containing the 
introduced plasmid(s) can be selected. LT SD-plates contain every essential amino 
acid except for leucine and tryptophan. They are used as a transformation control 
because only cells containing bait and prey plasmids are able to grow. To confirm a 
direct interaction of two proteins, co-transformed yeast cells are plated on LTHA 
SD-plates (the medium includes every essential amino acid except for leucine, 
tryptophan, histidine and adenine). Only cells are able to grow that harbor bait and 





prey plasmids and additionally express proteins that interact with each other to 
activate HIS3 and ADE2, so the lacking nutritional factors in the medium can be 
expressed.  
In this work the LiAc method (Ito et al., 1983) modified by Schiestl and Gietz 
(1989); Hill et al. (1991); Gietz et al. (1992) was used as a simple and highly 
reproducible method according to the Yeast Protocols Handbook 
(Clontech_Laboratories, 2009b) with slightly modifications. 
Yeast cells (Y2H Gold, Clontech) from a working stock plate were inoculated in 
25 ml instead of 50 ml yeast medium. The yeast containing medium was vigorously 
mixed to disperse the cells and cultured overnight (16-18 hours) at 30 °C shaking at 
220 rpm instead of 250 rpm. To get a mid-log phase culture, 4.5 ml of the overnight 
culture (OD600 > 1.5) was transferred to 150 ml fresh yeast medium to have an 
OD600 ~ 0.2-0.3 and cultured at 30 °C shaking at 220 rpm (Clontech protocol: 
230 rpm) for 3-5 hours until the culture had an OD600 ~ 0.5. The culture was poured 
into 50 ml tubes and centrifuged at 1,000 x g for 5 minutes at room temperature. The 
supernatants were discarded and the pellets thoroughly resuspended in ddH2O and 
then pooled in one tube with a final volume of 25 ml. The sample was centrifuged 
again at 1,000 x g for 5 minutes at room temperature and the supernatant discarded. 
The cell pellet was resuspended in 1 ml freshly prepared, sterile 1 x TE/1 x LiAc 
(Clontech protocol: 1.5 ml). 1 µg of each plasmid and 0.1 mg of denaturised carrier 
DNA were mixed with 100 µl of yeast competent cells. 600 µl freshly prepared 40 % 
PEG/1 x TE/1 x LiAc was added and vortexed. Probes were incubated at 30 °C for 
30 minutes shaking at 200 rpm. 70 µl DMSO were added and mixed by gentle 
inversion. Next, a heat shock was performed at 42 °C for 15 minutes to promote the 
intake of plasmids into cells. After that, samples were incubated on ice for 
12 minutes. Cells were centrifuged for 5 seconds at 14,000 rpm at room 
temperature, the supernatant was discarded and the cells resuspended in 300 µl 
ddH2O (Clontech protocol: 500 µl TE buffer). Cells were plated on LT SD agar 
plates as transformation control and on a LTHA SD agar plate. Plates were 
incubated up-side-down at 30 °C for 3-7 days. 





2.2.19 Cytological and histological methods 
2.2.19.1 Immunocytochemistry with eukaryotic cells 
Immunocytochemistry (ICC) is a common method to detect proteins in cells using 
primary antibodies against the protein of interest. With a secondary antibody 
conjugated with a fluorophore, the localisation of the target protein can be visualised 
by a fluorescence microscope. The ICC was performed according to the ICC protocol 
from abcam with some modifications according to incubation times and 
concentrations (Abcam, n.d.). 
One day before, HeLa cells were cultured on slides (BD Biosciences). The medium 
was removed and cells were washed twice with PBS. After that, cells were fixated 
for 20 minutes with 4 % formaldehyde in PBS (abcam protocol: 15 minutes). If not 
indicated differently, all steps were carried out at room temperature. After the 
fixation cells were washed twice for 5 minutes with PBS and then permeabilised for 
10 minutes using 0.1 % Triton X-100 in PBS (abcam protocol: 0.25 % Triton X-
100). After washing the cells twice with PBS for 5 minutes (abcam protocol: 3 times 
for 5 minutes), 3 % BSA in PBS were added to the cells to block unspecific binding 
sides (abcam protocol: 1 % BSA in PBST). After 20-30 minutes the blocking 
solution was removed and the primary antibody 1:100 diluted in 3 % BSA/PBS was 
added to the cells and incubated overnight at 4 °C (abcam protocol: 1 % BSA in 
PBST). The next day the primary antibody dilution was removed and cells were 
washed twice for 10 minutes with PBS (abcam protocol: 3 times 5 minutes). The 
secondary antibody conjugated with Cy3 was diluted 1:200 in 3 % BSA/PBS and 
added to the cells which were incubated afterwards for 2 hours (abcam protocol: 1 % 
BSA for 1 hour). The last steps of the abcam protocol were performed differently. 
After washing the cells three times for 10 minutes in PBS and once with ddH2O, 
Vectashield containing DAPI were added to the cells to stain the nuclei. The cells on 
the slide were closed by a cover slip and edges were sealed with nail polish. 
2.2.19.2 Duolink PLA  
The Duolink PLA method can be used to detect, visualise and quantify protein 
interaction in cells and tissues prepared for microscopy. The principle of this assay is 
based on in situ PLA
®
, a proximity ligation assay technology (OlinkBiosciences, 





2010). Two primary antibodies are used which are raised in two different species to 
detect the protein of interest. As secondary antibodies serve PLA probe PLUS and 
PLA probe MINUS which are conjugated with oligonucleotides (OlinkBiosciences, 
2010). The two PLA probes generate a signal only when they bind to primary 
antibodies which have bound the target in close proximity (OlinkBiosciences, 2010). 
The signal is visible as an individual fluorescent spot. 
In this work adherent human HeLa cells were used cultured in 8-well chamber slides 
(BD Biosciences) one day before starting the Duolink PLA method according to the 
manufacturer’s instructions with some modifications. All steps were carried out at 
room temperature unless otherwise described. Cells were carefully washed twice 
with PBS to fully remove the medium. Next, the cells were fixed for 20 minutes in 
PBS with 3.7 % formaldehyde. After cells were washed twice for 5 minutes in PBS, 
a permeabilisation step was performed for 10 minutes using PBS with 0.1 % Triton 
X-100 to ensure access of the antibodies. Again, cells were washed twice for 
5 minutes in PBS. To ensure that all non-specific binding sites are neutralised, cells 
were blocked in a preheated humidity chamber for 30 minutes at 37 °C with 
Blocking Solution (1 drop per reaction area), a component of the Duolink reagents. 
Primary antibodies were diluted 1:100 in Antibody Diluent which is another Duolink 
reagent. Cells were incubated overnight in a humidity chamber at 4 °C with diluted 
primary antibody combinations (30 µl per reaction area): The next day the primary 
antibodies were tapped off the slides which were then washed three times instead of 
two times for 5 minutes with gentle shaking in cuvettes containing at least 70 ml of 
Buffer A (prepared according to the manufacturer’s instructions, Tab. 10). The two 
PLA probes were diluted 1:5 in Antibody Diluent and added to the cells (25 µl per 
reaction area). The slides were incubated in a preheated humidity chamber for 1 hour 
at 37 °C. After the incubation, the PLA probe solution was tapped off the slides. 
Before adding the ligation-ligase solution to the cells, slides were washed three times 
instead of two times for 5 minutes with Buffer A. The 5 x ligation stock was diluted 
1:5 in ddH2O. It contains two oligonucleotides that hybridise to the conjugated 
oligonucleotides of the PLA probes as well as all components necessary for ligation, 
except for the ligase. The ligase (1 U/µl) was diluted 1:40. The ligation-ligase 
solution was added to the cells (25 µl per reaction area) which were then incubated in 
a preheated humidity chamber for 30 minutes at 37 °C. The hybridised 
oligonucleotides will join to a close circle if the two PLA probes are in close 





proximity, acting as a template for the following amplification step. The slides were 
washed twice for 2 minutes in Buffer A. Next, the amplification solution consisting 
of the 1:5 diluted amplification stock (light sensitive!) and the 1:80 diluted 
Polymerase (10 U/µl) were added (30 µl per reaction area) and slides were incubated 
in a preheated humidity chamber for 100 minutes at 37 °C. During the amplification 
reaction the ligated circle of oligonucleotides acts as a template for rolling-circle 
amplification (OlinkBiosciences, 2010). The oligonucleotide of one PLA probe 
functions as a primer (OlinkBiosciences, 2010). Fluorescently labeled 
oligonucleotides hybridise to the amplified product which will be visible as a distinct 
fluorescent spot under the fluorescence microscope indicating a protein interaction 
(OlinkBiosciences, 2010). After that slides were washed twice for 10 minutes in 
minimum 70 ml Buffer B (prepared according to the manufacturer’s instructions, 
Tab. 10) followed by an additional wash step with 0.1 x Buffer B for 1 minute. 
Divergent from the manufacturer’s protocol the cytoskeleton of the cells were stained 
with FITC Phalloidin (Sigma-Aldrich) using a 1:700 dilution in Antibody Diluent 
(20 µl per reaction area) for 30 minutes. After two final wash steps with 0.1 x Buffer 
B for 10 minutes, the slides were air dried in the dark before they were mounted with 
cover slips and Mounting Medium containing DAPI (Vector) to stain the nuclei. The 
edges were sealed using nail polish. Slides were incubated at least 15 minutes in the 
dark before documented using a fluorescence microscope (Olympus) and a confocal 
laser scanning microscope (Olympus). 
2.2.19.3 Immunohistochemistry (3,3'-Diaminobenzidine (DAB) staining) 
For immunohistochemistry the Novocastra
TM
 Novostain Universal Detection Kit 
(Leica) and DAB (Roche) were used after Batsukh et al. (2012) with slightly 
modifications. Paraffin sections on slides were deparaffinised by incubating 
10 minutes in xylene followed by two additional incubating steps in fresh xylene for 
5 minutes, respectively. Next, tissue samples were hydrated by a decreasing ethanol 
row (100 %, 95 %, 90 %, 80 %, 70 % and 50 % ethanol/H2O). Additionally to the 
procedure conducted by Batsukh et al. (2012), slides were rinsed carefully with 
ddH2O and then incubated for 5 minutes instead of 2 minutes in PBS. Next, slides 
were placed in a cuvette with an antigen retrieval buffer (Tab. 9) and boiled for 
10 minutes in a steam cooker. Then, the cuvette with the slides was placed on ice for 
approximately 10-20 minutes. To block the endogenous peroxidase activity, the 





tissue samples were incubated with 3 % H2O2 in methanol instead of 6 % H2O2 in 
H2O for 15 minutes in a humidity chamber. After that, non-specific binding sites 
were blocked using prediluted horse serum (Leica). After 10 minutes incubation, the 
primary antibodies (1:50 to 1:100 diluted in 1:1 horse serum and TPBS (PBS + 0.2 % 
Tween 20) were added on the tissue samples. Samples were incubated overnight 
(maximum 16 hours) at 4 °C in a humidity chamber. The next day the slides were 
taken from 4 °C and incubated for 1 hour at room temperature before they were 
washed for 5 minutes in PBS with 0.1 % Tween 20. The prediluted biotinylated 
universal secondary antibody (Leica) was added to the tissue samples which were 
incubated for 10 minutes. After washing the slides for 5 minutes in PBS with 0.01 % 
Triton X-100, tissue samples were incubated for 5 minutes in a prediluted 
Streptavidin peroxidase complex reagent (Leica). Streptavidin has a high affinity to 
biotin, so it binds to the biotinylated universal secondary antibody. Slides were 
washed again for 5 minutes in PBS with 0.1 % Tween 20 and then tissue samples 
were incubated up to 2 minutes in 1 x DAB solution (Roche). DAB is oxidised by the 
peroxidase conjugated to Streptavidin which causes a brown colour. After washing 
the slides for 5 minutes in PBS with 0.1 % Tween 20 instead of water, the nuclei 
were stained with haematoxylin. The slides were washed three times with ddH2O, 
then covered with Aqua-Poly/Mount Coverslipping Medium (Polysciences) and a 
cover slip and the samples were analysed using a BX60 microscope (Olympus). 
2.2.20 Mutational analysis 
To screen for mutations in genes, the sequence of all coding exons and flanking 
intronic areas of the concerning gene was analysed by touchdown PCR (2.2.7.1). The 
PCR products were cleaned up by vacuum purification using MultiScreen Filter 
Plates (Merck Millipore). Each well of the plate was equilibrated with 100 µl TE 
buffer. Another 100 µl TE buffer was added to the 25 µl PCR reactions and mixed by 
pipetting. Then, each mixture was put onto a well of the plate. The vacuum pump 
(Merck Millipore) was turned on and the liquid in the wells were sucked off. To elute 
the DNA, 50 µl ddH2O was added to each well and pipetted up and down several 
times. Next, the purified DNA was sequenced in both directions (2.2.7.2). 
Oligonucleotides used for touchdown PCR and sequencing are listed in table 20. 
To screen for large deletions or duplications within a gene, qPCRs were performed 
for each coding exon (Tab. 33). 





2.2.21 Molecular biological methods concerning the model organism Xenopus 
laevis 
2.2.21.1 In vitro transcription of sense RNA 
To synthesise large amount of capped RNA that mimics most eukaryotic mRNAs in 
vivo, the mMESSAGE mMACHINE
®
 SP6 or T7 Transcription Kits (Ambion) were 
used. These synthesised capped RNAs are ideal for oocyte microinjection (Ambion, 
2012). The transcription reaction was assembled at room temperature according to 
the company’s instructions. A 20 µl transcription mixture was prepared using 1 µg 
linearised plasmid template, 10 µl 2 x NTP/CAP, 2 µl 10 x reaction buffer and 2 µl 
10 x enzyme mix containing the appropriate RNA polymerase. The mixture was 
brought to a final volume of 20 µl with nuclease free H2O and then mixed thoroughly 
and incubated 2 hours at 37 °C. Next, the template DNA was removed by adding 
1 µl TURBO DNase (2 U/µl) during a 15 minutes incubation at 37 °C. After the 
DNase treatment, the sense RNA was purified. 
2.2.21.2 Purification of sense RNA 
To purify sense RNA for oocyte microinjection, the Illustra
TM
 RNAspin Mini (GE 
Healthcare) was used according to the manufacturer’s instructions. All centrifugation 
steps were carried out at room temperature. To purify a 20 µl transcription reaction, 
3.5 volume of Buffer RA1 (70 µl) and 95-100 % ethanol (70 µl), respectively were 
added, mixed and supplied on a column (blue). Next, samples were centrifuged at 
8,000 x g for 30 seconds and the flow through was discarded. 200 µl Buffer RA2 was 
added onto the column which was centrifuged at 11,000 x g for 1 minute. The 
column was placed in a new collection tube and 600 µl Buffer RA3 was added. After 
centrifugation at 11,000 x g for 1 minute, the flow through was discarded and 250 µl 
of Buffer RA3 was supplied onto the column. To dry the membrane, the column was 
centrifuged at 11,000 x g for 2 minutes. The column was placed into a new 1.5 ml 
tube. 33-35 µl preheated RNase free H2O was added directly to the center of the 
membrane. The column was incubated for 2 minutes at 80 °C and then centrifuged at 
11,000 x g for 1 minute. The concentration of sense RNA was determined using the 
NanoDrop 2000c spectrometer (Thermo Scientific) and stored at -80 °C. 





2.2.21.3 In vitro transcription of labeled anti-sense RNA 
For whole mount in situ hybridisation (WMISH) experiments digoxigenin (DIG) 
labeled anti-sense RNA was synthesised using a DIG-RNA labeling mixture (Roche) 
according to Hedderich (2012) with additional use of Pyrophosphatase, different 
amount of polymerases and modification of DNase incubation time. For a total 
transcription reaction of 25 µl following chemicals were assembled (Tab. 37).  
Table 37: Reaction conditions (in vitro transcription of labeled anti-sense RNA) 
volume  chemicals 
5 µl 5 x transcription buffer (Fermentas) 
0.5 µl Pyrophosphatase (4 U/ml) 
4 µl DIG-mix (ATP, CTP, GTP, UTP/digoxigenin UTP (Roche) 
1 µl 0.75 M DTT 
1 µl RNaseOut (40 U/µl, Invitrogen) 
0.2-1 µg linearised template DNA 
1 µl T7 or SP6 RNA polymerase (20 U/μl, Fermentas) 
to 25 µl RNase free H2O 
The transcription reaction was incubated at 37 °C for 2 hours. To remove the 
template DNA, 1 µl TURBO DNase (2 U/µl) was added and the sample was 
incubated at 37 °C for 15 minutes. Next, the anti-sense RNA was purified. 
2.2.21.4 Purification of labeled anti-sense RNA 
To clean up labeled anti-sense RNA for oocyte microinjection, the RNeasy
TM
 Mini 
Kit (Qiagen) was used according to manufacturer’s manual. All centrifugation steps 
were carried out at room temperature. First, the transcription mixture was adjusted to 
a volume of 100 µl using RNase free H2O. Next, 350 µl Buffer RLT was added and 
mixed well. After that, 250 µl ethanol (96-100 %) was added to the diluted RNA and 
mixed well. The solution was transferred immediately onto an RNeasy Mini spin 
column that was centrifuged at 10,000 rpm for 15 seconds. The flow-through was 
discarded and 500 µl Buffer RPE was added to the column for washing. The column 





was centrifuged at 10,000 rpm for 15 seconds and the flow-throw was discarded. 
Again, 500 µl Buffer RPE was added to the column that was centrifuged at 
10,000 rpm for 2 minutes. The column was placed into a new 2 ml collection tube 
and centrifuged at full-speed for 1 minute. The column was placed into a new 1.5 ml 
receiver tube. 50 µl preheated RNase free H2O was added to the center of the 
membrane and the column was incubated at 80 °C for 2 minutes. To elute the RNA, 
the column was centrifuged at 10,000 rpm for 1 minute. To determine the 
concentration of the anti-sense RNA, the NanoDrop 2000c spectrometer (Thermo 
Scientific) was used. The anti-sense RNA was stored at -80 °C. 
2.2.21.5 Morpholino oligonucleotides 
The Morpholino oligonucleotides (MO) were purchased from Gene Tools, LLC. The 
MO were dissolved at 65 °C in RNase free H2O and diluted to a final concentration 
of 8 μg/10 nl. MO were stored at 4 °C and heated up for 10 minutes at 65 °C before 
usage.  
2.2.21.6 Preparation of Xenopus laevis testis and fertilisation of oocytes 
The preparation of the testis and fertilisation of oocytes have been carried out by Dr. 
Peter Wehner according to Wehner (2012). To isolate sperm from testis, male 
Xenopus laevis were put into a 0.05 % benzocaine/water solution for 30 minutes at 
room temperature. Frogs were decapitated and the testis was removed, then washed 
three times with MBS and stored in 1 x MBS buffer at 4 °C. To stimulate the egg 
deposition, female Xenopus laevis frogs were injected into the dorsal lymph sac with 
1,000 units human chorionic gonadotropin (hCG) hormone (Sigma-Aldrich). 
Approximately 12 hours after injection the female frogs lay eggs. These eggs were 
fertilised in vitro. Therefore, a piece of testis was macerated in 0.1 x MBS. To 
remove the jelly coat from fertilised eggs, they were incubated for 3-5 minutes with 
2 % cysteine hydrochloride (pH 8). 
2.2.21.7 Microinjection of Xenopus laevis embryos and culture 
Microinjections of Xenopus laevis blastomeres have been performed by Dr. Peter 
Wehner according to Wehner (2012). For microinjection fertilised eggs were put into 
injection buffer and placed on a cooling plate. Glass capillaries that were prepared 
with a needle puller were loaded with the substances needed for microinjection. The 





injection was carried out using the Microinjector 5242 (Eppendorf). 4-10 nl β-
galactosidase (lacZ) mRNA (W. C. Smith and Harland, 1991) and MO were injected 
animally into one blastomere of a two-cell stage embryo. The MO used are short 
oligonucleotides that interfere with the target mRNA to block translation. To allow 
the heeling after injection, embryos were kept for 1-2 hours in injection buffer. After 
that, they were washed twice with 0.1 x MBS. Embryos were cultured to the desired 
stage in 0.1 x MBS at 12.5 to 18 °C. The developmental stages were determined 
according to Nieuwkoop and Faber (Hubrecht-Laboratorium (Embryologisch 
Instituut) et al., 1967). 
2.2.21.8 Fixation of injected Xenopus laevis embryos and X-gal staining 
Fixation and X-gal staining of Xenopus laevis embryos have been performed by Dr. 
Peter Wehner and me according to Wehner (2012). This procedure is used for 
WMISH to determine the lacZ mRNA injected region of the embryo (Hardcastle et 
al., 2000). The lacZ mRNA is co-injected as a lineage tracer with the appropriate 
MO. After injected embryos developed to the desired stage, they were fixated for 
1 hour in MEMFA. All steps were carried out at room temperature. After the 
fixation, embryos were washed three times for 10 minutes with 1 x PBS and then 
stained with X-gal solution in the dark until the requested intensity of staining was 
achieved. The X-gal solution was removed and embryos were washed three times for 
10 minutes in 1 x PBS. Next, embryos were fixed again for 1 hour in MEMFA. 
Afterwards, embryos were washed three times with 100 % ethanol. Embryos were 
long term stored in 100 % ethanol at -20 °C.   
2.2.21.9 Whole mount in situ hybridisation 
With this technique the localisation of mRNA within an embryo can be visualised 
using a labeled specific complementary RNA probe. The WMISH was performed as 
described by Harland (1991) with some modifications. 
Detailed procedure of the WMISH on Xenopus laevis: 
Day 1 
All incubation steps were performed under gentle shaking. Xenopus laevis embryos 
were rehydrated by a decreasing ethanol row (75 % EtOH/H2O, 50 % EtOH/H2O, 





25 % EtOH/PTw) followed by five washing steps with PTw. Each step was carried 
out for 5 minutes at room temperature. 
To permeabilise the embryos to ensure fully penetration of RNA probes, embryos 
were treated with proteinase K (10 µg/ml) in PTw as described in table 38. 
Table 38: Proteinase K treatment of Xenopus laevis embryos 
Developmental stage of 
Xenopus laevis embryos 
Incubation time (min) Temperature 
9-10.5 6-8 room temperature 
14-16 8-10 room temperature 
20-25 15-18 room temperature 
36 22-25 room temperature 
40 17-20 37 °C 
42-43 27-30 37 °C 
46 32-35 37 °C 
 
The following acetylation step increases the specific binding of the probe to mRNA. 
Therefore, the embryos were washed twice in 0.1 M Triethanolamine (pH 7.5) for 
5 minutes, respectively. After that, embryos were incubated for 5 minutes in 4 ml 
Triethanolamine with 12.5 µl Acetic Anhydride. Additional 12.5 µl Acetic 
Anhydride was added followed by two 5 minute washing steps with PTw. 
Subsequent to the acetylation embryos were fixed for 20 minutes in PTw containing 
4 % formaldehyde and then washed five times with PTw buffer for 5 minutes, 
respectively. 
For the following hybridisation embryos were left in 1 ml PTw and 250 µl 
prewarmed Hybmix was added and carefully mixed. The solution was replaced by 
1 ml fresh Hybmix and after 10 minutes incubation at 60 °C replaced again by 1 ml 
Hybmix. After 4-5 hours incubation at 60 °C, the Hybmix was exchanged and the 
embryos hybridised over night at 60 °C with the desired antisense RNA probe 
diluted in Hybmix.   






The next day the RNA probe was removed and preheated Hybmix was added to the 
embryos which were incubated for 10 minutes at 60 °C. After that, the embryos were 
incubated three times for 15 minutes in 2 x SSC at 60 °C. An RNase mix containing 
2 x SSC, 10 µg/ml RNase A and 0.01 U/ml RNase T1 was added to the embryos to 
degrade mismatched double stranded RNA. After an incubation time of approximate 
40 minutes at 37 °C and 30 rpm, the RNase mix was washed away with 2 x SSC for 
5 minutes at room temperature followed by two additional washing steps with 0.2 x 
SSC for 30 minutes at 60 °C as well as two further wash steps with 1 x MAB for 
15 minutes at room temperature.  
Next, the antibody reaction took place. First, embryos were washed once with MAB 
containing 2 % of the blocking reagent BMB for 15 minutes at room temperature 
followed by 40 minutes incubation in MAB containing 2 % BMB and 20 % horse 
serum at room temperature. The next 4 hours the embryos were treated with MAB 
containing 2 % BMB, 20 % horse serum and 1:5,000 diluted Sheep Alkaline 
phosphatase-coupled anti-Dig antibody at room temperature. After the antibody 
incubation, the embryos were washed three times with MAB for 10 minutes at room 
temperature. Embryos were kept in fresh MAB over night at 4 °C. 
Day 3 
The next day, the washing with MAB was continued five times for 5 minutes at room 
temperature, respectively. In preparation to the colour reaction the embryos were 
washed twice for 5 minutes at room temperature with fresh prepared APB. For the 
colour reaction itself the embryos were incubated up to 3 days at 4 °C in 3 ml APB 
solution containing 2.4 µl NBT (100 mg/ml) and 10.5 µl BCIP (50 mg/ml). 
To reduce background after staining, a decreasing methanol row (one minute or 
longer in 100 % methanol, one minute in 75 %, 50 % and 25 % methanol/H2O, 
respectively) can be performed. After removing the background, the pigmented 
embryos were bleached at room temperature to remove the pigmentation which can 
interfere the staining. Therefore, the embryos were fixated in MEMFA for 
30 minutes and washed twice for 5 minutes in 5 x SSC. Next, the embryos were 
bleached up to 30 minutes in 5 x SSC containing 50 % formamide and 2 % H2O2. 
Finally, embryos were washed twice for 5 minutes in 5 x SSC and 30 minutes in 





MEMFA. Before documentation, the embryos were washed three times for 5 minutes 
in PTw. Embryos were stored in 100 % ethanol at -20 °C.    







 generation of constructs (recloning of the gene of interest in the pCMV-HA 
vector) 
 PCR to amplify the plasmid with gene of interest 
 gel extraction 
 restriction digestion 
 ethanol precipitation 
 cloning by In-FusionTM or ligation 
 transformation 
 mini-preparation of plasmid with appropriate insert 
 test digestion 
 purification of mini-preparation 
 sequencing 
 midi-preparation of plasmid with appropriate insert 
 transfection of HeLa cells 
 isolation of nuclear proteins from HeLa cells 
 Co-IP 
 separation according to the molecular weight on SDS gel 
 western blot 
 antibody treatment 
 detection of protein signals 
Immunocytochemistry 
 culture HeLa cells on slides 
 fixation of cells 
 permeabilisation of cells 
 blocking 
 antibody treatment 
 data analysis 
Duolink  
 culturing HeLa cells on 8-well chamber slides 
 fixation of cells 





 permeabilisation of cells 
 Duolink  
 staining the cytoskeleton of cells with FITC Palloidin and the nuclei with 
DAPI 
 data analysis (fluorescence microscope/confocal laser scanning microscope) 
Yeast two-hybrid  
 generation of constructs 
 PCR to amplify the gene of interest 
 gel extraction 
 restriction digestion of the plasmid 
 if necessary ethanol precipitation and treatment with Antarctic 
phosphatase 
 cloning by In-FusionTM  
 transformation 
 mini-preparation of plasmid with appropriate insert 
 test digestion 
 purification of mini-preparation 
 sequencing 
 (midi-preparation of plasmid with appropriate insert) 
 Yeast two-hybrid 
Transcriptome, micro array 
 mating heterozygous (Chd7Whi/+) female and male mice 
 preparation of E9.5 embryos 
 tail biopsy for genotyping and shock freezing of the embryo 
 determination of the genotype 
 isolating of genomic DNA 
 genotyping PCR 
 test agarose gel 
 purification of genotyping PCR samples 
 sequencing PCR 
 determination of gender by PCR 
 RNA isolation of E9.5 embryos 
 micro array 





 data analysis 
Confirmation of micro array by RT-qPCR 
 mating heterozygous (Chd7Whi/+) female and male mice 
 preparation of E9.5 embryos 
 tail biopsy for genotyping and shock freezing of the embryo 
 determination of the genotype 
 determination of gender by PCR 
 RNA isolation of E9.5 embryos 
 reverse transcription (cDNA synthesis) 
 test primer for RT-qPCR by PCR 
 RT-qPCR 
 data analysis 
 
DAB staining 
 mating wild-type female and male mice of the CD-1 strain 
 preparation of E12.5 embryos 
 fixating embryos overnight in 4 % paraformaldehyde/PBS 
 prepare embryos for embedding in paraffin 
 paraffin sections 
 preparing the sections for immunostaining with DAB 
 Xylenel treatment and rehydration 
 boiling in EDTA 
 blocking step and antibody incubation 
 DAB staining 
 data analysis  
Patient screen 
          Mutation screen 
 generate primers for each exon of the gene of interest 
 PCR to amplify each exon of the gene of interest 
 purify PCR samples 
 sequencing 
 data analysis 





          Deletion/Duplication screen 
 generating primers for each exon of the gene of interest 
 test primers in a qPCR using wild-type genomic DNA 
 measurement of DNA concentration of patient samples 
 qPCR 
 data analysis 
Whole mount in situ hybridisation 
 generating sense and labeled anti-sense probes 
 digestion of plasmid with the appropriate gene 
 purification of digested plasmids 
 in vitro transcription of sense and labeled anti-sense RNA 
 purification of sense and labeled anti-sense RNA 
 measurement of RNA concentration of sense and labeled anti-sense 
RNA 
 injection of one blastomere of a two-cell Xenopus laevis oocytes with MO 
 collection of embryos at the desired stage 
 fixation and X-gal staining of embryos 
 whole mount in situ hybridisation 












3.1 CHD7 interacts with components of the WAR complex 
Chromatin remodelling enzymes are known to form large multi-subunit complexes 
(Mohrmann and Verrijzer, 2005; Ho et al., 2009a). It was shown that CHD7 interacts 
with the chromatin remodelling enzyme CHD8, which in turn interacts with 
components of the WAR complex (Batsukh et al., 2010; Yates et al., 2010). The 
following described data are published by us (Schulz et al., 2014a). To prove 
whether CHD7 also interacts with the members of the WAR complex WDR5, 
ASH2L and RBBP5, Co-IP experiments on human HeLa cells were performed 
(Fig. 5).  
HeLa cells were single transfected with pCMV-HA plasmids containing the human 
full-length sequence of ASH2L (NP_004665.2) or RBBP5 (NP_005048.2). 
Untransfected HeLa cells were used as a negative control. Using a CHD7 antibody, 
endogenous CHD7 was precipitated. With an HA antibody the overexpressed 
proteins ASH2L (Fig. 5A, lane 1) and RBBP5 (Fig. 5A, lane 2) were detected. As 
expected no band was observed for the negative control (Fig. 5A, lane 3). Bands of 
the appropriate size were observed after detecting the overexpressed proteins ASH2L 
and RBBP5 with an HA antibody, confirming the successful transfection (Fig. 5A, 
lane 4+5). Co-IPs where endogenous CHD8 was precipitated with a CHD8 antibody 
and overexpressed ASH2L (Fig. 5B, lane 1), RBBP5 (Fig. 5B, lane 2) and the CHD7 
fragment (amino acids 1591-2181, NP_060250.2) (Fig. 5B, lane 3) were detected 
with an HA antibody confirmed the known interaction of CHD8 and CHD7 as well 
as CHD8 and the WAR complex members. The reciprocal experiment was 
performed by single transfection of HeLa cells with pCMV-HA plasmids containing 
either ASH2L or RBBP5. Untransfected HeLa cells served as a negative control. 
Next, the overexpressed proteins were precipitated using an HA antibody. With a 
CHD7 antibody endogenous CHD7 was detected at ~320 kDa. A band at the 
estimated size was observed after ASH2L (Fig. 5C, lane 1) and RBBP5 single 
transfection (Fig. 5C, lane 2). No band was observed for the negative control, 
showing that endogenous CHD7 does not bind unspecifically to the beads (Fig. 5C, 
lane 3). Untransfected HeLa cells were used to precipitate endogenous WDR5 using 






(~320 kDa) was detected (Fig. 5C, lane 4). Furthermore, endogenous CHD7 was 
detected in untransfected HeLa cells used as an input control (Fig. 5C, lane 5). In 
conclusion, the data obtained by Co-IP experiments demonstrate that CHD7 interacts 
with WDR5, ASH2L and RBBP5. 
 
Figure 5: Co-immunoprecipitation experiments with HeLa cells. 
(A) HeLa cells were single transfected with the pCMV-HA plasmids containing either the human full-
length sequence of ASH2L (NP_004665.2) (lane 1) or RBBP5 (NP_005048.2) (lane 2). Endogenous 
CHD7 was precipitated using a CHD7 antibody. With an HA antibody bands of the estimated size of 
ASH2L (~ 76 kDa; lane 1) and RBBP5 (~ 59 kDa; lane 2) were observed. Untransfected HeLa cells 
served as a negative control (lane 3). After precipitating endogenous CHD7, no band was detected 
with an HA antibody. Lane 4 and 5 represent the transfection controls: input after ASH2L-pCMV-HA 
single-transfection of HeLa cells (lane 4); input after RBBP5-pCMV-HA single transfection of HeLa 
cells (lane 5). Overexpressed ASH2L and RBBP5 were detected with an HA antibody. (B) Positive 
control, confirming the interaction of CHD8 with ASH2L, RBBP5 and CHD7. HeLa cells were single 
transfected with ASH2L-pCMV-HA (lane 1), RBBP5-pCMV-HA (lane 2) or CHD7-CR1-3-pCMV-
HA (NP_060250.2) (lane 3). The pCMV-HA plasmids contain the human full-length sequence of 
ASH2L or RBBP5 or a part of CHD7 (amino acids 1591-2181). A CHD8 antibody was used for 
precipitation of endogenous CHD8 and an HA antibody for detection of the overexpressed proteins. A 
band at ~ 76 kDa corresponding to the estimated size of ASH2L (lane 1), a band (~ 59 kDa) of the 
predicted size of RBBP5 (lane 2) and a band (~ 70 kDa) of the CHD7 part was detected. As a negative 
control untransfected HeLa cells were used (lane 4). Endogenous CHD8 was precipitated with a 
CHD8 antibody. No band was observed by using an HA antibody for detection (lane 4). Lane 5-7 
show the transfection controls. Input after single transfection of HeLa cells with ASH2L-pCMV-HA 
(lane 5), RBBP5-pCMV-HA (lane 6) and CHD7-CR1-3-pCMV-HA (lane 7). The overexpressed 
A
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1            2            3 4 5         6        7
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1       2       3         4         5 
~ 320 kDa CHD7
Anti - HA - IP  input transfection control









proteins were detected with an HA antibody. (C) Vice versa experiment to experiment A. HeLa cells 
were single transfected with the plasmids ASH2L-pCMV-HA (lane 1) or RBBP5-pCMV-HA (lane 2). 
The overexpressed proteins were precipitated with an HA antibody and endogenous CHD7 
(~ 320 kDa) was detected using a CHD7 antibody. Untransfected HeLa cells were used as a negative 
control (lane 3). No CHD7 was detected after precipitation with an HA antibody, indicating that 
endogenous CHD7 does not bind unspecifically to the beads. Endogenous WDR5 was precipitated 
with a WDR5 antibody using untransfected HeLa cells and a ~ 320 kDa band was observed with a 
CHD7 antibody (lane 4). The transfection controls are shown in lane 6 and 7. Overexpressed ASH2L 
(lane 6) and RBBP5 (lane 7) were detected with an HA antibody after single transfection of HeLa 
cells with either ASH2L-pCMV-HA or RBBP5-pCMV-HA. Three biological replicates were 
performed for each Co-IP experiment (A - C). Figure modified after Schulz et al. (2014a). 
3.2 CHD7 and the members of the WAR complex are co-localised in the 
nucleus 
To confirm the Co-IP data and determine where in the cell interactions occur, the 
Duolink PLA method was used. The antibodies used to detect the target proteins 
were tested in an immunocytochemistry performed on untransfected HeLa cells. The 
results are shown in figure 6. The cell nuclei were stained with DAPI. Primary 
antibodies were used to detect CHD7, CHD8, WDR5, ASH2L and RBBP5. With 
secondary antibodies conjugated with Cy3 the localisation of the proteins was 
visualised (Fig. 6B, E, H, K, L). Merging the DAPI (nuclei) and the Cy3 channel 
(detected target proteins) revealed that all analysed proteins were localised 
specifically in the nucleus: CHD7 (Fig. 6C), CHD8 (Fig. 6F), WDR5 (Fig. 6I), 







Figure 6: Protein localisation after immunocytochemistry performed with HeLa cells. 
Untransfected HeLa cells were incubated overnight with following antibodies to detect the target 
proteins CHD7 (B, C), CHD8 (E, F), WDR5 (H, I), ASH2L (K, L) and RBBP5 (N, O). Cy3 
conjugated secondary antibodies (anti-goat: B, C and anti-rabbit: E, F, H, I, K, L, N, O) were used for 
visualisation. All proteins analysed were detected in the nucleus. The nuclei of cells were stained with 
DAPI (A, D, G, J, M, P, S). To validate the specificity of the secondary antibody, HeLa cells were 
incubated only with the Cy3 conjugated antibody (anti-goat: P-R and anti-rabbit: S-U). It was shown 
that the anti-goat Cy3 antibody causes a slightly background (Q, R). 
For analysing protein interactions by the Duolink PLA method, untransfected HeLa 
cells were used. The results are presented in figure 7 and published by us (Schulz et 
al., 2014a). Cell nuclei were stained with DAPI and the cytoskeleton of cells with 
FITC Phalloidin. PLA signals (red dots) indicate the protein interactions. By merging 
the channels the localisation of the protein interaction within the cells could be 
determined. Positive PLA signals were detected in the nucleus using antibodies 
against CHD7 and WDR5 (Fig. 7C, D, E), CHD7 and ASH2L (Fig. 7H, I, J), CHD7 
and RBBP5 (Fig. 7M, N, O), CHD7 and CHD8 (Fig. 7R, S, T). The known 






treated with one primary antibody served as a negative control. Only few PLA 
signals were observed in the cytoplasm and nuclei showing no specific preference, 
indicating that nearly no unspecific binding of the PLA probes to the antibodies is 
present (Fig. 7U, V, W, X, Y). In summary, the interaction of CHD7 with the 
members of the WAR complex WDR5, ASH2L and RBBP5 was confirmed by 
Duolink PLA. Furthermore, it was shown that the interactions were localised in the 
nuclei of HeLa cells. 
 
Figure 7: Analysing protein interactions in HeLa cells using the Duolink PLA method.  
The nuclei of cells were stained with DAPI (A, F, K, P) and the cytoskeleton of cells were stained 
with FITC Phalloidin (B, G, L, Q). Positive PLA signals (red dots) indicate protein interactions. PLA 
signals were mainly detected in the nuclei using antibodies against CHD7 and WDR5 (C, D, E), 
CHD7 and ASH2L (H, I, J), CHD7 and RBBP5 (M, N, O) and CHD7 and CHD8 (R, S, T) which was 
used as a positive control. A higher magnification of the merged pictures is shown (E, J, O, T). Only 
few PLA signals were observed in the cytoplasm and nuclei with no specific preference using an 
antibody against WDR5 (U), ASH2L (V), RBBP5 (W), CHD8 (X) or CHD7 (Y). These results 










































PLA experiment was carried out three times. Scale bars indicated in the merged pictures correspond to 
20 µm. Figure modified after Schulz et al. (2014a). 
3.3 CHD7 shows no direct interaction with WAR complex members 
To further analyse whether the identified interactions of CHD7 with components of 
the WAR complex are direct ones, Y2H experiments were carried out (Fig. 8) and 
published by us (Schulz et al., 2014a). The recently described constructs CHD7-
CR1-3-pGBKT7 containing the CHD7 fragment spanning the amino acids 1591-
2181 (NP_060250.2) and the CHD8-pGBKT7 plasmid containing a CHD8 part 
(amino acids 1789-2302, NP_065971.2) were used as bait plasmids (Batsukh et al., 
2010). WDR5-pGADT7 (NP_060058.1), ASH2L-pGADT7 (NP_004665.2) and 
RBBP5-pGADT7 (NP_005048.2) served as prey plasmids, respectively. Colonies on 
the LT plates indicated a successful transformation (Fig. 8A, C, D, F). As a positive 
control the CHD8-pGADT7-Rec prey plasmid and the CHD7-CR1-3-pGBKT7 bait 
plasmid were used (Batsukh et al., 2010). The auto activation test using the empty 
pGBKT7 plasmid and pGADT7 with WDR5, ASH2L or RBBP5 revealed no auto 
activation of the yeast strain reporter genes (Fig. 8C, E, G). While the direct 
interaction of the recently described CHD8 fragment (Batsukh et al., 2010) and 
WDR5, ASH2L and RBBP5 was confirmed, the direct Y2H experiments revealed no 
direct interaction of the CHD7-CR1-3-part with the WAR complex members 







Figure 8: Results of the direct yeast two-hybrid assay.  
CHD7-CR1-3-pGBKT7 was used as a bait plasmid to analyse a direct interaction of the CHD7 part 
(amino acids 1591-2181, NP_060250.2) and the components of the WAR complex (WDR5, ASH2L 
and RBBP5). The pGADT7 prey plasmid contained either the full-length sequence of WDR5 
(NP_060058.1), ASH2L (NP_004665.2) or RBBP5 (NP_005048.2). CHD7-CR1-3-pGBKT7 and 
CHD8-pGADT7-Rec (containing CHD8 amino acids 1789-2302, NP_065971.2) were used as a 
positive control. Colonies for each sample on the LT plate indicated a successful transformation (A, 
C, D, F). No colonies were detected on LTHA + Aba (Aureobasidin A) plates using the empty 
pGBKT7 plasmid and the pGADT7 plasmid with WDR5, ASH2L or RBBP5, showing no auto 
activation of the yeast strain reporter genes (C, E, G). The direct interaction of the CHD8 part (CHD8-
pGBKT7, amino acids 1789-2302, NP_065971.2) and the WAR complex members was confirmed 
whereas no direct interaction was detected for CHD7-CR1-3-pGBKT7 and the components of the 
WAR complex (B, E, G). Three biological replicates were performed. Figure modified after Schulz et 
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Considering the fact, that the interaction region could be located outside of the 
analysed CHD7-CR1-3 fragment, further constructs for CHD7 were generated. 
Therefore, the whole CHD7 gene was divided into four overlapping fragments 
without interrupting any known functional domain (Fig. 9). 
 
Figure 9: Schematic representation of the CHD7 constructs for yeast two-hybrid experiments. 
The ATP-dependent chromatin remodelling enzyme CHD7 belongs to the CHD family and consists of 
two N-terminal located chromodomains, a helicase/ATPase domain, three conserved regions (CR1-
CR3), a SANT domain and two BRK domains at the C-terminus. As indicated, the CHD7 gene was 
divided into four overlapping parts without interrupting any known functional domains (CHD7-1-
pGBKT7, 1-799 aa; CHD7-2-pGBKT7, 732-1567 aa; CHD7-3-pGBKT7, 1533-2380 aa; CHD7-4-
pGBKT7, 2325-2997 aa). In addition, the CHD7-CR1-3-pGBKT7 plasmid is shown (Batsukh et al., 
2010). Figure modified after Schulz et al. (2014a). 
In conclusion, the data from the direct Y2H experiments revealed no direct 
interaction of CHD7 with the WAR complex members and the known direct 
interaction of CHD8 with the components of the WAR complex was confirmed. At 
the same time the region which is responsible for the direct interaction was identified 
to be located within the CHD8 fragment spanning the amino acids 1789-2302, 
NP_065971.2. 
3.4 Genome-wide expression analysis demonstrates a misregulation of 
NCC guidance genes in case of CHD7 loss of function 
Already in 1985 Siebert et al. (1985) assumed that the malformations and defects 
seen in CHARGE syndrome patients result from abnormalities during NCC 
development. Chd7 knockdown experiments in Xenopus laevis demonstrated that 
Chd7 is essential for the formation of NCCs (Bajpai et al., 2010). However, only a 
few Chd7 target genes involved in the formation and migration of NCCs were 
described (Bajpai et al., 2010). Because nothing is known about the role of Chd7 in 
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the guidance of migrating NCCs and the process of EMT, a genome-wide microarray 
expression analysis was performed with embryos of the Whirligig mouse line at E9.5 
at the time of NCCs migration (Schulz et al., 2014b). Animals were kindly provided 
by K. P. Steel (Sanger Centre, Cambridge, United Kingdom) and the Helmholtz 
Zentrum, Munich, Germany. The Whirligig mouse line was generated by a large-
scale ENU mutagenesis programme (Hrabe de Angelis et al., 2000; Hawker et al., 
2005). In exon 11 of the Chd7 gene a nonsense mutation (p.W973X) leads to a 
premature stop codon (Bosman et al., 2005). Heterozygous (Chd7
Whi/+
) mice reveal 
symptoms which are also present in CHARGE syndrome patients, therefore 
providing a good model to study features of CHARGE syndrome (Bosman et al., 
2005).  
The data presented below are published by us (Schulz et al., 2014b). The microarray 
analysis was performed on four female wild-type (Chd7
+/+
), four heterozygous 
(Chd7
Whi/+
) and four homozygous (Chd7
Whi/Whi
) mouse embryos. 98 differentially 
expressed genes showing more than two-fold differences (log2 fold-change (FC) ≤ -1 
or ≥1) and a false discovery rate (FDR) <5 % were identified by comparing 
homozygous (Chd7
Whi/Whi
) and wild-type (Chd7
+/+
) embryos. For 71 of these genes 
the expression was decreased and 27 genes were found with increased expression. 
The heat map shown in figure 10 displays some of the genes recognised by 
microarray analysis. Interestingly, many of these differentially expressed genes are 
known to play a role in NCC migration and axon guidance. Examples are members 
of the semaphorin family like Sema3a (sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3A), Sema3c (sema domain, 
immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C) or 
Sema3d (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3D) which are required for guiding migrating NCCs (Eickholt et al., 
1999; Brown et al., 2001; Gitler et al., 2004; Lepore et al., 2006; Sato et al., 2006) 
and Epha3 (Eph receptor A3), Epha5 (Eph receptor A5) and Epha7 (Eph receptor 
A7) belonging to the family of ephrin receptors. Ephrin receptors are also involved in 
the guidance of NCCs (Kuriyama and Mayor, 2008). Furthermore, transcription 
factors like Sox10 (SRY (sex determining region Y)-box 10) and Foxd3 (forkhead box 
D3) which play a role in the early migration process of NCCs were found to be 
upregulated. A complete list of the 98 differentially expressed genes is shown in 







Figure 10: Heatmap of differentially expressed genes found by microarray.  
The heatmap shows some of the differentially expressed genes found by comparison of the expression 
profile of four female mouse embryos (E9.5) per genotype (wild-type (Chd7
+//+
): WT 1-4, 
heterozygous (Chd7
Whi/+




Homo 1-4). The results illustrate a 
regulating function of CHD7 of genes involved in NCC and axon guidance and transcription factors. 





























































































3.5 Expression analysis by RT-qPCR confirms the results of the 
microarray 
To validate the data of the genome-wide microarray analysis, the expression of genes 
involved in NCC guidance, namely Sema3a, Sema3d, Epha3, Sox10 and the two 
further genes Trp53bp2 (transformation related protein 53 binding protein 2) and 
Gfra2 (glial cell line derived neurotrophic factor family receptor alpha 2) were 
analysed by RT-qPCR. Furthermore, these genes were chosen to have a complete 
validation of upregulated, nonregulated and downregulated genes. The relative 
expression of these genes is shown in figure 11 and published by us (Schulz et al., 
2014b). The same RNA used for the microarray analysis was employed for the RT-
qPCR. Four biological replicates for heterozygous (Chd7
Whi/+
) and homozygous 
(Chd7
Whi/Whi
) mice were analysed. Four wild-type (Chd7
+/+
) embryos were pooled 
and used as a calibrator. Data were normalised against three reference genes (Tbp 
(TATA box binding protein), Sdha (Succinate dehydrogenase complex, subunit A) 
and Hprt (Hypoxanthin-phosphoribosyl-transferase)). The microarray expression 
analysis revealed a clear upregulation of Sema3a, Sema3d and Epha3. The results of 
the RT-qPCR showed that in heterozygous (Chd7
Whi/+
) animals the relative 
expression of Sema3a was decreased up to 50 %. Homozygous (Chd7
Whi/Whi
) mice 
showed a reduction of Sema3a expression between 60-70 %. A similar decrease in 
expression was observed for Sema3d. The relative expression of Epha3 was reduced 
more than 50 % in heterozygous (Chd7
Whi/+
) embryos and 60-80 % in homozygous 
(Chd7
Whi/Whi
) embryos. The average relative expression of Trp53bp2 remained 
mostly unchanged in heterozygous (Chd7
Whi/+
) and homozygous (Chd7
Whi/Whi
) 
embryos compared to wild-type (Chd7
+/+
). According to the microarray data the 
expression of the transcription factor Sox10 and Gfra2 was upregulated (appendix, 
Tab. 39). The relative expression of Sox10 measured by RT-qPCR was increased 
about 35 % in heterozygous (Chd7
Whi/+
) mice. The increase in expression of Sox10 
was even stronger in the homozygous (Chd7
Whi/Whi
) stage where in half of the 
embryos Sox10 was double as high as in wild-type (Chd7
+/+
) embryos. The Gfra2 
expression was in half of the heterozygous (Chd7
Whi/+
) embryos 0.7-2.3 times higher 
compared to the wild-type (Chd7
+/+
) control embryos. In the majority of homozygous 
(Chd7
Whi/Whi






expression in the wild-type (Chd7
+/+
) embryos. Altogether, the results of the RT-
qPCR reflect the data of the genome-wide microarray analysis. 
 
Figure 11: Results of the gene expression analysis by RT-qPCR. 
A selection of six genes (Sema3a, Sema3d, Epha3, Trp53bp2, Sox10 and Gfra2) was used to validate 
the microarray data by RT-qPCR. The same RNA from female embryos of the Whirligig mouse line 





). The RNA from the four wild-type (Chd7
+/+
) embryos was 
pooled and utilised as a calibrator. The data were normalised against the three reference genes Tbp, 
Sdha and Hprt. The expression of Sema3a, Sema3d and Epha3 is downregulated, Trp53bp2 is mostly 
unaffected and Sox10 and Grfa2 are upregulated. These results confirm the data from the whole-


























































































3.6 There is no gender specific effect on the expression of Sema3a, 
Sema3d, Epha3, Trp53bp2, Sox10 and Gfra2 in Whirligig mouse 
embryos 
To further validate whether the data from the microarray and the RT-qPCR are 
female specific, the same genes were analysed by another RT-qPCR approach using 







) mouse embryos (E9.5). The results described below are 
published by us (Schulz et al., 2014b). Three biological replicates for each genotype 
were analysed. The three wild-type (Chd7
+/+
) embryos were pooled and served as a 
calibrator. The data were normalised against the reference genes Tbp, Sdha and Hprt. 
The results are represented in figure 12. The relative expression of Sema3a was 
downregulated in all embryos. Homozygous (Chd7
Whi/Whi
) mice showed with a 
decrease of more than 50 % up to 70 % the most precise effect. In the majority of 
heterozygous (Chd7
Whi/+
) individuals Sema3d expression was about half reduced 
compared to wild-type (Chd7
+/+
) embryos. The Sema3d expression was even more 
decreased (> 70 %) in homozygous (Chd7
Whi/Whi
) mice. Epha3 was also found to be 
downregulated in the majority of heterozygous (Chd7
Whi/+
) and homozygous 
(Chd7
Whi/Whi
) embryos with about 70 %. While the expression of Trp53bp2 remained 
unaffected, the expression of Sox10 and Grfa2 was increased. Especially 
homozygous (Chd7
Whi/Whi
) mice showed a three times higher expression level of 
Gfra2 than wild-type (Chd7
+/+
) embryos. In summary, it can be stated that female 
and male embryos showed a similar expression of the analysed genes which 







Figure 12: Repetition of RT-qPCR. 





). Pooled RNA from three wild-type (Chd7
+/+
) embryos served as 
a calibrator. Data were normalised against the three reference genes Tbp, Sdha and Hprt. The same 
genes were analysed under identical conditions as described before (Fig. 11). The Sema3a, Sema3d 
and Epha3 expression is found to be downregulated. Trp53bp2 expression is mostly unaffected and 
the Sox10 and Grfa2 expression is upregulated, demonstrating that there is no gender specific CHD7 




mouse embryos analysing the Epha3 expression was excluded due to technical issues. Figure 



























































































3.7 CHD7 and SEMA3D show a similar expression pattern in mouse 
embryos 
The data from the genome-wide microarray analysis revealed a high number of 
differentially expressed genes which play a role in NCC migration (Schulz et al., 
2014b). It was shown that CHD7 has a regulatory effect on some members of the 
semaphorin family (Fig. 10) (Schulz et al., 2014b). Therefore, the expression pattern 
of CHD7 and SEMA3D was analysed on paraffin sections of wild-type mouse 
embryos (E12.5) and compared with each other. Figure 13 shows three serial made 
sagittal sections from the embryo (Fig. 13A, B, C) after immunohistochemistry 
(DAB staining). Picture A shows the negative control, picture B represents the 
expression pattern of CHD7 and the expression profile of SEMA3D can be seen in 
picture C. CHD7 is expressed mainly in the brain, heart, vertebrae and nerves along 
the spine and the sensory nerve ends above the eye. SEMA3D is also expressed in 
the brain, heart and different structures of the nervous system like CHD7. While 
CHD7 seems to be more restricted to a specific area, SEMA3D is expressed also in 
the surrounding epithelium. Unfortunately, further investigation of SEMA3D and 
CHD7 expression in wild-type (Chd7
+/+
) and heterozygous (Chd7
Whi/+
) mouse 
embryos of the Whirligig mouse line failed as well as the expression analysis of 
SEMA3A due to technical issues affecting the colour reaction. Several repetitions 
with different mouse embryos were performed, solutions, such as paraffin, fixating 
solution and the DAB staining solutions were exchanged but the technical problem 
could not be solved. It would be interesting to analyse the changes in the expression 







Figure 13: CHD7 and SEMA3D expression analysis using paraffin sections of mouse embryos 
stained with DAB. 
Serial sagittal paraffin sections were prepared using wild-type mouse embryos (E12.5). The 
expression pattern of CHD7 (B) and SEMA3D (C) were analysed by DAB staining. No primary 
antibody was used for the negative control (A). Different regions of the embryos are shown in higher 
magnification: front head (a), neck (b) and dorsum (c). The negative control showed no unspecific 
staining, indicating that the universal secondary antibody does not bind unspecifically to the tissue of 
the embryos (A). CHD7 expression was found in the medulla oblongata, choroid plexus 
differentiating from roof of fourth ventricle, cochlea, heart, cartilage primordium of body of vertebra 
and in different ganglia e.g. along the spine and above the eye (B). The SEMA3D expression pattern 
resembles the expression of CHD7 in the medulla oblongata, choroid plexus differentiating from roof 
of fourth ventricle, cochlea, heart, cartilage primordium of body of vertebra and in different ganglia 
(C). c = cochlea, cc = cartilage condensation being primordium of vertebral body, chp = choroid 
plexus differentiating from roof of fourth ventricle, cp = cartilage primordium of body of vertebra, fv 
= forth ventricle, g = ganglia, h = heart, l = liver, mo = medulla oblongata, mv = mesencephalic 
vesicle, oe = olfactory epithelium, sb = segmental bronchus within accessory lobe of right lung, tv = 
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3.8 Results of SEMA3A and SEMA3D mutation screens in patients with 
CHARGE syndrome 
CHARGE syndrome is a phenotypically heterogeneous disorder, so it is possible that 
there are other genes which might act as modifiers leading to a more severe 
phenotype when they are mutated. In 5-10 % of typical CHARGE patients and 40-
60 % of patients suspected of having CHARGE the underlying cause remains 
unknown (Janssen et al., 2012) so it could be possible that other “CHARGE genes” 
exist. For that reason 45 CHARGE syndrome patients without a mutation in the 
CHD7 gene were screened for mutations in SEMA3A (GenBank accession number: 
NM_006080.2) and SEMA3D (GenBank accession number: NM_152754.2). All 17 
coding exons and flanking intronic sequences of SEMA3A and SEMA3D were 
analysed by amplifying these regions by PCR and screening for mutations by 
sequencing. The results from the SEMA3A mutation screen are published by us 
(Schulz et al., 2014b). For SEMA3A three non-synonymous variants were found: 
c.196C>T (p.R66W), c.2002A>G (p.I668V) and c.2062A>G (p.T688A). Sequences 
are shown in figure 14. The variants are indicated by red arrows. The variant 
p.R66W was located in the sema domain, a conserved module of ligand-receptor 
interaction, also present in other proteins like plexins (Antipenko et al., 2003) and 
was predicted to be damaging (Polyphen 2, SIFT and mutation taster). By screening 
the parents of the patient carrying the c.196C>T (p.R66W) variant it was shown that 
this variant was inherited from the healthy father. The two other identified variants 
p.I668V and p.T688A were predicted to be benign (Polyphen 2). The parents were 







Figure 14: Results of the SEMA3A mutation screen.  
All coding exons of the SEMA3A gene were sequenced in 45 CHD7 negative patients diagnosed with 
CHARGE syndrome. Three non-synonymous variants were identified: c.196C>T (p.R66W), 
c.2002A>G (p.I668V) and c.2062A>G (p.T688A). The mutations are indicated by red arrows in the 
forward and reverse sequence, respectively. 
Sequencing of SEMA3D revealed following non-synonymous variants: c.193T>C 
(p.S65P), c.1272C>A (p.H424Q) and c.2101A>C (p.K701Q) (Fig. 15). While the 
non-synonymous SNP p.K701Q is a common variant with an allele frequency of 
0.346 in the ESP cohort population (SNPdev, n.d.), the variant p.S65P is less 
common. In the ESP cohort population it has an allele frequency of 0.017 (SNPdev, 
n.d.). Both variants are predicted to be benign (Polyphen and Polyphen 2). The 
variant p.H424Q is quite rare. It was observed in the ESP cohort population with an 
allele frequency of 0.002 (SNPdev, n.d.) and it was found to be located in a highly 
conserved domain. In silico programms predicted the variant p.H424Q as a protein 
“damaging” variant (Polyphen, Polyphen 2, SIFT). For further clarification the 
parents of the patients were screened. It was shown that the variant p.H424Q was 
inherited from the healthy father.  
Furthermore, in ten CHD7 negative CHARGE patients all 17 coding exons of 
SEMA3A and SEMA3D were analysed for copy number defects (large deletions and 

















Figure 15: Results of the SEMA3D mutation screen.  
The 17 exons of the SEMA3D gene were sequenced in 45 CHD7 negative CHARGE patients. Three 
non-synonymous variants were found: c.193T>C (p.S65P), c.1272C>A (p.H424Q) and c.2101A>C 
(p.K701Q). The mutations are shown in the forward and reverse sequence indicated by red arrows.   
3.9 Knockdown of Chd7 causes alteration in sema3a expression in 
Xenopus laevis 
Chd7 is highly conserved throughout different species (Bosman et al., 2005; Bajpai 
et al., 2010; Schnetz et al., 2010). It was shown that Chd7 deficient Xenopus laevis 
embryos mimic basic features of CHARGE syndrome (Bajpai et al., 2010). To study 
the effect of Chd7 on the expression of sema3a in another species, Chd7 was 
downregulated in Xenopus laevis mediated by Chd7 MO. The data below are 
published by us (Schulz et al., 2014b). The sema3a expression pattern was analysed 
by WMISH at the neurula stage 20 (Fig. 16) and the tailbud stage 27 (Fig. 17). 
Embryos were injected with a MO in combination with lacZ RNA as a lineage tracer 
in one blastomere at a two-cell stage. The injected side is indicated by the blue lacZ 
staining (Fig. 16A-F; Fig. 17B, D, F). Control embryos were injected with 20 ng 
control MO (Co MO) which has no target RNA. Embryos injected with the Co MO 
showed as expected a normal sema3a expression pattern in the midbrain-hindbrain 
boundary (mh) (Fig. 16A; Fig. 17A, B) and somites (s) (Fig. 16B; Fig. 17A, B). 
















(Fig. 17A, B). After Chd7 was downregulated by injecting 10 ng Chd7 MO, in about 
70 % of the embryos a reduction of sema3a expression were detected. 
Approximately 60 % of these embryos showed a severe downregulation of the 
sema3a expression pattern in general or the expression in one district region was 
completely missing (Fig. 16C, D; Fig. 17D). After injecting 20 ng Chd7 MO, in 
almost all analysed embryos of the neurula and tailbud stage the sema3a expression 
was dramatically decreased or completely absent (Fig. 16E, F; Fig. 17F).  
 
Figure 16: Sema3a expression analysis by whole mount in situ hybridisation after Chd7 
knockdown in Xenopus laevis (neurula stage 20). 
One blastomere of the two-cell stage embryos was injected with a MO and lacZ RNA as a lineage 
tracer. Embryos were injected with 20 ng control MO (A, B), 10 ng Chd7 MO (C, D) or 20 ng CHD7 
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MO (E, F). The injected side of the embryo is indicated by a blue lacZ staining. The expression 
pattern of sema3a (purple staining) was analysed. Nearly all control embryos showed a normal 
expression pattern of sema3a (A, B); midbrain hindbrain boundary (mh); somites (s). After knocking 
down Chd7 with 10 ng Chd7 MO, in about 60 % of the embryos a clear reduced sema3a expression in 
the somites and the head region was observed (C, D). An injection of 20 ng Chd7 MO led to a 
complete loss of sema3a expression or to a drastic reduced expression pattern in 90 % of the embryos 
(E, F). The graph summarises three independent experiments (G). The diagram reflects the percentage 
of the embryos showing a normal sema3a expression pattern (light grey columns), moderate (grey 
columns) or severe defects (black columns). Standard error of the means is shown. On top of each 
column the total number of the embryos counted in the different categories is listed. Figure modified 
after Schulz et al. (2014b).  
 
Figure 17: Sema3a expression after Chd7 knockdown in Xenopus laevis (tailbud stage 27).  
One blastomere of two-cell embryos was injected with a MO (20 ng control MO (A, B), 10 ng Chd7 



















































lacZ staining indicates the injected side of the embryo (B, D, F). The expression pattern of sema3a 
(purple staining) was analysed by whole mount in situ hybridisation. In 99 % of the control embryos 
the expression pattern of sema3a remained unchanged (A, B); midbrain hindbrain boundary (mh); 
somites (s); splanchic mesoderm (sm). After the knockdown of Chd7 with 10 ng Chd7 MO 60 % of 
the embryos showed a reduced sema3a expression in the somites and the head region (C, D). A 
complete loss of sema3a expression or a drastic reduced expression was observed in all embryos after 
20 ng Chd7 MO injections (E, F). The columns of the diagram show the percentage of embryos with 
normal sema3a expression (light grey), moderate (grey) or severe changes in the expression pattern 
(black). On top of each column the amount of embryos obtained in the different categories are listed. 
The data refer to one biological replicate. Figure modified after Schulz et al. (2014b). 
3.10 The Chd7 MO phenotype was successfully rescued by human CHD7 
RNA 
Rescue experiments were performed to check whether human CHD7 RNA is able to 
rescue the Chd7 MO phenotype. The human CHD7 full-length plasmid was kindly 
provided by J. Wysocka (Department of Developmental Biology, Stanford 
University School of Medicine, Stanford, California). The following data are 
published by us (Schulz et al., 2014b). CHD7 DNA was transcribed into sense RNA 
to obtain the rescue construct (hCHD7 RNA). Xenopus laevis embryos were injected 
as described before. A WMISH was performed at neurula stages 20 and 21 to analyse 
the expression of sema3a. Embryos injected with Co MO and the rescue construct 
and uninjected embryos were used as controls. More than 95 % of these embryos 
showed a normal sema3a expression (Fig. 18A-D; Fig. 19A-D). After injecting 10 ng 
Chd7 MO, half of the embryos showed a massively reduced sema3a expression and 
more than 30 % a moderate reduction (Fig. 18E, F). For the rescue experiments 
embryos were injected with 10 ng of Chd7 MO to knockdown Chd7 in combination 
with 1 ng of the rescue construct hCHD7 RNA which is not recognised by the MO. 
The embryos of the Chd7 knockdown were compared with the embryos after the 
rescue. The percentage of embryos showing a severe reduction of sema3a expression 
was reduced from 53 % down to 6 %. At the same time the percentage of embryos 
with a normal expression pattern was increased from 13 % to 52 % (Fig. 18I). The 
rescue of the Chd7 MO phenotype was slightly more effective after injecting 1.5 ng 
hCHD7 RNA (Fig. 19I). The percentage of severe alterations in sema3a expression 
was decreased from 61 % to 4 % and the percentage of embryos showing a normal 







Figure 18: Rescue of the Chd7 MO phenotype in Xenopus laevis (neurula stage 21).  
As a rescue construct human CHD7 RNA (hCHD7 RNA) was used which is not recognised by the 
Chd7 MO. Embryos were injected (one blastomere of a two-cell stage) with either 10 ng of a Co MO 
and 1 ng hCHD7 RNA for the rescue (C, D), 10 ng Chd7 MO (E, F) or 10 ng Chd7 MO and 1 ng 
hCHD7 RNA (G, H). All embryos were co-injected with lacZ RNA as lineage tracer. By whole 
mount in situ hybridisation the sema3a expression was analysed (purple staining). Uninjected 
embryos were used as a control. Nearly all uninjected embryos showed the normal sema3a expression 
pattern (A, B). In more than 90 % of the embryos co-injected with a Co MO and hCHD7 RNA the 
sema3a expression pattern remained unchanged (C, D). After downregulation of Chd7 by injecting 
10 ng Chd7 MO, more than 50 % of the embryos showed severe defects, meaning a clear reduced 
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In more than 30 % of these embryos moderate reduction of sema3a was detected and in about 10 % of 
the embryos the sema3a expression pattern remained unaltered. More than half of the embryos co-
injected with 10 ng Chd7 MO to knockdown Chd7 and 1 ng hCHD7 RNA to rescue the Chd7 MO 
phenotype showed a normal sema3a expression pattern (G, H) and about 40 % had a moderate 
reduced sema3a expression pattern. (I) Graph summarises the percentage of embryos obtained from 
one biological replicate with normal sema3a expression (light grey columns), moderate (grey 
columns) or severe changes in the expression pattern (black columns). Numbers on top of each 
column represent the amount of embryos counted in the different categories. Figure modified after 
Schulz et al. (2014b). 
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Figure 19: Repetition of the rescue of the Chd7 MO phenotype in Xenopus laevis (neurula stage 
20).  
Single blastomeres of two-cell stages were injected with either 10 ng of a control MO and 1.5 ng 
human rescue CHD7 RNA (hCHD7 RNA) (C, D), 10 ng Chd7 MO (E, F) or 10 ng Chd7 MO and 
1.5 ng hCHD7 RNA (G, H). Co-injection of lacZ RNA served as a lineage tracer. Sema3a expression 
was analysed by whole mount in situ hybridisation (purple staining). Nearly all uninjected control 
embryos showed a normal sema3a expression pattern (A, B). In more than 95 % of the embryos co-
injected with a Co MO and hCHD7 RNA the sema3a expression pattern remained unchanged (C, D). 
After injection of 10 ng Chd7 MO, more than 60 % of the embryos showed severe changes in the 
sema3a expression pattern (E, F). After co-injection of 10 ng Chd7 MO to knockdown Chd7 and 
1.5 ng hCHD7 RNA to rescue the Chd7 MO phenotype, in about 60 % of the embryos a normal 
sema3a expression pattern was observed (G, H) and 40 % showed moderate changes in the sema3a 
expression pattern. (I) The graph summarises the data obtained from one biological replicate. 
Columns represent the percentage of embryos with normal sema3a expression (light grey), moderate 
(grey) or severe reduction of the expression pattern (black). Numbers on top of each column indicate 
the amount of embryos counted in the different categories. Figure modified after Schulz et al. (2014b). 
3.11 Knockdown of Sema3a and Sema3d causes migration defects of 
NCCs in Xenopus laevis 
It was shown in Xenopus laevis embryos that a MO mediated downregulation of 
Chd7 leads to migration defects of NCCs (Bajpai et al., 2010). Semaphorins are 
involved in the process of NCC guidance (Kuriyama and Mayor, 2008). Because 
Sema3a and Sema3d were found to be downregulated in CHD7 deficient mice 
(Schulz et al., 2014b), these genes were chosen for knockdown experiments in 
Xenopus laevis to analyse the effect on NCC migration. Embryos were injected in 
one blastomere of a two-cell stage. The expression of the NCC marker twist was 
analysed by WMISH at the neurula stage 21 in three independent experiments 
(Fig. 20) and the tailbud stage 26 in two independent experiments (Fig. 21). Control 
embryos injected with 20 ng Co MO showed as expected a normal twist expression 
of the three cranial-crest segments: mandibular (m), hyoid (h) and branchial (b) 
(Fig. 20A; Fig. 21A, B). By injecting 20 ng Chd7 MO to knockdown Chd7 almost 
80 % of the analysed embryos of the neurula and tailbud stage showed severe 
migration and induction defects of NCCs highlighted by red arrowheads (Fig. 20B; 
Fig. 21C, D). About half of the embryos at the neurula stage revealed moderate 
migrating defects of NCCs (yellow arrowheads) after Sema3a (Fig. 20C) and 






embryos severe migration defects were detected after a Sema3a knockdown. If 
Sema3d is downregulated, 10 % of the embryos revealed severe defects of migrating 
NCCs. About 20 % of the embryos at the tailbud stage showed moderate migration 
defects after Sema3a was downregulated (Fig. 21E, F) and in almost 40 % of the 
embryos moderate defects of migrating NCCs were observed after downregulation of 
Sema3d indicated by yellow arrowheads (Fig. 21G, H). A rescue of the Chd7 MO 
phenotype (twist expression) was successfully performed using the same human 
CHD7 RNA as a rescue construct as described before on page 109 (results not 
shown). This data confirms the results of the rescue experiment with Xenopus laevis 
embryos performed by Bajpai et al. (2010). In conclusion, a loss of function of Chd7 
severely affects the NCC induction and migration in the majority of analysed 
embryos while a loss of function of either Sema3a or Sema3d led in about half of the 
embryos to moderate NCC migration defects. 
 
Figure 20: Twist expression analysis after knockdown of Chd7, Sema3a or Sema3d in Xenopus 
laevis (neurula stage 21).  
Embryos were injected with 20 ng Co MO (A), 20 ng Chd7 MO (B), 20 ng Sema3a MO (C) or 20 ng 
Sema3d MO (D) in one blastomere of a two-cell stage. LacZ RNA was co-injected as a lineage tracer. 
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At the neurula stage 21 a whole mount in situ hybridisation was performed to analyse the expression 
of the NCC marker twist (purple staining). The injected side is indicated by the blue lacZ staining (B, 
D, F, H). More than 90 % of the embryos injected with 20 ng Co MO revealed a normal twist 
expression (A). After injecting 20 ng Chd7 MO more than 70 % showed severe defects in form of 
extreme migration or induction defects of NCCs (red arrowhead) (B). A knockdown of Sema3a and 
Sema3d led in about 50 % of the embryos to moderate migration defects of NCCs (yellow 
arrowheads) (C, D). The diagram represents the percentage of embryos after injection of MO showing 
normal twist expression indicating normal NCC migration (light grey), moderate (grey) or severe 
migration defects (black) of NCCs (E). (I) The data include three independent experiments. Standard 
error of the means is given. Total numbers of animals dedicated to each category are shown on top of 
each column. 
 
Figure 21: Effect of Chd7, Sema3a or Sema3d knockdown on NCCs (twist expression) in 
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One blastomere of a two-cell stage was injected with a MO in combination with lacZ RNA. The 
injected side of the embryo is recognisable by the blue lacZ staining (B, D, F, H). Control embryos 
were injected with 20 ng of Co MO (A, B). For the knockdown 20 ng Chd7 MO (C, D), 20 ng 
Sema3a MO (E, F) or 20 ng Sema3d MO were injected (G, H). At the tailbud stage 26 a whole mount 
in situ hybridisation was performed to analyse the expression pattern of the NCC marker twist. Most 
embryos (> 90 %) injected with 20 ng Co MO showed a normal twist expression pattern of the three 
cranial-crest segments: mandibular (m), hyoid (h) and branchial (b) (A, B). After injecting 20 ng Chd7 
MO to knockdown Chd7, in almost 80 % of the analysed embryos severe defects were observed like 
massive migration and induction defects (red arrowhead) of NCCs (D). About 20 % of the embryos 
injected with 20 ng Sema3a MO (F) and 40 % of those injected with 20 ng Sema3d MO (H) showed 
moderate migration defects of NCCs (yellow arrowhead). In the diagram the results of two 
independent experiments are shown (I). The columns represent the percentage of embryos showing a 
normal NCC migration indicated by a normal twist expression (light grey), moderate migration 
defects (grey) or severe migration or induction defects of NCCs (black). The total number of embryos 
obtained in each category is shown on top of the columns. Standard error of the means is given. 
3.12 Double knockdown of Chd7 and Sema3a or Sema3d has no clear 
synergistic effect on twist expression in Xenopus laevis 
To determine whether the Chd7 MO phenotype on twist expression can be increased, 
double knockdown experiments on Xenopus laevis embryos were performed. Chd7 
was downregulated in combination with either Sema3a or Sema3d. Embryos were 
injected in one blastomere of a two-cell stage. Twist expression was analysed by 
WMISH at the neurula stage 20 (Fig. 22A) and the tailbud stage 27 (Fig. 22B), 
respectively. Uninjected embryos as well as embryos injected with 10 ng Co MO 
served as controls showing a normal twist expression. Chd7 alone was 
downregulated by injecting 10 ng Chd7 MO. 35 % of the embryos at the neurula 
stage revealed moderate migration defects and further 35 % showed severe migration 
defects of NCCs (Fig. 22A). At the tailbud stage about 60 % of the analysed embryos 
revealed severe alteration in twist expression after Chd7 was downregulated (10 ng 
Chd7 MO) (Fig. 22B). Embryos co-injected with 5 ng Chd7 MO and 5 ng Co MO 
were used as a reference control. Compared to the reference control, embryos 
(neurula stage) co-injected with 5 ng Chd7 MO and 5 ng Sema3a MO showed a 
slightly increase in moderate migration defects in NCCs. While no severe migration 
defects were detected in the reference control, 4 % of the embryos revealed severe 






reference control embryos (tailbud stage) moderate defects in migrating NCCs were 
observed, while 48 % were detected after a double knockdown of Chd7 and Sema3a 
(Fig. 22B). The combination of 5 ng Chd7 MO and 5 ng Sema3d MO led in 75 % of 
the embryos of the neurula stage to moderate migration defects while in the reference 
control only 63 % of the embryos were detected with moderate migration defects of 
NCCs (Fig. 22A). In tailbud stage embryos the percentage of embryos showing 
moderate defects of migrating NCCs was increased (39 %) compared to the reference 
control (28 %). Furthermore, 5 % showed severe migration and induction defects 
whereby none of the reference control embryos were detected with this phenotype 








Figure 22: Effect on twist expression after Chd7 knockdown, Chd7/Sema3a and Chd7/Sema3d 
double knockdown in Xenopus laevis.  
Embryos from one batch were either not injected or injected with 10 ng of Co MO, 10 ng Chd7 MO or 
co-injected with 5 ng Co MO and 5 ng Chd7 MO, 5 ng Chd7 MO and 5 ng Sema3a MO or 5 ng Chd7 
MO and 5 ng Sema3d MO. At neurula stage 20 a whole mount in situ hybridisation was performed to 
analyse the expression of the NCC marker twist (A). The diagram summarises the results of one 
experiment. The columns represent the percentage of the embryos showing a normal expression of 
twist (normal NCC migration) (light grey), moderate migration defects (grey) or severe migration and 
induction defects of NCCs (black). Numbers on top of each column indicate the number of embryos 
found in the different categories. Nearly all control embryos (uninjected and injected with 10 ng Co 
MO) showed a normal twist expression. After injecting 10 ng Chd7 MO, 35 % of the embryos showed 
severe migration and induction defects of NCCs and 35 % had moderate migration defects. In about 



















































NCCs were observed but no severe defects. After co-injection of 5 ng Chd7 MO and 5 ng Sema3a 
MO, more than 60 % of the embryos showed moderate migration defects. In 4 % severe migration 
defects were detected. A co-injection of 5 ng Chd7 MO and 5 ng Sema3d MO led in almost 80 % of 
the embryos to moderate migration defects of NCCs. Another whole mount in situ hybridisation (one 
biological replicate) was performed at the tailbud stage 27 (B). More than 95 % of the uninjected 
embryos and embryos injected with 10 ng Co MO showed a normal twist expression pattern. After an 
injection of 5 ng Co MO and 5 ng Chd7 MO, about 30 % of the embryos had moderate migration 
defects. An injection of 10 ng Chd7 MO led in approximately 60 % of the embryos to moderate 
migration defects of NCCs. Half of the embryos showed moderate defects in migrating NCCs if 5 ng 
Chd7 MO and 5 ng Sema3a MO were injected. After co-injection of 5 ng Chd7 MO and 5 ng Sema3d 
MO, about 40 % of the embryos revealed moderate migration defects and 5 % showed severe 
migration defects of NCCs.  
To analyse whether the increase of defects seen of NCC migration and induction 
after the double knockdown (Chd7 and Sema3a or Sema3d) can be intensified, the 
MO concentration were doubled to 10 ng. The expression pattern of twist was 
analysed in four independent experiments in neurula stages 20/21 (Fig. 23) and the 
tailbud stages 27, respectively (Fig. 23B). About 80 % of the embryos showed severe 
migration and induction defects of NCCs after a downregulation of Chd7 by 
injecting 20 ng Chd7 MO. Embryos, co-injected with 10 ng Chd7 MO and 10 ng Co 
MO were used as a reference control. In comparison of embryos of the reference 
control to embryos injected with either 10 ng Sema3a MO or Sema3d MO instead of 
the Co MO, the percentage of embryos showing defects of NCC migration was 
increased.  
After a Chd7/Sema3a double knockdown, more embryos (neurula stage) revealed 
severe migration and induction defects (68 %) as the reference control (56 %). The 
percentage of embryos with moderate defects of NCC migration was also increased 
(23 %) in comparison to the reference control (12 %). No changes in the percentage 
of embryos with defects of NCC migration were observed in tailbud stages.  
Comparing the embryos after a double knockdown of Chd7/Sema3d to the reference 
control, it was observed that the percentage of embryos showing severe migration 
and induction defects was increased from 56 % to 73 %. The percentage of embryos 
with moderate migration defects were slightly increased as well. In the tailbud stages 
a higher percentage of severe migration and induction defects was detected after 






Furthermore, it was observed in the neurula and tailbud stages that a double 
knockdown mediated by an injection of 10 ng Chd7 MO + 10 ng Sema3a MO or 
Sema3d MO did not reach the percentage of embryos showing defects in the 
migration of NCCs detected after single knockdown of Chd7 by injecting 20 ng 
Chd7 MO. Although, a higher percentage of embryos showed defects of NCC 
migration and induction after downregulation of Chd7 in combination with Sema3a 
or Sema3d the effect is to less to conclude a clear synergistic effect. All experiments 
with the model organism Xenopus laevis were performed within the collaboration 
with Prof. Dr. Annette Borchers and Dr. Peter Wehner in the Department of 
Developmental Biochemistry, Goettingen. Handling of Xenopus laevis, including 
fertilisation, injecting embryos and caring until embryos reached the desired 







Figure 23: Effect on the NCC marker twist after Chd7 knockdown, Chd7/Sema3a and 
Chd7/Sema3d double knockdown in Xenopus laevis. 
The graphs summarise four independent experiments where knockdowns were performed and the 
expression pattern of twist was analysed at the neurula stage 20/21 (A) and the tailbud stage 27 (B). 
The columns represent the percentage of the embryos showing a normal expression of twist indicating 
normal NCC migration (light grey), moderate migration defects (grey) or severe migration and 
induction defects of NCCs (black). Numbers on top of each column indicate the number of embryos 
obtained in the different categories. Standard error of the means is shown. At a two-cell stage embryos 
were injected in one blastomere with 20 ng Co MO, 10 ng Co MO and 10 ng Chd7 MO, 20 ng Chd7 
MO, 10 ng Chd7 MO and 10 ng Sema3a MO or 10 ng Chd7 MO and 10 ng Sema3d MO. The twist 



























































injection of 20 ng Co MO. An injection of 10 ng Co MO and 10 ng Chd7 MO led in more than 50 % 
of the embryos to severe defects of migrating NCCs. In more than 80 % of the embryos injected with 
20 ng Chd7 MO severe migration and induction defects were observed. After double knockdown of 
Chd7 and Sema3a, about 70 % of the embryos showed severe migration and induction defects of 
NCCs and more than 20 % were observed with moderate migration defects. An injection of 10 ng 
Chd7 MO and 10 ng Sema3d MO led in more than 70 % of the embryos to severe migration and 
induction defects and about 20 % showed moderate defects of migrating NCCs. The whole mount in 
situ hybridisation performed at the tailbud stage revealed for the majority of uninjected and the 
injected embryos with 20 ng Co MO a normal expression pattern of twist. More than 40 % of embryos 
co-injected with 10 ng Co MO and 10 ng Chd7 MO showed severe defects of migrating NCCs and 
about 20 % were detected with moderate migration defects. After downregulation of Chd7 by 
injecting 20 ng Chd7 MO, more than 80 % of the analysed embryos showed severe migration and 
induction defects of NCCs. More than 40 % of the embryos were detected with severe migration and 
induction defects after a double knockdown of Chd7 and Sema3a by injecting 10 ng of each MO and 
more than 20 % showed moderate migration defects. A co-injection of 10 ng Chd7 MO and 10 ng 
Sema3d MO led in about 60 % of the embryos to severe migration and induction defects and more 







4.1 Short summary 
It was shown in two independent experiments performed with HeLa cells that CHD7 
interacts with WDR5, ASH2L and RBBP5 (WAR complex). By Co-IP experiments 
the interaction of CHD7 with members of the WAR complex was shown in two 
ways: by precipitation of endogenous CHD7 and detection of overexpressed ASH2L 
and RBBP5 (Fig. 5A) as well as by precipitation of endogenous WDR5 and 
overexpressed ASH2L and RBBP5 and detection of endogenous CHD7, respectively 
(Fig. 5C) (Schulz et al., 2014a). With the Duolink PLA method these interactions 
were confirmed and at the same time the localisation of the interactions was found to 
be in the nuclei of HeLa cells (Fig. 7) (Schulz et al., 2014a). Furthermore, Y2H 
experiments revealed no direct interaction of the analysed CHD7 fragment (amino 
acids 1591-2181) with full-length constructs of WDR5, ASH2L and RBBP5 (Fig. 8) 
(Schulz et al., 2014a). 
The genome-wide microarray analysis performed with embryos of the Whirligig 
mouse line which carry a nonsense mutation in the Chd7 gene, revealed 98 genes 
showing a differential expression (compare appendix, Tab. 39) (Schulz et al., 2014b). 
Interestingly, a lot of these genes are involved in the process of axon and NCC 
guidance, such as members of the semaphorin family SEMA3A, SEMA3C and 
SEMA3D (Fig. 10) (Schulz et al., 2014b).  
Knockdown experiments of Chd7 carried out with embryos of the African clawed 
frog Xenopus laevis resulted in severe reduction or complete absence of sema3a 
expression (Fig. 16; Fig. 17) (Schulz et al., 2014b). Furthermore, the negative effect 
of a Chd7 downregulation on NCCs formation (twist expression) observed by Bajpai 
et al. (2010) was confirmed. After Chd7 downregulation, severe migration and 
induction defects of NCCs were determined (Fig. 20; Fig. 21). Downregulation of 
either Sema3a or Sema3d in Xenopus laevis embryos resulted in moderate migration 
defects (Fig. 20; Fig. 21). A double knockdown of Chd7 in combination with either 
Sema3a or Sema3d led to a higher number of Xenopus laevis embryos with more 






4.2 CHARGE syndrome shows phenotypical overlap with other 
syndromes 
CHARGE syndrome is a highly heterogeneous disorder and shows a phenotypical 
overlap with other syndromes (Sanlaville and Verloes, 2007; Jongmans et al., 2009; 
Bergman et al., 2011). An example is the Kabuki syndrome (OMIM 147920) which 
is a rare developmental disorder characterised by a typical facial gestalt, short 
stature, skeletal abnormalities, cardiac malformations, immunological defects and 
intellectual disabilities (Ng et al., 2010; Li et al., 2011; Bogershausen and Wollnik, 
2013). Heterozygous mutations in the KMT2D (MLL2) gene are described as the 
major genetic cause of Kabuki syndrome (Ng et al., 2010). KMT2D is a 
methyltransferase responsible for histone 3 lysine 4 (H3K4) di- and trimethylation 
(Song JJ, 2008).  
Our working group described a patient who was initially diagnosed as having 
CHARGE syndrome because he fulfilled the diagnostic criteria for CHARGE 
provided by Pagon et al. (1981) (five of six features) and Blake et al. (1998) (three of 
four major and three of seven minor signs). According to the CHARGE syndrome 
criteria from Verloes (2005), the patient fulfilled the criteria for having an atypical 
CHARGE syndrome (one of three major and three of five minor signs). To confirm 
the clinical diagnosis, a CHD7 mutation analysis was performed but no mutation was 
found. Further clinical examinations of the patient revealed emerging facial features, 
such as long palpebral fissures, long dense eyelashes and arched eye-brows, leading 
to the clinical diagnosis of Kabuki syndrome. A KMT2D mutation analysis revealed 
in exon 22 a heterozygous nonsense mutation confirming the clinical diagnosis of 
Kabuki syndrome (Schulz et al., 2014a). 
4.3 CHD7 is associated with the WAR complex 
KMT2D, the gene mutated in patients with Kabuki syndrome, belongs to the SET1 
family of enzymes which are commonly associated with multi-subunit complexes to 
be able to activate the methyltransferase (Miller et al., 2001; Yokoyama et al., 2004; 
Wysocka et al., 2005; Steward et al., 2006; Ernst and Vakoc, 2012). In Drosophila 
the homologous gene of KMT2D is trx (trithorax) of the trithorax group which 






of trithorax group proteins are polycomb group proteins which are most commonly 
linked to the repression of homeotic genes (Ringrose and Paro, 2004). 
One of the “core” complexes of KMT2D consists of WDR5, ASH2L and RBBP5 
(WAR complex) (Steward et al., 2006; Song JJ, 2008; Yates et al., 2010). The ATP-
dependent chromatin remodelling enzyme CHD8 interacts with the components of 
the WAR complex in the absence of MLL (Steward et al., 2006; Thompson et al., 
2008; Thompson BA, 2008; Yates et al., 2010). Yates et al. (2010) suggested a role 
of CHD8 in the regulation of gene transcription at the HOXA locus. They 
demonstrated a negative regulation of HOXA2 gene expression by CHD8 (Yates et 
al., 2010). Furthermore, it was shown by our working group that CHD7 interacts 
directly and indirectly with CHD8 (Batsukh et al., 2010), both proteins belong to the 
same subgroup of the CHD family (Flaus et al., 2006).  
Co-IP experiments performed with HeLa cells demonstrated an interaction of CHD7 
with WDR5, ASH2L and RBBP5 (Fig. 5) (Schulz et al., 2014a). Luisa Freese (PhD 
student of our group) completed successfully the Co-IP experiment using the pCMV-
HA-WDR5 construct, which was generated during writing my thesis. Full-length 
WDR5 was overexpressed in HeLa cells, endogenous CHD7 was precipitated and 
the overexpressed WDR5 was detected using an HA antibody (data not shown).  
The interaction between CHD7 and members of the WAR complex was confirmed 
by the Duolink PLA method (Fig. 7) (Schulz et al., 2014a). Further, it was 
demonstrated that the interaction takes place in the nuclei of HeLa cells (Fig. 7) 
(Schulz et al., 2014a) where eukaryotic gene transcription takes place (Georgiev, 
1972). Factors involved in the regulation of gene transcription such as the MLL2-
WAR methyltransferase complex are localised in the nucleus (MIPS et al., 2008) as 
well as the CHD family members of ATP-dependent chromatin remodelling enzymes 
CHD7 and CHD8 (Marfella and Imbalzano, 2007). In fact, it was shown by ICC that 
CHD7, CHD8 and the members of the WAR complex are specifically expressed in 
the nuclei of HeLa cells (Fig. 6). 
Direct Y2H experiments revealed no direct interaction for CHD7 and the WAR 
complex members (Fig. 8) (Schulz et al., 2014a). It is possible that the interaction 
region is located outside of the analysed CHD7 fragment (amino acids 1,591-2,181). 
Therefore, four overlapping fragments were generated spanning the whole CHD7 
protein without interrupting any known functional domains (Fig. 9) (Schulz et al., 






experiments with the four CHD7 fragments. CHD7-1pGBKT7 showed an auto 
activation of the yeast strain reporter genes and the other three CHD7 fragments 
revealed no direct interaction with the WAR complex members (Schulz et al., 
2014a).  
As shown by Yates et al. (2010) CHD8 interacts directly with WDR5, ASH2L and 
RBBP5. The direct Y2H experiments confirmed these interactions and narrowed 
down the responsible interaction side of CHD8 to the amino acids 1,789-2,302 
(Fig. 8) (Schulz et al., 2014a). Furthermore, the recently shown direct interaction of 
the CHD7 fragment and the CHD8 fragment was observed (Fig. 8) (Batsukh et al., 
2010; Schulz et al., 2014a). These data indicate that CHD7 is associated to the WAR 
complex most likely via the direct interaction with CHD8 (Schulz et al., 2014a). The 
association of CHD7 and KMT2D with the WAR complex connects these two genes 
to the same process of remodelling and modifying chromatin (Schulz et al., 2014a). 
Probably, CHD7 and KMT2D regulate the transcription of a subset of common genes 
(Schulz et al., 2014a). Therefore, it is likely that a mutation in either CHD7 or 
KMT2D causes misregulation of common target genes, which could explain the 
phenotypic overlap of CHARGE syndrome and Kabuki syndrome (Schulz et al., 
2014a).  
4.4 CHD7 regulates genes required for proper NCC development 
CHD7 is included within different complexes regulating time and tissue specific 
gene expression (Layman et al., 2010). Already in 1985, several years before 
mutations in CHD7 were discovered to cause CHARGE syndrome, Siebert et al. 
(1985) postulated that a disturbance in NCC development is the pathogenic 
mechanism behind CHARGE syndrome. Recent studies demonstrated the 
involvement of Chd7 in NCC development (Bajpai et al., 2010). Bajpai et al. (2010) 
showed that Chd7 activates components, such as Slug, Sox9 and Twist which are 
critical for the formation of migratory NCCs. Furthermore, Bajpai et al. (2010) found 
that Chd7 binds to the PBAF complex and assumed that Chd7 cooperates with the 
PBAF complex to regulate gene expression during NCC formation in Xenopus 
laevis. In the mouse CHD7 is required in the pharyngeal ectoderm for normal 






CHD7 based on alterations in NCC migration observed in Chd7 heterozygous mouse 
embryos (Randall et al., 2009).  
To analyse which genes are regulated by CHD7, a genome-wide microarray analysis 







) at E9.5, a developmental stage during NCC migration (Schulz et al., 
2014b). By using whole mouse embryos one important advantage is to identify genes 
involved in NCC development in different tissues although possible cancellation 
effects cannot be excluded (Schulz et al., 2014b). Differences in gene expression 
between females and males are present in several species, affecting not only sex 
chromosome linked genes, but also autosomal genes (Vawter et al., 2004; Yang et 
al., 2006; Zhang et al., 2009). To avoid gender specific effects on gene expression, 
the genome-wide microarray analysis was performed only with female mouse 
embryos. To confirm the data of the genome-wide microarray analysis by RT-qPCR, 
six genes were chosen which were identified to be differentially effected by CHD7. 
The expression of Sema3a, Sema3d and Epha3 was found to be downregulated while 
the expression of Sox10 and Gfra2 was increased and the Trp53bp2 expression was 
unaffected (appendix, Tab. 39) (Schulz et al., 2014b). The RNA of female mouse 
embryos which was also used for the microarray analysis was used for RT-qPCR. A 
similar expression of the selected genes was observed confirming the microarray data 
(Fig. 11) (Schulz et al., 2014b). Additionally, these genes were analysed by another 
RT-qPCR performed on male embryos. A gender specific affect for the analysed 
genes Sema3a, Sema3d, Epha3, Sox10, Gfra2 and Trp53bp2 was excluded (Fig. 12) 
(Schulz et al., 2014b). Since embryos from different breedings were obtained and 
used for the RT-qPCR experiments, slight differences in the developmental stage 
might occur, explaining the differences in expression of the same gene between the 
biological replicates. 
The microarray data revealed 98 differentially expressed genes (appendix, Tab. 39); 
many of them are involved in NCC migration and NCC and axons guidance as well 
as in interaction between NCCs and other tissues (Schulz et al., 2014b). For instance, 
several cadherins were identified which play a role in cell adhesion (Takeichi, 1995). 
Changes in cell adhesion are important during EMT which enables NCC migration 
(Kuriyama and Mayor, 2008). Transcription factors such as Sox10 and Foxd3 were 
found to be differentially expressed (Schulz et al., 2014b). They are involved in early 






to be important for the specification of NCCs (Gammill and Bronner-Fraser, 2003). 
In addition, secreted signalling molecules such as semaphorins, ephrins and slits 
were identified which act through protein kinase receptors to guide migrating NCCs 
(Perris, 1997; Gammill and Bronner-Fraser, 2003; Yazdani and Terman, 2006; 
Kuriyama and Mayor, 2008; Kirby and Hutson, 2010). Guidance molecules such as 
semaphorins and slits are expressed, for instance, in the surrounding epithelium of 
NCC localisation, guiding NCCs along specific pathways to their destination 
(Yazdani and Terman, 2006; Kuriyama and Mayor, 2008). Randall et al. (2009) 
observed that a rescue of CHD7 in murine NCCs alone did not rescue the phenotype 
of pharyngeal arch artery defects in CHD7 deficient mice whereas a rescue of CHD7 
in NCCs and the pharyngeal ectoderm led to full rescue of pharyngeal arch artery 
alterations. Randall et al. (2009) assumed ephrins, Pdgfs (platelet-derived growth 
factors), semaphorins, slits and Vegfs (vascular endothelial growth factors) as 
downstream candidate genes of CHD7 involved in ectoderm-NCC interaction. The 
data from the microarray analysis (compare 3.4) revealed among others members of 
all signalling families postulated by Randall et al. (2009): Epha3, Epha5, Epha7 
(ephrins), Pdgfc (Pdgfs), Sema3a, Sema3c, Sema3d (semaphorins), Slitrk6, Slitrk1 
(slits) and Vegfc (Vegfs). It is likely that CHD7 regulates genes which expression is 
important in NCCs and the surrounding tissue to ensure proper NCC development 
(specification, migration and differentiation). Furthermore, the data of the microarray 
analysis indicate that disturbance of NCC development plays a role in the 
pathogenesis of CHARGE syndrome. It seems that additional pathogenic 
mechanisms exist behind CHARGE syndrome. Possibly, till now untested theories, 
are a disruption of the interaction of mesoderm and NCCs (Van Meter and Weaver, 
1996) or the disturbance of mesenchymal-epithelial interaction (Williams, 2005).   
4.5 Chd7 regulates sema3a expression and NCC induction and 
migration in Xenopus laevis  
Chd7 is highly conserved across different species, for instance, human, mouse, 
zebrafish and Xenopus laevis (Bosman et al., 2005; Bajpai et al., 2010). Disruption of 
Chd7 function in Xenopus laevis exposed defects comparable to symptoms seen in 
CHARGE syndrome (Bajpai et al., 2010). A downregulation of Chd7 in Xenopus 






demonstrating alteration in NCC migration (Bajpai et al., 2010). Disruption of CHD7 
function in mouse was found to result in a decreased expression of members of the 
semaphorin family, such as Sema3a and Sema3d (Schulz et al., 2014b).  
To analyse whether there is a conserved regulatory mechanism across species, 
knockdown experiments on Xenopus laevis embryos were performed injecting MO 
in one blastomere of a two-cell stage. Analysis of sema3a expression after 
downregulation of Chd7 caused either decreased or complete depletion of sema3a 
expression (Fig. 16; Fig. 17) (Schulz et al., 2014b), exposing a conserved mechanism 
between mouse and Xenopus laevis.  
4.6 SEMA3A and SEMA3D seem to play a role in the pathogenesis of 
CHARGE syndrome  
To test whether disruption of Sema3a or Sema3d phenocopies the NCC defects 
observed after Chd7 loss of function, knockdown experiments of Chd7, Sema3a and 
Sema3d were performed with Xenopus laevis embryos and the expression pattern of 
the NCC marker twist was analysed by WMISH. While a Chd7 loss of function 
caused severe migration and induction defects of NCCs, knockdown of Sema3a or 
Sema3d revealed moderate migration defects of NCCs (Fig. 20; Fig. 21). The severe 
NCC alterations observed in Xenopus laevis after Chd7 downregulation are likely 
caused by the regulatory effect of Chd7 on several genes involved in NCC formation 
and migration (Schulz et al., 2014b). Nevertheless, the semaphorins Sema3a and 
Sema3d partially phenocopy the NCC defects observed during the Chd7 loss of 
function indicating a possible participation of these semaphorins in the pathogenesis 
of CHARGE syndrome.   
Double knockdown of Chd7 and Sema3a or Sema3d was performed to analyse 
whether there is a synergistic effect. The percentage of embryos showing severe 
migration defects of NCCs was clearly increased but insufficient to determine a 
synergistic effect. In the mouse a significant decreased expression of different 
semaphorins were shown (appendix, Tab. 39) and in Xenopus laevis a Chd7 loss of 
function caused also a reduced sema3a expression (Fig. 16; Fig. 17) (Schulz et al., 
2014b). A clear synergistic effect after the double knockdown of Chd7 and Sema3a 
or Chd7 and Sema3d was not observed (Fig. 22; Fig. 23). A possible explanation 






expression of sema3a and sema3d that an additional knockdown of either Sema3a or 
Sema3d cannot cause a synergistic effect.  
The CHD7 expression pattern studied in different species (human, mouse, chick and 
others) correlates with the malformations observed in CHARGE syndrome (Bosman 
et al., 2005; Sanlaville et al., 2006; Aramaki et al., 2007; Hurd et al., 2007; Layman 
et al., 2009; Bergman et al., 2010; Kosaki, 2011; Janssen et al., 2012). CHD7 is 
expressed, for instance, in the brain, heart, inner ear, olfactory epithelium and ganglia 
(Bosman et al., 2005; Lalani et al., 2006; Sanlaville et al., 2006; Aramaki et al., 
2007; Hurd et al., 2007; Layman et al., 2009; Bergman et al., 2010). SEMA3D 
expression has been observed in bones and cartilage, heart, endothelial cells, 
fibroblasts, epidermis, glia and neurons (Luo et al., 1995; Halloran et al., 1999; 
Cohen et al., 2003; Serini et al., 2003; Lallier, 2004; Jin et al., 2006). In paraffin 
sections of mouse embryos (E12.5) CHD7 and SEMA3D showed an overlapping 
expression pattern in the medulla oblongata, choroid plexus, cochlea, heart, cartilage 
primordium of body of vertebra and in different ganglia (Fig.19) indicating a 
possible role of SEMA3D in the pathogenesis of CHARGE syndrome, although 
further studies are needed to clarify this aspect. 
4.7 Semaphorins might act as modifier in CHARGE syndrome 
Semaphorins are conserved secreted and membrane-associated proteins which can be 
divided into eight classes according to domain architecture and phylogenetic tree 
analysis ("Unified nomenclature for the semaphorins/collapsins. Semaphorin 
Nomenclature Committee," 1999; Yazdani and Terman, 2006). Classes 3-7 are found 
only in vertebrates (Yazdani and Terman, 2006). Class 3 of semaphorins was 
identified to be required for NCC migration (Eickholt et al., 1999; Osborne et al., 
2005; Yu and Moens, 2005). 
The malformation disorder CHARGE syndrome was postulated to belong to the 
neurocristopathies (Siebert et al., 1985). Mutations in the CHD7 gene were identified 
as the genetic cause in about two-thirds of CHARGE syndrome patients (Vissers et 
al., 2004; Sanlaville and Verloes, 2007). In 5-10 % of typical CHARGE patients and 
in 40-60 % of patients suspected of having CHARGE syndrome the cause remains 
unknown (Janssen et al., 2012). Several candidate genes, such as PAX2 (paired box 






identified (Tellier et al., 2000; Martin et al., 2002). In a CHARGE syndrome patient 
originally described by Martin et al. (2001) with a de novo balanced translocation 
involving chromosomes 2 and 7, Lalani et al. (2004) mapped the translocation 
breakpoints and identified SEMA3E within 200 kb of the breakpoint on 7q21.11. By 
screening additional patients with CHARGE syndrome for mutations in the SEMA3E 
gene a de novo mutation was found (S703L) in an unrelated patient (Lalani et al., 
2004). The S703L mutation was not found in the parents (Lalani et al., 2004). CHD7 
mutations were not detected in these two patients, but CHD7 deletions could not be 
excluded (Lalani et al., 2006). 
While the Sema3e expression was found to be unchanged in the genome-wide 
microarray analysis performed on Whirligig mouse embryos described in section 3.4, 
the expression of Sema3a, Sema3c and Sema3d were significantly reduced (Schulz et 
al., 2014b). Additional sequencing of the SEMA3C gene that is located 1.9 Mb 
centromeric from the translocation breakpoint in 24 patients revealed no mutation 
(Lalani et al., 2004). The SEMA3D gene lies with SEMA3E on 7q21.11, so it is 
possible that its function is disturbed by the translocation (Database, 2014a, b).  
Sema3a knockout mice show altered olfactory bulb innervation and hypogonadism 
caused by abnormal development of Gonadotropin-releasing hormone (GnRH) 
neurons exhibiting a phenotype similar to Kallmann syndrome (Schwarting et al., 
2000; Cariboni et al., 2011). Kallmann syndrome is a developmental disorder 
associated with idiopathic hypogonadotropic hypogonadism and congenitally absent 
or impaired sense of smell (anosmia) (Kallmann et al., 1944). Both features are also 
found in patients with CHARGE syndrome (Chalouhi et al., 2005; Pinto et al., 2005; 
Asakura et al., 2008; Blustajn et al., 2008). Additional abnormalities may occur in 
patients with Kallmann syndrome, such as cleft lip and palate, dental agenesis, 
unilateral renal agenesis, abnormal eye movements and neurological alterations 
(Santen and Alvin Paulsen, 1972; Wegenke et al., 1975; Lieblich et al., 1982; 
Schwankhaus et al., 1989; Hardelin et al., 1993a; Hardelin et al., 1993b; Kirk et al., 
1994; de Zegher et al., 1995; Molsted et al., 1997; Soderlund et al., 2002; Dode et al., 
2003; Kim et al., 2008a). Among others, mutations in CHD7 were identified in some 
patients with Kallmann syndrome (Kim et al., 2008b; Jongmans et al., 2009). It was 
assumed that Kallmann syndrome represents the mild end of CHARGE syndrome 






Young et al. (2012) reported a SEMA3A deletion in a family with Kallmann 
syndrome. A screen of 386 patients with Kallmann syndrome for mutations in 
SEMA3A revealed non-synonymous mutations in 24 patients (Hanchate et al., 2012). 
As described before, semaphorins seem to be involved in the pathogenesis of 
CHARGE syndrome. To analyse whether semaphorins contribute to the phenotype of 
CHARGE syndrome, 45 patients diagnosed with CHARGE but lacking a mutation in 
the CHD7 gene were sequenced for the presence of mutations in the coding sequence 
of SEMA3A and SEMA3D. 
Three non-synonymous mutations for SEMA3A in a heterozygous state, namely 
c.196 C>T (p.R66W), c.2002 A>G (p.I668V) and c.2062 A>G (p.T688A), were 
identified (Fig.14) (Schulz et al., 2014b). Interestingly, two of the identified missense 
mutations (p.R66W and p.T688A) were described in patients with Kallmann 
syndrome (Hanchate et al., 2012). Hanchate et al. (2012) exposed that the missense 
mutation p.R66W results in altered secretion of SEMA3A while p.T668A causes a 
reduced signalling activity of SEMA3A. Based on these findings a pathogenic effect 
in Kallmann syndrome was assumed (Hanchate et al., 2012). Further, it was 
postulated that a heterozygous mutation in SEMA3A alone is not sufficient to induce 
the phenotypic features of Kallmann syndrome, while in combination with mutations 
in other Kallmann syndrome causing genes it could contribute to it (Hanchate et al., 
2012).  
It was shown in this work that the non-synonymous mutation (p.R66W) identified in 
a CHARGE patient was inherited by the healthy father (Schulz et al., 2014b).  
A mutation screen of the coding sequence of SEMA3D in 45 CHD7 negative 
CHARGE patients revealed no disease causing nucleotide alteration nor a small 
deletion or insertion. Three non-synonymous mutations were identified in a 
heterozygous state, namely c.193 T>C (p.S65P), c.1272 C>A (p.H424Q) and c.2101 
A>C (p.K701Q) (Fig. 15). The missense mutation p.His424Gln affects a conserved 
residue. While the common variant p.K701Q (allele frequency of 0.346 in the ESP 
cohort population) and the less common variant p.S65P (allele frequency of 0.017 in 
the ESP cohort population) are predicted to be benign (Polyphen and Polyphen2), the 
missense mutation p.H424Q with an allele frequency of 0.002 is predicted to be 
damaging (Polyphen, Polyphen2, Sift). Screening the parents of the patient carrying 
the p.H424Q variant revealed that the variation was inherited by the healthy father. 






sufficient to cause CHARGE syndrome but it is possible that these mutations 
contribute to the pathogenesis of CHARGE syndrome as suggested for SEMA3A 
mutations for Kallmann syndrome (Hanchate et al., 2012). CHARGE syndrome is a 
highly heterogeneous malformation disorder showing inter- and intra-familial 
heterogeneity (Aramaki et al., 2006; Jongmans et al., 2006; Lalani et al., 2006). 
Mutations in other genes like SEMA3A and SEMA3D might act as modifiers leading 
to a more severe phenotype explaining the heterogeneous appearance of patients with 
CHARGE syndrome (Schulz et al., 2014b). 
4.8 Future perspective 
Since CHD7 is associated with different complexes to regulate gene expression in a 
developmental stage and tissue specific manner, it would help to analyse the 
composition of CHD7 protein complexes. One method to analyse the structure and 
composition of especially heterogenic protein complexes is by chemical cross-
linking combined with mass spectrometry (XL-MS) (Herzog et al., 2012). 
Furthermore, arrangement of proteins within complexes and the interplay of protein 
complexes in a signal transduction pathway can be investigated. 
CHARGE syndrome is a phenotypic variable malformation syndrome and in the 
present work it is assumed that SEMA3A and SEMA3D might have modifying 
functions contributing to a more severe phenotype if they are mutated. Therefore, 
CHARGE patients carrying a CHD7 mutation should be screened for additional 
mutations in SEMA3A and SEMA3D. Especially familial cases showing phenotypic 
variations would be of great value. 
For the Sema3a and Sema3d knockdown experiments performed with Xenopus laevis 
embryos, rescue experiments have to be accomplished to prove that the observed 
phenotype is caused by the loss of Sema3a and Sema3d function. 
The genome-wide microarray analysis revealed 98 differentially expressed genes. 
Several of these genes play a role in NCC development (specification, EMT, 
guidance of NCC migration and interaction of NCCs with other tissues). Functional 
analysis of other guidance factors, such as ephrins or slits can be performed which 
are also involved in axon guidance during neurogenesis (Kirby and Hutson, 2010). 






syndrome, for instance, cranial nerve palsy, arhinencephaly or abnormal olfactory 
bulbs and anosmia (Chalouhi et al., 2005; Sanlaville et al., 2005).  
Further expression analysis by WMISH or immunohistochemistry in the mouse is 
recommendable. It would be interesting to analyse the expression pattern of 









)) of the Whirligig mouse 
line. Furthermore, NCC migration and development should be checked in these mice. 
Disturbances in NCC migration can be visualised by staining the expression pattern 
of the NCC marker Twist and the correct NCC differentiation can be checked, for 
instance, by observing the formation of dorsal root ganglia. Another possibility to 
analyse the process of NCC migration in vitro is to plate NCCs on a fibronectin layer 
(Rovasio et al., 1983). Fibronectin is one component of the extracellular matrix 
which migrating NCCs encounter (Tosney, 1978; Lofberg et al., 1980; D. Newgreen 
and Thiery, 1980; Duband and Thiery, 1982; D. F. Newgreen et al., 1982; Spieth and 
Keller, 1984; Brauer et al., 1985; Duband et al., 1986; Krotoski et al., 1986). It would 










mice by explanting NCCs on fibronectin containing matrices with alternating stripes 
of the semaphorin. Furthermore, the described non-synonymous mutations identified 
in the SEMA3A and SEMA3D screen in 45 CHD7 negative CHARGE patients could 
be induced by side-directed mutagenesis into a wild-type semaphorin plasmid to 
generate a semaphorin with this defect and to test whether these mutations cause 
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Wild-type vs. Chd7Whi/Whi 
log2 FC      P-Value         FDR 
 
Gene Ontology category and 





       
  1 Casp12 caspase 12 1.69 3.48E-04 4.253  
  2 Rasl10a RAS-like, family 10, member A 1.65 2.56E-07 0.086  
  3 Mt1 metallothionein 1 1.50 1.36E-04 2.653 ion homeostasis 
  4 Acsbg1 acyl-CoA synthetase bubblegum 
family member 1 
1.53 5.53E-06 0.363  
  5 Pkp1 plakophilin 1 1.41 3.83E-04 4.513 Cell adhesion 
  6 Foxd3 forkhead box D3 1.30 1.51E-04 2.768 Neural crest cell migration 
embryonic organ development 
positive regulation of gene expression 
chordate embryonic development 
  7 Vstm2l V-set and transmembrane 
domain containing 2-like 
1.26 2.74E-04 3.774  
  8 Cdh22 cadherin 22 1.21 3.06E-04 3.896 Cell adhesion 
  9 Sox10 SRY-box containing gene 10 1.16 7.26E-05 1.952 Neural crest cell migration 
positive regulation of gene expression 
chordate embryonic development 
 10 Igfbp6 insulin-like growth factor 
binding protein 6 
1.16 1.20E-04 2.481  
 11 Pcsk9 proprotein convertase 
subtilisin/kexin type 9 
1.15 2.88E-04 3.847 neuron differentiation 
 12 Jph4 junctophilin 4 1.13 4.47E-04 4.77  
 13 Mt2 metallothionein 2 1.13 2.19E-04 3.424 ion homeostasis 
 14 Gfra2 glial cell line derived 
neurotrophic factor family 
receptor alpha 2 
1.13 5.25E-06 0.363 transmembrane receptor protein tyrosine 
kinase signaling pathway 
 15 Grik3 glutamate receptor, ionotropic, 
kainate 3 
1.13 1.25E-05 0.62 ion homeostasis 
 16 Cdh13 cadherin 13 1.12 1.49E-04 2.754 Cell adhesion 
 17 Flrt1 fibronectin leucine rich 
transmembrane protein 1 
1.11 8.65E05 2.097  
 18 Lmo1 LIM domain only 1 1.06 4.25E-04 4.642  
 19 Phf15 PHD finger protein 15 1.06 5.28E-06 0.363  
 20 2200002K
05Rik 
RIKEN cDNA 2200002K05 
gene 
1.04 4.13E-04 4.583  
 21 Fam162b family with sequence similarity 
162, member B 
1.01 3.04E-06 0.290  




       
 22 Pcdh19 protocadherin 19 -1.00 1.06E-04 2.271 Cell adhesion 
 23 Vegfc vascular endothelial growth 
factor C 
-1.00 2.00E-06 0.245 Neural crest cell guidance 
transmembrane receptor protein tyrosine 







Table 1 (Continued) 
     
No. Gene 
symbol 
Gene name Wild-type vs. Chd7Whi/Whi 
log2 FC        P-Value        FDR 
Gene Ontology category and 
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 24 Tmeff2 transmembrane protein with 
EGF-like and two follistatin-like 
domains 2 
-1.02 1.57E-04 2.814  
 25 Gm2496 predicted gene 2496 -1.02 1.04E-04 2.262  
 26 Gpm6a glycoprotein m6a -1.03 2.75E-04 3.774  
 27 Pdgfc platelet-derived growth factor, C 
polypeptide 
-1.04 1.55E-05 0.68 Neural crest cell migration 
transmembrane receptor protein tyrosine 
kinase signaling pathway 
 28 Txlnb taxilin beta -1.05 4.13E-04 4.583  
 29 Sema3c semaphorin 3C -1.05 1.46E-05 0.666 Neural crest cell guidance 
vasculature development 
cellular component movement 
 30 D030007L
05Rik 
RIKEN cDNA D030007L05 gene -1.06 2.22E-05 0.853  
 31 Clec1b C-type lectin domain family 1, 
member b 
-1.06 6.23E-05 1.752  
 32 Flrt2 fibronectin leucine rich 
transmembrane protein 2 
-1.06 7.21E-05 1.952 Neural crest cell migration 
 33 Slc35d3 solute carrier family 35, member 
D3 
-1.07 1.28E-04 2.554  
 34 Clec9a C-type lectin domain family 9, 
member a 
-1.08 2.77E-05 1.007  
 35 Lin7a lin-7 homolog A (C. elegans) -1.08 5.59E-05 1.671 regulation of neurotransmitter levels 
 36 6720420G
18Rik 
RIKEN cDNA 6720420G18 gene -1.08 6.03E-05 1.744  
 37 Lhx9 LIM homeobox protein 9 -1.09 1.39E-04 2.676  




RIKEN cDNA A930038C07 
gene 
-1.11 1.52E-05 0.68 Extracellular matrix organization 
 40 Gad2 glutamic acid decarboxylase 2 -1.17 3.21E-05 1.21 regulation of neurotransmitter levels 
 41 Saa2 serum amyloid A 2 -1.18 4.15E-06 0.34  
 42 Pcdh17 protocadherin 17 -1.19 2.12E-04 3.374 Cell adhesion 
 43 St8sia4 ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyl-transferase 4 
-1.19 8.98E-05 2.104  
 44 D030024E
09Rik 
RIKEN cDNA D030024E09 gene -1.20 6.49E-05 1.789  
 45 Pcdhac2 protocadherin alpha subfamily C, 
2 
-1.24 1.85E-04 3.108 Cell adhesion 
 46 Tnfaip6 tumor necrosis factor alpha 
induced protein 6 
-1.25 1.68E-04 2.936 Cell adhesion 
 47 Inpp4b inositol polyphosphate-4-
phosphatase, type II 
-1.25 4.47E-05 1.51  
 48 Asb4 ankyrin repeat and SOCS box-
containing 4 
-1.26 2.60E-05 0.96  
 49 Sema3a  semaphorin 3A -1.26 2.21E-06 0.26 Neural crest cell guidance, Axonogenesis 
neuron differentiation 
cellular component movement 
 50 Hnmt histamine N-methyltransferase -1.27 1.68E-04 2.936 regulation of neurotransmitter levels 
 51 Aldh1a7 aldehyde dehydrogenase family 
1, subfamily A7 
-1.27 1.57E-04 2.814  
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 52 Zic1 zinc finger protein of the 
cerebellum 1 
-1.30 4.36E-04 4.708 Neural crest induction 
inner ear development 
embryonic organ development 
 53 Dmrta2 doublesex and mab-3 related 
transcription factor like family A2 
-1.32 2.57E-04 3.658  
 54 Pou3f2 POU domain, class 3, 
transcription factor 2 
-1.34 4.25E-04 4.642 neuron differentiation 
positive regulation of gene expression 
cellular component movement 
ion homeostasis 
 55 Slitrk1 SLIT and NTRK-like family, 
member 1 
-1.37 1.90E-07 0.07 Neural crest cell guidance, Axonogenesis 
neuron differentiation 
 56 Epha7 Eph receptor A7 -1.38 5.58E-06 0.363 Neural crest cell guidance, Axonogenesis, 
neuron differentiation, transmembrane 
receptor protein tyrosine kinase signaling 
pathway, cellular component movement 
 57 Abca9 ATP-binding cassette, sub-family 
A, member 9 
-1.39 1.02E-06 0.196  
 58 Gm7325 predicted gene 7325 -1.40 1.78E-04 3.035  
 59 Zfhx4 zinc finger homeodomain 4 -1.42 4.81E-05 1.553  
 60 1700042O
10Rik 
RIKEN cDNA 1700042O10 gene -1.43 2.62E-04 3.668  
 61 Clvs1 clavesin 1 -1.44 1.75E-04 3.015  
 62 Cdh10 cadherin 10 -1.44 4.50E-05 1.51 Cell adhesion 
 63 Col3a1 collagen, type III, alpha 1 -1.51 1.86E-05 0.794 Extracellular matrix organization 
vasculature development 
 64 Meox2 mesenchyme homeobox 2 -1.51 3.15E-05 1.114 Palate development, limb development 
muscle tissue development 
chordate embryonic development 
vasculature development 
 65 Mmrn1 multimerin 1 -1.52 1.01E-04 2.229  
 66 Dach1 dachshund 1 (Drosophila) -1.59 1.42E-06 0.202  
 67 Anxa1 annexin A1 -1.60 5.76E-06 0.363  
 68 Tnfsf18 tumor necrosis factor (ligand) 
superfamily, member 18 
-1.60 1.10E-04 2.348  
 69 Chd7 chromodomain helicase DNA 
binding protein 7 
-1.60 1.56E-07 0.07 inner ear development, limb development 
embryonic organ development 
chordate embryonic development 
vasculature development 
 70 Gm715 predicted pseudogene 715 -1.61 4.84E-07 0.145  
 71 Myf6 myogenic factor 6 -1.64 9.57E-07 0.196 positive regulation of gene expression 
muscle tissue development 
chordate embryonic development 
 72 Scn3a sodium channel, voltage-gated, 
type III, alpha 
-1.66 5.20E-06 0.363  
 73 Foxp2 forkhead box P2 -1.74 1.26E-04 2.552 muscle tissue development 
 74 Rspo2 R-spondin 2 homolog (Xenopus 
laevis) 
-1.74 4.05E-04 4.583  
 75 Olig3 oligodendrocyte transcription 
factor 3 
-1.79 1.29E-05 0.62  
 76 Armc4 armadillo repeat containing 4 -1.85 8.26E-07 0.196  
 77 Tnnc2 troponin C2, fast -1.85 5.45E-06 0.363  
 78 Sema3d  semaphorin 3D -1.87 1.36E-06 0.20 Neural crest cell guidance 
 79 Pcdh10 protocadherin 10 -1.96 1.33E-06 0.20 Cell adhesion 
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81 Lrrn3 leucine rich repeat protein 3, 
neuronal 
-2.07 9.13E-06 0.50  
82 Zic4 zinc finger protein of the 
cerebellum 4 
-2.09 3.80E-04 4.513 Neural crest induction 
 83 Vit vitrin -2.14 5.04E-08 0.036 Extracellular matrix organization 
 84 Alx1 ALX homeobox 1 -2.15 7.09E-07 0.191 Palate development 
inner ear development 
limb development 
embryonic organ development 
positive regulation of gene expression 
chordate embryonic development 
 85 Nts neurotensin -2.15 5.37E-08 0.036  
 86 9530003O
04Rik 
RIKEN cDNA 9530003O04 gene -2.16 1.17E-04 2.464  
 87 Dach2 dachshund 2 (Drosophila) -2.16 3.74E-04 4.469  
 88 Slitrk6 SLIT and NTRK-like family, 
member 6 
-2.23 1.53E-07 0.07 Neural crest cell guidance, Axonogenesis 
neuron differentiation 
 89 Pln phospholamban -2.43 3.07E-04 3.896  
 90 Epha3 Eph receptor A3 -2.42 4.47E-05 1.51 Neural crest cell  guidance 
transmembrane receptor protein tyrosine 
kinase signaling pathway 
 91 Epha5 Eph receptor A5 -2.48 1.29E-05 0.62 Neural crest cell guidance 
transmembrane receptor protein tyrosine 
kinase signaling pathway 
 92 Gm5127 predicted gene 5127 -2.50 1.35E-04 2.639  
 93 Myh3 myosin, heavy polypeptide 3, 
skeletal muscle, embryonic 
-2.52 3.24E-04 4.088  
 94 Chl1 cell adhesion molecule with 
homology to L1CAM 
-2.56 4.79E-06 0.363 Cell adhesion, Axonogenesis 
neuron differentiation 
cellular component movement 
 95 Tecrl trans-2,3-enoyl-CoA reductase-
like 
-2.61 8.55E-05 2.097  
 96 Csn3 casein kappa -2.68 4.99E-10 0.001  
 97 D030025E
07Rik 
RIKEN cDNA D030025E07  -2.72 4.13E-08 0.036  
 98 Myog myogenin -3.50 5.52E-06 0.363 positive regulation of gene expression 
muscle tissue development 
Differentially expressed genes with a log2 fold-change (FC) ≤ -1 or ≥1 and a false discovery rate (FDR) <5%. Genes are listed 
in the order of the most upregulated to the most downregulated gene. Selected gene ontology categories are shown  
(GO:0060021: palate development, GO:0007155 cell adhesion, GO:0007409 axonogenesis, GO:0048839 inner ear development, GO:0060173 limb development, 
GO:0030182 neuron differentiation, GO:0048568 embryonic organ development, GO:0010628 positive regulation of gene expression, GO:0060537 muscle tissue 
development, GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway, GO:0001944 vasculature development, GO:0043009 chordate embryonic 
development, GO:0006928 cellular component movement, GO:0001505 regulation of neurotransmitter levels. GO:0050801 ion homeostasis, GO:0030198 extracellular 
matrix organization).  
* Kirby and Hutson (2010) 
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